Appendix CExcluded Studies

  1. Electroconvulsive therapy. JAMA. 1985;254(15):2103–8. OVID-Embase. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 4046138]
  2. Separate and combined anxiolytic and anti-depressant treatment of mixed anxiety/depression: A double-blind, placebo controlled comparison. Sussex Clinical Trials Group. Acta Psychiatr Scand. 1985;72(1):81–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2863922]
  3. APA issues practice guideline for major depressive disorder in adults. Am Fam Physician. 1993;48(7):1312–3. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 8237743]
  4. Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. J Psychopharmacol. 1993;7(1):19–23. OVID-PsycINFO. Exclude: Not an eligible guideline. [PubMed: 22290366]
  5. Practice guideline for major depressive disorder in adults. American Psychiatric Association. Am J Psychiatry. 1993;150(4:Suppl):1–26. OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 8465906]
  6. The effect of sequential antidepressant treatment on geriatric depression. Erratum. J Affect Disord. 1996;41(1):77. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 8821312]
  7. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: A randomized controlled trial. JAMA. 2002;287(14):1807–14. Exclude: Not an eligible population treatment. [PubMed: 11939866]
  8. St John’s wort = SSRI for moderate-severe depression. S Afr Fam Pract. 2005;47(4):18. OVID-Embase. Exclude: Not an eligible study design.
  9. Adjunctive aripiprazole effective for treatment-resistant depression. Prim Psychiatr. 2005;12(1):19. OVID-PsycINFO. Exclude: Not an eligible study design.
  10. Botox treatment of depression. Prim Psychiatr. 2006;13(7):26–7. OVID-PsycINFO. Exclude: Not an eligible study design.
  11. Augmenting standard antidepressant treatment may help recovery in elderly. Brown Univ Geriatr Psychopharmacol Update. 2007;11(8):1–7. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  12. Do omega-3 fatty acids help in depression? Drug Ther Bull. 2007;45(2):9–12. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 17357473]
  13. TADS results show fluoxetine plus CBT safer and more effective for teen depression. (Treatment for Adolescents with Depression Study)(cognitive-behavioral therapy) Brown Univ Child Adolesc Psychopharmacol Update. 2007;9(1):1–4. EBSCO-CINAHL. Exclude: Not an eligible study design.
  14. Cognitive therapy equal to medication in augmentation for citalopram-resistant depression. Brown Univ Psychopharmacol Update. 2007;18(7):1–8. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  15. Cognitive behavioral therapy + alternative selective serotonin reuptake inhibitor better than alternative SSRI alone in adolescent depression. J Natl Med Assoc. 2008;100(6):762–3. OVID-Embase. Exclude: Not an eligible study design.
  16. Omissions in acknowledgments in: “The treatment for adolescents with depression study (TADS): Long-term effectiveness and safety outcomes” Arch Gen Psychiatr. 2008;65(1):101. OVID-PsycINFO. Exclude: Not an eligible study design.
  17. POEMs. CBT plus alternative SSRI is better than alternative SSRI alone in adolescent depression. JAAPA. 2008;21(5):58. EBSCO-CINAHL. Exclude: Not an eligible study design.
  18. Switching antidepressants plus CBT best for treatment-resistant depression in teens. (cognitive behavioral therapy) Brown Univ Child Adolesc Psychopharmacol Update. 2008;10(5):1–3. EBSCO-CINAHL. Exclude: Not an eligible study design.
  19. Treating depression with comorbid personality disorder: meds, CT or both?... Cognitive therapy. Brown Univ Psychopharmacol Update. 2008;19(4):1–3. EBSCO-CINAHL. Exclude: Not an eligible study design.
  20. Getting fitter, improving depression. J Sport Exerc Psychol. 2008;30(3):435. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  21. Cognitive behavioral therapy effective for depressed elderly. J Natl Med Assoc. 2010;102(4):358. OVID-Embase. Exclude: Not an eligible study design.
  22. Omega-3 fatty acids not effective for depression in patients with coronary heart disease. J Natl Med Assoc. 2010;102(2):151. OVID-Embase. Exclude: Not an eligible study design.
  23. Aan Het, Rot MCD, Mathew S. Intravenous ketamine for treatment-resistant major depressive disorder. Prim Psychiatr. 2008;15(4):39–47. Wiley-CCTR. Exclude: Not an eligible study design.
  24. aan het RM, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatr. 2010;67(2):139–45. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19897179]
  25. Aarnell G, Borjesson A, Eder DN, et al. Treatment resistant major depression - a comparison of fluoxetine/olanzapine combination therapy with venlafaxine. Int J Neuropsychopharmacol. 2002;5(Suppl 1):141. Wiley-CCTR. Exclude: Not an eligible study design.
  26. Aarsland D, Larsen JP, Lim NG, et al. Citalopram plus mianserin in patients with Parkinson’s disease and depression: An open-label study. Nord J Psychiatr. 1998;52(2):115–6. OVID-Embase. Exclude: Not an elligible population design.
  27. Abbass AA. Intensive short-term dynamic psychotherapy of treatment-resistant depression: A pilot study. Depress Anxiety. 2006;23(7):449–52. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 16845654]
  28. Abbass AA, Hancock JT, Henderson J, et al. Short-term psychodynamic psychotherapies for common mental disorders. Cochrane Database Syst Rev. 2006;(4):CD004687. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17054212]
  29. Aberg-Wistedt A. Comparison between zimelidine and desipramine in endogenous depression. A cross-over study. Acta Psychiatr Scand. 1982;66(2):129–38. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 6215831]
  30. Aberg A. Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant. Acta Psychiatr Scand Suppl. 1981;63(Suppl 290):244–55. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 6452794]
  31. Abraham G, Milev R, Lawson SJ. T3 augmentation of SSRI resistant depression. J Affect Disord. 2006;91(2–3):211–5. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 16483669]
  32. Abraham IL, Neundorfer MM, Currie LJ. Effects of group interventions on cognition and depression in nursing home residents. Nurs Res. 1992;41(4):196–202. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1383947]
  33. Abraham IL, Onega LL, Reel SJ, et al. Effects of cognitive group interventions on depressed frail nursing home residents. 1997. pp. 154–68. 1997. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  34. Abt KL. The effects of a group exercise intervention in the adjunctive treatment of depression Abt. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  35. Adlersberg S, Toren P, Mester R, et al. Verapamil is not an antidepressant in patients resistant to tricyclic antidepressants. Clin Neuropharmacol. 1994;17(3):294–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9316675]
  36. Adli M, Berghofer A, Linden M, et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry. 2002;63(9):782–90. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12363118]
  37. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):387–400. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15868067]
  38. Adli M, Pilhatsch M, Bauer M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatr. 2008;41(6):252–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19067263]
  39. Adli M, Bschor T, Bauer M, et al. Long-term outcome after lithium augmentation in unipolar depression: Focus on HPA system activity. Neuropsychobiol. 2009;60(1):23–30. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 19684420]
  40. Adson DE, Kushner MG, Eiben KM, et al. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004;19(2):121–6. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 15022147]
  41. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86(1):99–104. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15820277]
  42. Aekwarangkoon S, Oakley LD, Suttharangsee W, et al. Effectiveness of brief cognitive-support treatment in mild to moderate depressed Thai adolescent students. Thai J Nurs. 2006;10(4):288–300. EBSCO-CINAHL. Exclude: Not an eligible study design.
  43. Afuwape SA, Craig TK, Harris T, et al. The Cares of Life Project (CoLP): an exploratory randomised controlled trial of a community-based intervention for black people with common mental disorder. J Affect Disord. 2010;127(1–3):370–4. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20547421]
  44. Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: Clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol. 2003;6(1):41–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12899735]
  45. Agnoli A, Martucci N, Manna V. On the antidepressant effect of SAMe: Clinical and pharmaco-EEG study with SAMe alone and in association with a beta-2 stimulant drug, phenoterole. J Psychiatr Biol Therapeut. 1984;7(Suppl 1):104–5. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment.
  46. Agosti V, Ocepek-Welikson K. The efficacy of imipramine and psychotherapy in early-onset chronic depression: A reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Affect Disord. 1997;43(3):181–6. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 9186788]
  47. Agosti V. One year clinical and psychosocial outcomes of early-onset chronic depression. J Affect Disord. 1999;54(1–2):171–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10403160]
  48. Agrawal A, Dixit SP, Dubey GP, et al. Clinical evaluation of anti-depressant properties of Basant (Hypericum perforatum) Pharmacopsychoecol. 1994;7(3):253–6. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI.
  49. Agricola R, Dalla VG, Urani R, et al. S-adenosyl-L-methionine in the treatment of major depression complicating chronic alcoholism. Curr Ther Res Clin Exp. 1994;55(1):83–92. OVID-Embase. Exclude: Not an eligible study design.
  50. Aguilera A, Garza MJ, Munoz RF. Group cognitive-behavioral therapy for depression in Spanish: culture-sensitive manualized treatment in practice. J Clin Psychol. 2010;66(8):857–67. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC4167732] [PubMed: 20549680]
  51. Ahmed SH, Zaheeruddin Early experience with fluoxetine. JPMA. 1991;41(11):275–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1766070]
  52. Aiken CB. Pramipexole in psychiatry: A systematic review of the literature. J Clin Psychiatry. 2007;68(8):1230–6. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17854248]
  53. Aikens JE, Kroenke K, Swindle RW, et al. Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. Gen Hosp Psychiatry. 2005;27(4):229–36. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15993253]
  54. Ajel K, Bhogal K, Baldwin D. Prescribing of the antidepressant duloxetine: Can local clinical audit findings facilitate medicines management decisions? Int J Psychiatr Clin Pract. 2008;12(2):156–9. OVID-Embase. Exclude: Not an eligible study design.
  55. Akechi T, Okuyama T, Onishi J, et al. Psychotherapy for depression among incurable cancer patients. Cochrane Database of Systematic Reviews. 2008;(2):CD005537. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18425922]
  56. Akhondzadeh BA, Moshiri E, Noorbala AA, et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439–42. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17174460]
  57. Akhondzadeh S, Kashani L, Fotouhi A, et al. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: A double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(1):123–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 12551734]
  58. Akhondzadeh S, Fallah-Pour H, Afkham K, et al. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Compl Alternative Med. 2004;4:12. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC517724] [PubMed: 15341662]
  59. Akhondzadeh S, Fallah-Pour H, Afkham K, et al. A comparative trial of Crocus sativus L. (saffron) and imipramine in mild to moderate depression. Focus Alternative Compl Ther. 2005;10(1):22–3. OVID-Embase. Exclude: Not an eligible population treatment.
  60. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005;19(2):148–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15852492]
  61. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607–11. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19496103]
  62. Akizuki N, Okamura H, Akechi T, et al. Clinical experience of the pharmacological treatment algorithm for major depression in advanced cancer patients: Preliminary study. Int J Psychiatr Clin Pract. 2002;6(2):83–9. Exclude: Not an eligible study design.
  63. Alamo C, Lopez-Munoz F, Rubio G, et al. Combined treatment with reboxetine in depressed patients with no response to venlafaxine: A 6-week follow-up study. Acta Neuropsychiatr. 2007;19(5):291–6. OVID-Embase. Exclude: Not an eligible study design.
  64. Albanese MJ, Clodfelter RC Jr, Khantzian EJ. Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry. 2000;61(12):916–21. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11206596]
  65. Albin JI. A study measuring the effectiveness of cognitive/psychosocial intervention with a life-threatening illness: My thoughts, my illness, my life. 1998. OVID-PsycINFO. Exclude: Not an eligible study design.
  66. Alexopoulos GS, Raue P, Arean P. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. Am J Geriatr Psychiatr. 2003;11(1):46–52. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12527539]
  67. Alexopoulos GS, Sirey JA, Raue PJ, et al. Outcomes of depressed patients undergoing inpatient pulmonary rehabilitation. Am J Geriatr Psychiatr. 2006;14(5):466–75. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16670251]
  68. Alexopoulos GS, Raue PJ, Kiosses DN, et al. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction: Effect on disability. Arch Gen Psychiatr. 2011;68(1):33–41. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3018861] [PubMed: 21199963]
  69. Alladin A, Alibhai A. Cognitive hypnotherapy for depression: an empirical investigation. Int J Clin Exp Hypnosis. 2007;55(2):147–66. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17365072]
  70. Allart-van Dam E, Hosman CM, Hoogduin CA, et al. Prevention of depression in subclinically depressed adults: follow-up effects on the ‘Coping with Depression’ course. J Affect Disord. 2007;97(1–3):219–28. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16860874]
  71. Allart-van Dam E, Hosman CMH, Hoogduin CAL, et al. The Coping With Depression course: Short-term outcomes and mediating effects of a randomized controlled trial in the treatment of subclinical depression. Behav Ther. 2003;34(3):381–96. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  72. Allen JJB. Depression and acupuncture: A controlled clinical trial. Psychiatr Times. 2000;17(3):6. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  73. Allen JJB, Schnyer RN, Chambers AS, et al. Acupuncture for depression: A randomized controlled trial. J Clin Psychiatr. 2006;67(11):1665–73. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17196044]
  74. Allen JJB, Schnyer RN, Hitt SK. The efficacy of acupuncture in the treatment of major depression in women. Psychol Sci. 1998;9(5):397–401. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  75. Almeida OP, Marsh K, Alfonso H, et al. B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol. 2010;68(4):503–10. OVID-Medline. Exclude: Not an eligible population/treatment. [PubMed: 20976769]
  76. Alpert JE, Mischoulon D, Rubenstein GE, et al. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatr. 2002;14(1):33–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12046638]
  77. Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004;24(6):661–4. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15538131]
  78. Altshuler LL, Cohen LS, Moline ML, et al. Expert consensus guidelines for the treatment of depression in women: A new treatment tool. Econom Neurosci. 2001;3(6):48–61. OVID-Embase. Exclude: Not an eligible guideline.
  79. Altshuler LL, Cohen LS, Moline ML, et al. Treatment of depression in women: A summary of the expert consensus guidelines. J Psychiatr Pract. 2001;7(3):185–208. OVID-PsycINFO. Exclude: Not an eligible guideline. [PubMed: 15990522]
  80. Alvarez E, Perez-Sola V, Perez-Blanco J, et al. Predicting outcome of lithium added to antidepressants in resistant depression. J Affect Disord. 1997;42(2–3):179–86. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9105959]
  81. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55(1):11–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10512601]
  82. Amsterdam JD, Berwish N. Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. J Clin Psychopharmacol. 1987;7(4):238–42. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 3305592]
  83. Amsterdam JD, Berwish NJ. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatr. 1989;22(1):21–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2710808]
  84. Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84–90. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9262938]
  85. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression: A retrospective study. J Affect Disord. 2005;89(1–3):183–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16213594]
  86. Ancarani E, Biondi B, Bolletta A, et al. Major depression complicating hemodialysis in patients with chronic renal failure: A multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus placebo. Curr Ther Res Clin Exp. 1993;54(6):680–6. Exclude: Not an eligible population treatment.
  87. Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2000;14(1):3–20. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 10757248]
  88. Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study. J Affect Disord. 2009;117(1–2):116–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 19171384]
  89. Anderson L, Lewis G, Araya R, et al. Self-help books for depression: How can practitioners and patients make the right choice? Br J Gen Pract. 2005;55(514):387–92. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC1463163] [PubMed: 15904559]
  90. Anderson T, Watson M, Davidson R. The use of cognitive behavioural therapy techniques for anxiety and depression in hospice patients: A feasibility study. Palliat Med. 2008;22(7):814–21. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18755828]
  91. Andersson G, Bergstrom J, Hollandare F, et al. Internet-based self-help for depression: Randomised controlled trial. Br J Psychiatr. 2005;187:456–61. Exclude: Not an eligible population treatment. [PubMed: 16260822]
  92. Ando M, Morita T, Akechi T, et al. The efficacy of mindfulness-based meditation therapy on anxiety, depression, and spirituality in japanese patients with cancer. J Palliat Med. 2009;12(12):1091–4. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 19715397]
  93. Ando M, Morita T, Miyashita M, et al. Effects of bereavement life review on spiritual well-being and depression. J Pain Symptom Manage. 2010;40(3):453–9. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 20594802]
  94. Andrade C, Aswath A, Chaturvedi SK, et al. GS-02 for dysthymic disorder: Results of a preliminary, open study. J Herb Pharmacother. 2002;2(1):49–55. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 15277106]
  95. Andruskevicius S. Parameters of the spectral analysis of the heart rate variability in treating depression. Medicina. 2009;45(3):214–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19357451]
  96. Anghelescu IG, Kohnen R, Szegedi A, et al. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: Results from a randomized multicenter study. Pharmacopsychiatr. 2006;39(6):213–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17124643]
  97. Annesi JJ. Changes in depressed mood associated with 10 weeks of moderate cardiovascular exercise in formerly sedentary adults. Psychol Rep. 2005;96(3):855–62. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 16050652]
  98. Ansseau M, Pitchot W, Gonzalez MA, et al. Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature. Hum Psychopharmacol. 1993;8(4):279–83. OVID-Embase. Exclude: Not an eligible population treatment.
  99. Antikainen R, Lehtonen J, Koponen HJ, et al. The effect of hospital treatment on depression and anxiety in patients with borderline personality organization. Nord J Psychiatr. 1992;46(6):399–405. OVID-PsycINFO. Exclude: Not an eligible study design.
  100. Antonuccio DO, Akins WT, Chatham PM, et al. An exploratory study: The psychoeducational group treatment of drug-refractory unipolar depression. J Behav Ther Exp Psychiatr. 1984;15(4):309–13. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6396319]
  101. Antonuccio DO, Thomas M, Danton WG. A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. Behav Ther. 1997;28(2):187–210. OVID-Embase. Exclude: Not an eligible study design.
  102. Antunes HKM, Stella SG, Santos RF, et al. Depression, anxiety and quality of life scores in seniors after an endurance exercise program. Revista Brasileira de Psiquiatria. 2005;27(4):266–71. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16358106]
  103. Apóstolo JLA, Kolcaba K. The effects of guided imagery on comfort, depression, anxiety, and stress of psychiatric inpatients with depressive disorders. Arch Psychiatr Nurs. 2009;23(6):403–11. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 19926022]
  104. Appelhof BC, Brouwer JP, van Dyck R, et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Edocrinol Metab. 2004;89(12):6271–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15579788]
  105. Appleton KM, Hayward RC, Gunnell D, et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: Systematic review of published trials. Am J Clin Nutr. 2006;84(6):1308–16. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17158410]
  106. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91(3):757–70. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20130098]
  107. Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low-income women in Santiago, Chile: A randomised controlled trial. Lancet. 2003;361(9362):995–1000. Exclude: Not an eligible population treatment. [PubMed: 12660056]
  108. Araya R, Flynn T, Rojas G, et al. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. Am J Psychiatry. 2006;163(8):1379–87. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16877650]
  109. Arean PA, Perri MG, Nezu AM, et al. Comparative effectiveness of social problem-solving therapy and reminiscence therapy as treatments for depression in older adults. J Consult Clin Psychol. 1993;61(6):1003–10. Exclude: Not an eligible population treatment. [PubMed: 8113478]
  110. Arean PA, Gum A, McCulloch CE, et al. Treatment of depression in low-income older adults. Psychol Aging. 2005;20(4):601–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16420135]
  111. Arean P, Miranda J. The treatment of depression in elderly primary care patients: A naturalistic study. J Clin Geropsychol. 1996;2(3):153–60. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  112. Arean PA, Gum A, McCulloch CE, et al. Treatment of depression in low-income older adults. Psychol Aging. 2005;20(4):601–9. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 16420135]
  113. Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatr. 2008;20(4):187–93. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 19034749]
  114. Arsland D, Larsen JP, Neh GL, et al. Alpha2-adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson disease and depression. Nord J Psychiatr. 2000;54(6):411–5. OVID-Embase. Exclude: Not an eligible study design.
  115. Artigas F, Pérez V, Alvarez E, et al. Neurobiological differences between responders and non-responders to SSRI treatments: Evidence from pindolol augmentation. J Eur College Neuropsychopharmacol. 1999;9(Suppl 5):S177. Wiley-CCTR. Exclude: Not an eligible study design.
  116. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatr. 1994;51(3):248–51. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 8122960]
  117. Artigas F, Romero L, de Montigny C, et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996;19(9):378–83. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 8873352]
  118. Asarnow JR, Scott CV, Mintz J. A combined cognitive-behavioral family education intervention for depression in children: A treatment development study. Cognit Ther Res. 2002;26(2):221–9. OVID-Embase. Exclude: Not an eligible population treatment.
  119. Asarnow JR, Jaycox LH, Tang L, et al. Long-term benefits of short-term quality improvement interventions for depressed youths in primary care. Am J Psychiatry. 2009;166(9):1002–10. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19651711]
  120. Asarnow JR, Jaycox LH, Duan N, et al. Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: A randomized controlled trial. JAMA. 2005;293(3):311–9. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 15657324]
  121. Asheychik R, Jackson T, Baker H, et al. The efficacy of L-tryptophan in the reduction of sleep disturbance and depressive state in alcoholic patients. J Stud Alcohol. 1989;50(6):525–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2685471]
  122. Aslan A, Balaceanu C, Manoiu A, et al. A double-blind study on the antidepressive effects of Gerovital H3 and Aslavital in the elderly. Rom J Gerontol Geriatr. 1986;7(2):79–88. OVID-Embase. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI.
  123. AstraZeneca. A multicenter, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended-release (SEROQUEL XR) in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment (Onyx Study) CSR Study D1448C00007-Synopsis. 2007. Exclude: Not an eligible study design.
  124. Atlantis E, Chow C-M, Kirby A, et al. An effective exercise-based intervention for improving mental health and quality of life measures: A randomized controlled trial. Prev Med. 2004;39(2):424–34. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 15226056]
  125. Atmaca M, Kuloglu M, Tezcan E, et al. Switching to tianeptine in patients with antidepressant-induced sexual dysfunction. Hum Psychopharmacol Clin Exp. 2003;18(4):277–80. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 12766932]
  126. Ayd FJ. Psychostimulant therapy for depressed medically ill patients. Psychiatr Ann. 1985;15(7):462–5. OVID-PsycINFO. Exclude: Not an eligible study design.
  127. Aydemir O, Deveci A, Taskin EO. Mirtazapine combination in treatment-resistant major depressive disorder: A retrospective evaluation of six weeks. Klinik Psikofarmakoloji Bulteni. 2009;19(4):347–52. OVID-Embase. Exclude: Not an eligible study design.
  128. Azhar MZ, Varma SL. Religious psychotherapy in depressive patients. Psychother Psychosom. 1995;63(3–4):165–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7624461]
  129. Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000;62(5):633–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11020092]
  130. Baca BE, Giner UJ, Leal CC, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005;22(2):68–76. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 16094658]
  131. Baert S, De RR, Schacht R, et al. Attentional bias training in depression: Therapeutic effects depend on depression severity. J Behav Ther Exp Psychiatr. 2010;41(3):265–74. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20227062]
  132. Baghai TC, Marcuse A, Brosch M, et al. The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatr. 2006;7(2):82–90. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16684680]
  133. Bailey HA. Coue revisited: An internet-based investigation of repetition and positive self-statements on depression, self-esteem, and automatic thoughts. 2004. OVID-PsycINFO. Exclude: Not an eligible study design.
  134. Baker AL, Wilson PH. Cognitive-behavior therapy for depression: The effects of booster sessions on relapse. Behav Ther. 1985;16(4):335–44. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment.
  135. Baker AL, Kavanagh DJ, Kay-Lambkin FJ, et al. Randomized controlled trial of cognitive-behavioural therapy for coexisting depression and alcohol problems: Short-term outcome. Addiction. 2010;105(1):87–99. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19919594]
  136. Bakish D, Hooper CL, West DL, et al. Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant anxiety and depressive disorders. Hum Psychopharmacol. 1995;10(2):105–9. OVID-Embase. Exclude: Not an eligible study design.
  137. Bakish D, Hooper CL, Thornton MD, et al. Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int Clin Psychopharmacol. 1997;12(2):91–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9219044]
  138. Balaceanu-Stolnici C, Covic M, Manoiu A, et al. Double blind study concerning the antidepressive effects and the clinical tolerance of Gerovital H3 without potassium metabisulphate. Rom J Gerontol Geriatr. 1996;17(1–2):46–61. OVID-Embase. Exclude: Not an eligible study design.
  139. Baldree BF. The self-statement: Cognitive mediation in affective disorder intervention strategies. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  140. Baldwin D, Hawley C, Szabadi E, et al. Reboxetine in the treatment of depression: Early clinical experience in the UK. Int J Psychiatr Clin Pract. 1998;2(3):195–201. OVID-Embase. Exclude: Not an eligible study design.
  141. Baldwin RC, Jeffries S, Jackson A, et al. Treatment response in late-onset depression: Relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med. 2004;34(1):125–36. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 14971633]
  142. Ball C, Rice F, Thapar A. Childhood depression. Curr Paediatr. 2000;10(4):259–63. OVID-Embase. Exclude: Not an eligible study design.
  143. Ball J, Kearney B, Wilhelm K, et al. Cognitive behaviour therapy and assertion training groups for patients with depression and comorbid personality disorders. Behav Cognit Psychother. 2000;28(1):71–85. OVID-Embase. Exclude: Not an eligible population treatment.
  144. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatr. 2006;67(4):554–66. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16669720]
  145. Balyk ED. An analysis of rational emotive hypnotherapy in the treatment of depression: A pilot study. 2004. OVID-PsycINFO. Exclude: Not an eligible study design.
  146. Bano M, Iqbal F, Irshad E. Treatment of depression: Different approaches. J Pers Clin Stud. 2003;19(1):63–9. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  147. Bar-Sela G, Atid L, Danos S, et al. Art therapy improved depression and influenced fatigue levels in cancer patients on chemotherapy. Psychooncol. 2007;16(11):980–4. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 17351987]
  148. Barak Y, Stein D, Levine J, et al. Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly: An open trial. Hum Psychopharmacol. 1996;11(6):463–7. OVID-Embase. Exclude: Not an eligible study design.
  149. Barak Y, Olmer A, Aizenberg D. Antidepressants reduce the risk of suicide among elderly depressed patients. Neuropsychopharmacol. 2006;31(1):178–81. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16123751]
  150. Baraniak A, Sheffield D. The efficacy of psychologically based interventions to improve anxiety, depression and quality of life in COPD: A systematic review and meta-analysis. Patient Educ Couns. 2011;83(1):29–36. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20447795]
  151. Barbato A, D’Avanzo Barbara BD. Marital therapy for depression. Cochrane Database Syst Rev. 2006;(2) Art No: CD004188. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16625597]
  152. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63(8):737–41. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12197456]
  153. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatr. 2004;16(4):189–94. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15702566]
  154. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry. 2004;65(7):975–81. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15291687]
  155. Barbee J, Jamhour N, Stewart J. Lamotrigine as an antidepressant augmentation agent in treatment refractory unipolar depression. 2007. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 21367355]
  156. Barbisoni P, Bertozzi B, Franzoni S, et al. Mood improvement in elderly women after in-hospital physical rehabilitation. Arch Phys Med Rehabil. 1996;77(4):346–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 8607757]
  157. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64(4):403–7. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 12716240]
  158. Barbui C, Tansella M. Identification and management of depression in primary care settings: A meta-review of evidence. Epidemiol Psichiatr Soc. 2006;15(4):276–83. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17203620]
  159. Barbui C, Ostuzzi G, Cipriani A. SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. Evid Based Ment Health. 2009;12(4):109. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 19854771]
  160. Bares M, Brunovsky M, Kopecek M, et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res. 2007;41(3–4):319–25. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16889798]
  161. Bares M, Brunovsky M, Kopecek M, et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatr. 2008;23(5):350–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18450430]
  162. Bares M, Novak T, Kopecek M, et al. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study. Neuroendocrinol Lett. 2009;30(6):723–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20038931]
  163. Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: A double-blind, single-centre, randomized study. J Affect Disord. 2009;118(1–3):94–100. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19249105]
  164. Bares M, Novak T, Kopecek M, et al. Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice: A retrospective study. Int J Psychiatr Clin Pract. 2010;14(4):303–8. OVID-Embase. Exclude: Mixed antidepressants; some failed on SSRI.
  165. Bares M, Brunovsky M, Novak T, et al. The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. Eur Neuropsychopharmacol. 2010;20(7):459–66. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 20421161]
  166. Barker WA, Scott J, Eccleston D. The Newcastle chronic depression study: Results of a treatment regime. Int Clin Psychopharmacol. 1987;2(3):261–72. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3121718]
  167. Barkham M, Moorey J, Davis G. Cognitive-behavioural therapy in two-plus-one sessions: A pilot field trial. Behav Psychother. 1992;20(2):147–54. OVID-AMED. Exclude: Not an eligible population treatment.
  168. Barkham M, Shapiro DA, Hardy GE, et al. Psychotherapy in two-plus-one sessions: Outcomes of a randomized controlled trial of cognitive-behavioral and psychodynamic-interpersonal therapy for subsyndromal depression. J Consult Clin Psychol. 1999;67(2):201–11. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10224730]
  169. Barkham M, Stiles WB, Connell J, et al. Effects of psychological therapies in randomized trials and practice-based studies. Br J Clin Psychol. 2008;47(4):397–415. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18625084]
  170. Barkham M, Shapiro DA. Brief psychotherapeutic interventions for job-related distress: A pilot study of prescriptive and exploratory therapy. Counsell Psychol Q. 1990;3(2):133–47. OVID-PsycINFO. Exclude: Not an eligible study design.
  171. Barkham M, Rees A, Shapiro DA, et al. Outcomes of time-limited psychotherapy in applied settings: Replicating the Second Sheffield Psychotherapy Project. J Consult Clin Psychol. 1996;64(5):1079–85. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 8916639]
  172. Barnhofer T, Crane C, Hargus E, et al. Mindfulness-based cognitive therapy as a treatment for chronic depression: A preliminary study. Behav Res Ther. 2009;47(5):366–73. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2866254] [PubMed: 19249017]
  173. Barrera MJ. Reaffirmation of behavioral approaches to depression treatment. Clin Psychol Sci Pract. 2009;16(4):416–9. OVID-PsycINFO. Exclude: Not an eligible study design.
  174. Barrett JE, Williams J, Oxman TE, et al. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: Background and research plan. Gen Hosp Psychiatry. 1999;21(4):260–73. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 10514950]
  175. Barrett JE, Williams JW, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: A randomized trial in patients aged 18 to 59 years. J Family Pract. 2001;50(5):405–12. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 11350703]
  176. Barrett PM, Farrell LJ, Ollendick TH, et al. Long-term outcomes of an Australian universal prevention trial of anxiety and depression symptoms in children and youth: An evaluation of the friends program. J Clin Child Adolesc Psychol. 2006;35(3):403–11. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16836477]
  177. Bartholomew JB, Morrison D, Ciccolo JT. Effects of acute exercise on mood and well-being in patients with major depressive disorder. Med Sci Sports Exerc. 2005;37(12):2032–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16331126]
  178. Basoglu C, Ates MA, Algul A, et al. Adjuvant folate with escitalopram treatment and homocystein, folate, vitamin B-12 levels in patients with major depressive disorder. Klinik Psikofarmakoloji Bulteni. 2009;19(2):135–42. OVID-Embase. Exclude: Not an eligible population treatment.
  179. Bastiaens L. Response to antidepressant treatment in a community mental health center. Community Ment Health J. 2004;40(6):561–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15672694]
  180. Bastiaens L. Adolescents’ response to antidepressant treatment in a community mental health center. Community Ment Health J. 2005;41(1):77–84. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15932054]
  181. Bauer M, Zaninelli R, Muller-Oerlinghausen B, et al. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: A double-blind study. J Clin Psychopharmacol. 1999;19(2):164–71. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10211918]
  182. Bauer M, Baur H, Berghofer A, et al. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J Affect Disord. 2002;68(2–3):285–94. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12063156]
  183. Bauer M, Berghofer A, Bschor T, et al. Supraphysiological doses of L-Thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacol. 2002;27(4):620–8. Exclude: Not an eligible study design. [PubMed: 12377398]
  184. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatr. 2002;3(1):5–43. OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 12479086]
  185. Bauer M, Pfennig A, Linden M, et al. Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression. J Clin Psychopharmacol. 2009;29(4):327–33. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19593170]
  186. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540–9. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 19358791]
  187. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009;259(3):172–85. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19165525]
  188. Bauer M, Hellweg R, Graf KJ, et al. Neuropsychopharmacol; 3rd International Conference on Refractory Depression; 1995, October 18–21; Napa, CA, US. 149th Annual Meeting of the American Psychiatric Association; 1996, May 4–9; New York, NY, US. 1998. pp. 444–55. OVID-PsycINFO. Exclude: Not an eligible study design.
  189. Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry. 2000;157(9):1429–35. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 10964859]
  190. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol. 2007;22(1):1–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17191266]
  191. Baxter J, Liston EH, Schwartz JM. Prolongation of the antidepressant response to partial sleep deprivation by lithium. Psychiatry Res. 1986;19(1):17–23. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 3097691]
  192. Beach SRH, O’Leary KD. Treating depression in the context of marital discord: Outcome and predictors of response of marital therapy versus cognitive therapy. Behav Ther. 1992;23(4):507–28. OVID-Embase. Exclude: Not an eligible population treatment.
  193. Beach SR, O’Leary KD. The treatment of depression occurring in the context of marital discord. Behav Ther. 1986;17(1):43–9. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  194. Beardslee WR, Salt P, Versage EM, et al. Sustained change in parents receiving preventive interventions for families with depression. Am J Psychiatry. 1997;154(4):510–5. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 9090338]
  195. Bearn J, Franey C, Arendt J, et al. A study of the effects of desipramine treatment alone and in combination with L-triiodothyronine on 6-sulphatoxymelatonin excretion in depressed patients. Br J Psychiatr. 1989;155:341–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2611544]
  196. Beasley CM Jr, Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord. 1990;20(3):193–200. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2148340]
  197. Beauchemin KM, Hays P. Sunny hospital rooms expedite recovery from severe and refractory depressions. J Affect Disord. 1996;40(1–2):49–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8882914]
  198. Beauchemin KM, Hays P. Phototherapy is a useful adjunct in the treatment of depressed in-patients. Acta Psychiatr Scand. 1997;95(5):424–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9197908]
  199. Beck AT, Hollon SD, Young JE. Treatment of depression with cognitive therapy and amitriptyline. Arch Gen Psychiatr. 1985;42(2):142–8. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 3883938]
  200. Beckman SE, Sommi RW, Switzer J. Consumer use of St. John’s wort: A survey on effectiveness, safety, and tolerability. Pharmacother. 2000;20(5):568–74. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10809344]
  201. Beckner V, Howard I, Vella L, et al. Telephone-administered psychotherapy for depression in MS patients: Moderating role of social support. J Behav Med. 2010;33(1):47–59. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2813530] [PubMed: 19941048]
  202. Bedi N, Chilvers C, Churchill R, et al. Assessing effectiveness of treatment of depression in primary care. Br J Psychiatr. 2000;177(4):312–8. OVID-AMED. Exclude: Not an eligible population treatment. [PubMed: 11116771]
  203. Bee PE, Bower P, Gilbody S, et al. Improving health and productivity of depressed workers: A pilot randomized controlled trial of telephone cognitive behavioral therapy delivery in workplace settings. Gen Hosp Psychiatry. 2010;32(3):337–40. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 20430241]
  204. Beets MW, Mitchell E. Effects of yoga on stress, depression, and health-related quality of life in a nonclinical, bi-ethnic sample of adolescents: A pilot study. Hispanic Health Care Int. 2010;8(1):47–53. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  205. Behnke K, Jensen GS, Graubaum HJ, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther. 2002;19(1):43–52. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12008860]
  206. Bell AC, D’Zurilla TJ. Problem-solving therapy for depression: A meta-analysis. Clin Psychol Rev. 2009;29(4):348–53. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19299058]
  207. Bell IR, Edman JS, Morrow FD, et al. Brief communication. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr. 1992;11(2):159–63. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1578091]
  208. Bell KM, Plon L, Bunney WE Jr, et al. S-adenosylmethionine treatment of depression: A controlled clinical trial. Am J Psychiatry. 1988;145(9):1110–4. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3046382]
  209. Bell KM, Potkin SG, Carreon D, et al. S-adenosylmethionine blood levels in major depression: Changes with drug treatment. Acta Neurol Scand. 1994 Suppl:154–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7941961]
  210. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res. 1990;10(6):355–60. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 2099360]
  211. Bellino S, Zizza M, Rinaldi C, et al. Combined treatment of major depression in patients with borderline personality disorder: A comparison with pharmacotherapy. Can J Psychiatr. 2006;51(7):453–60. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16838827]
  212. Bellino S, Zizza M, Rinaldi C, et al. Combined therapy of major depression with concomitant borderline personality disorder: Comparison of interpersonal and cognitive psychotherapy. Can J Psychiatr. 2007;52(11):718–25. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18399039]
  213. Belsher G, Wilkes TCR, Rush AJ. An open, multisite pilot study of cognitive therapy for depressed adolescents. J Psychother Pract Res. 1995;4(1):52–66. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC3330382] [PubMed: 22700213]
  214. Beltman MW, Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: Meta-analysis of randomised controlled trials. Br J Psychiatr. 2010;197(1):11–9. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20592427]
  215. Benedetti F, Colombo C, Pontiggia A, et al. Morning light treatment hastens the antidepressant effect of citalopram: A placebo-controlled trial. J Clin Psychiatry. 2003;64(6):648–53. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12823078]
  216. Benkert O, Szegedi A, Wetzel H, et al. Dose escalation vs continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand. 1997;95(4):288–96. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9150822]
  217. Bennett CF. Treatment effects of acupuncture on anxiety and depression in working women University of South Carolina. 1997. EBSCO-CINAHL. Exclude: Not an eligible study design.
  218. Bennett JA. Combined thioridazine and desipramine: Early antidepressant response. Psychopharmacol. 1984;82(3):263–5. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 6425911]
  219. Benton T, Staab J, Evans DL. Medical co-morbidity in depressive disorders. Ann Clin Psychiatr. 2007;19(4):289–303. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18058286]
  220. Berger S, Schad T, Von WV, et al. Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS. 2008;22(6):767–75. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18356607]
  221. Bergman J, Miodownik C, Palatnik A, et al. Efficacy of bupropion XR in treatment-resistant elderly patients: A case series study. Clin Neuropharmacol. 2011;34(1):17–20. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 21206361]
  222. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106–16. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12813116]
  223. Berlanga C, Ortega-Soto HA, Ontiveros M, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. 1992;44(3):257–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1289923]
  224. Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord. 1995;34(3):187–92. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7560546]
  225. Berlanga C, Mendieta D, Alva G, et al. Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression. J Womens Health. 2003;12(1):33–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12639367]
  226. Berlim MT, Pargendler J, Brenner J, et al. Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants. Psychiatry Res. 2007;153(3):253–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 17675247]
  227. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods. Can J Psychiatr. 2007;52(1):46–54. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17444078]
  228. Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696–707. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17521891]
  229. Berman RB, Fava M, Thase ME, et al. The third consecutive, positive, double-blind, placebo controlled trial of aripiprazole augmentation in the treatment of major depression. Am Coll Neuropsychopharmacol Ann Meeting Abst. 2008 [Abstract]
  230. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154(1):37–43. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 8988956]
  231. Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. Biol Psychiatr. 1999;45(9):1170–7. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 10331109]
  232. Bernardo CG, Singh V, Thompson PM. Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders. Expert Opinion on Drug Safety. 2008;7(4):435–45. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18613807]
  233. Bernstein GA, Borchardt CM, Perwien AR, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2000;39(3):276–83. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 10714046]
  234. Berstrom J, Hollandare F, Carlbring P, et al. Treatment of depression via the Internet: A randomized trial of a self-help programme. J Telemed Telecare. 2003;9(Suppl 2):85. OVID-PsycINFO. Exclude: Not an eligible study design.
  235. Bertschy G, Ragama-Pardos E, Ait-Ameur A, et al. Lithium augmentation in venlafaxine non-responders: An open study. Eur Psychiatr. 2003;18(6):314–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14611927]
  236. Beusterien KM, Buesching DP, Robison RN, et al. Evaluation of an information exchange program for primary care patients with depression. Dis Manage. 2000;3(1):1–9. OVID-Embase. Exclude: Not an eligible study design.
  237. Beutler LE, Scogin F, Kirkish P, et al. Group cognitive therapy and alprazolam in the treatment of depression in older adults. J Consult Clin Psychol. 1987;55(4):550–6. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 3624611]
  238. Beutler LE, Machado PP, Engle D, et al. Differential patientxtreatment maintenance among cognitive, experiential, and self-directed psychotherapies. J Psychother Integrat. 1993;3(1):15–31. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  239. Bhar SS, Gelfand LA, Schmid SP, et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. J Affect Disord. 2008;110(1–2):161–6. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2566850] [PubMed: 18276017]
  240. Bharucha AJ, Dew MA, Miller MD, et al. Psychotherapy in long-term care: A review. J Am Med Dir Assoc. 2006;7(9):568–80. EBSCO-CINAHL. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17095422]
  241. Bichescu D, Neuner F, Schauer M, et al. Narrative exposure therapy for political imprisonment-related chronic posttraumatic stress disorder and depression. Behav Res Ther. 2007;45(9):2212–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17288990]
  242. Bidzinski A, Swiecicki L, Tonderska A, et al. Effects of phototherapy on the activities of MAO, DBH, pseudocholinesterase and upon choline transport in erythrocytes of patients with seasonal and non-seasonal depression. New Trends Exp Clin Psychiatr. 1996;12(3):175–8. OVID-Embase. Exclude: Not an eligible study design.
  243. Biegel GM, Brown KW, Shapiro SL, et al. Mindfulness-based stress reduction for the treatment of adolescent psychiatric outpatients: A randomized clinical trial. J Consult Clin Psychol. 2009;77(5):855–66. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19803566]
  244. Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008;65(4):558–64. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2291379] [PubMed: 18070221]
  245. Bilich LL, Deane FP, Phipps AB, et al. Effectiveness of bibliotherapy self-help for depression with varying levels of telephone helpline support. Clin Psychol Psychother. 2008;15(2):61–74. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19115429]
  246. Bindemann S, Soukop M, Kaye SB. Randomised controlled study of relaxation training. Eur J Canc. 1991;27(2):170–4. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 1827283]
  247. Binder EB, Owens MJ, Liu W, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatr. 2010;67(4):369–79. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20368512]
  248. Birkenhager TK, Vegt M, Nolen WA. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression. Pharmacopsychiatr. 1997;30(1):23–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9065966]
  249. Birkenhager TK, van den Broek WW, Mulder PG, et al. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. Am J Psychiatry. 2004;161(11):2060–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15514407]
  250. Birkenhager TK, van den Broek WW, Moleman P, et al. Outcome of a 4-step treatment algorithm for depressed inpatients. J Clin Psychiatry. 2006;67(8):1266–71. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 16965206]
  251. Birmaher B, Waterman GS, Ryan ND, et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with “treatment-resistant” major depression. J Am Acad Child Adolesc Psychiatry. 1998;37(5):527–35. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9585655]
  252. Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatr. 2000;57(1):29–36. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10632230]
  253. Birnie K, Garland SN, Carlson LE. Psychological benefits for cancer patients and their partners participating in mindfulness-based stress reduction (MBSR) Psychooncol. 2010;19(9):1004–9. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 19918956]
  254. Bjerkenstedt L, Edman GV, Alken RG, et al. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: A randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci. 2005;255(1):40–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15538592]
  255. Blackburn IM, Bishop S, Glen AI, et al. The efficacy of cognitive therapy in depression: A treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatr. 1981;139:181–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7317698]
  256. Blackburn IM, Bishop S. Changes in cognition with pharmacotherapy and cognitive therapy. Br J Psychiatr. 1983;143:609–17. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6661604]
  257. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord. 1986;10(1):67–75. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 2939125]
  258. Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatr. 1997;171:328–34. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9373420]
  259. Blake H, Mo P, Malik S, et al. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil. 2009;23(10):873–87. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19675114]
  260. Blanch J, Rousaud A, Hautzinger M, et al. Assessment of the efficacy of a cognitive-behavioural group psychotherapy programme for HIV-infected patients referred to a consultation-liaison psychiatry department. Psychother Psychosom. 2002;71(2):77–84. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11844943]
  261. Blenkiron P. Coping with depression: A pilot study to assess the efficacy of a self-help audio cassette. Br J Gen Pract. 2001;51(466):366–70. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC1314000] [PubMed: 11360700]
  262. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15(3):217–22. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7636000]
  263. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005;66(Suppl 8):30–40. Exclude: Not an eligible study design. [PubMed: 16336034]
  264. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457–65. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 19345072]
  265. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study. Am J Psychiatry. 2010;167(3):281–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20008946]
  266. Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacol. 1997;16(5):333–8. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 9109104]
  267. Blitzer LE, Atchison-Nevel DJ, Kenny MC. Using acupuncture to treat major depressive disorder: A pilot investigation. Clin Acupunc Oriental Med. 2003;4(4):144–7. OVID-Embase. Exclude: Not an eligible study design.
  268. Bloch M, Schwartzman Y, Bonne O, et al. Concurrent treatment of nonresistant major depression with desipramine and lithium: A double-blind, placebo-controlled study. J Clin Psychopharmacol. 1997;17(1):44–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9004056]
  269. Blom MB, Jonker K, Dusseldorp E, et al. Combination treatment for acute depression is superior only when psychotherapy is added to medication. Psychother Psychosom. 2007;76(5):289–97. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17700049]
  270. Blumenthal JA, Emery CF, Rejeski WJ. The effects of exercise training on psychosocial functioning after myocardial infarction. J Cardpulm Rehabil. 1988;8(5):183–93. OVID-Embase. Exclude: Not an eligible population treatment.
  271. Blumenthal JA, Babyak MA, Moore KA, et al. Effects of exercise training on older patients with major depression. Arch Intern Med. 1999;159(19):2349–56. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10547175]
  272. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med. 2007;69(7):587–96. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2702700] [PubMed: 17846259]
  273. Blumer D. Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. J Clin Psychiatr. 1997;58(1):3–11. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 9055830]
  274. Bockting CL, Schene AH, Spinhoven P, et al. Preventing relapse/recurrence in recurrent depression with cognitive therapy: A randomized controlled trial. J Consult Clin Psychol. 2005;73(4):647–57. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16173852]
  275. Bockting CL, Spinhoven P, Wouters LF, et al. Long-term effects of preventive cognitive therapy in recurrent depression: A 5.5-year follow-up study. J Clin Psychiatr. 2009;70(12):1621–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20141705]
  276. Bodenmann G, Plancherel B, Beach SRH, et al. Effects of coping-oriented couples therapy on depression: A randomized clinical trial. J Consult Clin Psychol. 2008;76(6):944–54. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19045963]
  277. Bodin T, Martinsen EW. Mood and self-efficacy during acute exercise in clinical depression: A randomized, controlled study. J Sport Exerc Psychol. 2004;26(4):623–33. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  278. Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7714228]
  279. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58(4):137–45. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9164423]
  280. Boer Peter CAM, Wiersma D, Russo S, et al. Paraprofessionals for anxiety and depressive disorders. Cochrane Database Syst Rev. 2005;(2) Art No:CD004688. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15846727]
  281. Bogner HR, Morales KH, Post EP, et al. Diabetes, depression, and death: A randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT) Diabet Care. 2007;30(12):3005–10. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2803110] [PubMed: 17717284]
  282. Bohlmeijer E, Prenger R, Taal E, et al. The effects of mindfulness-based stress reduction therapy on mental health of adults with a chronic medical disease: A meta-analysis. J Psychosom Res. 2010;68(6):539–44. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20488270]
  283. Bolton P, Bass J, Neugebauer R, et al. Group interpersonal psychotherapy for depression in rural Uganda: A randomized controlled trial. JAMA. 2003;289(23):3117–24. Exclude: Not an eligible population treatment. [PubMed: 12813117]
  284. Bond M, Perry JC. Psychotropic medication use, personality disorder and improvement in long-term dynamic psychotherapy. J Nerv Ment Dis. 2006;194(1):21–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16462551]
  285. Bondolfi G, Lissner C, Kosel M, et al. Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol. 2000;3(1):55–60. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 11343579]
  286. Bondolfi G, Jermann F, der Linden MV, et al. Depression relapse prophylaxis with mindfulness-based cognitive therapy: Replication and extension in the Swiss health care system. J Affect Disord. 2010;122(3):224–31. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2866251] [PubMed: 19666195]
  287. Bonnet LH. Effects of aerobic exercise in combination with Cognitive Therapy on self-reported depression. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  288. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d’Experimentation Psychopharmacologique. Am J Psychiatry. 1998;155(10):1346–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9766765]
  289. Boren JJ, Leventhal AM, Edmund PH. Just how effective are antidepressant medications? Results of a major new study. J Contemp Psychother. 2009;39(2):93–100. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI.
  290. Borghcrini G, Conforti D, Cognolato S, et al. Efficacy and tolerability of venlafaxine in patients hospitalized with moderate to severe depression: An open-label pilot study. Curr Ther Res Clin Exp. 1999;60(12):672–80. OVID-Embase. Exclude: Not an eligible study design.
  291. Bornstein S. Cross-over trial comparing the antidepressant effects of amineptine and maprotiline. Curr Med Res Opin. 1979;6(2):107–10. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 380910]
  292. Bortolotti B, Menchetti M, Bellini F, et al. Psychological interventions for major depression in primary care: A meta-analytic review of randomized controlled trials. Gen Hosp Psychiatry. 2008;30(4):293–302. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18585531]
  293. Borup C, Unden M. Combined fluoxetine and disulfiram treatment of alcoholism with comorbid affective disorders: A naturalistic outcome study, including quality of life measurements. Eur Psychiatr. 1994;9(2):83–9. OVID-Embase. Exclude: Not an eligible study design.
  294. Bosmans JE, Hermens MLM, de Bruijne MC, et al. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. J Affect Disord. 2008;111(1):106–12. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18342952]
  295. Bosmans JE, van Schaik DJF, de Bruijne MC, et al. Are psychological treatments for depression in primary care cost-effective? J Ment Health Policy Econom. 2008;11(1):3–15. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18424872]
  296. Bosscher RJ. Running and mixed physical exercises with depressed psychiatric patients. Int J Sport Psychol. 1993;24(2):170–84. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  297. Bosworth HB, Hays JC, George LK, et al. Psychosocial and clinical predictors of unipolar depression outcome in older adults. Int J Geriatr Psychiatry. 2002;17(3):238–46. Exclude: Not an eligible study design. [PubMed: 11921152]
  298. Bottlender R, Rudolf D, Jager M, et al. Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. Eur Psychiatr. 2002;17(4):200–5. Exclude: Not an eligible study design. [PubMed: 12231265]
  299. Bouckoms A, Mangini L. Pergolide: An antidepressant adjuvant for mood disorders? Psychopharmacol Bull. 1993;29(2):207–11. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 8290667]
  300. Boulos C, Kutcher S, Gardner D, et al. An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol. 1992;2(2):103–11. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 19630647]
  301. Boulton DW, Balch AH, Royzman K, et al. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: Studies in healthy subjects and in patients with major depressive disorder. J Psychopharmacol. 2010;24(4):537–46. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18832427]
  302. Boury M, Treadwell T, Kumar VK. Integrating psychodrama and cognitive therapy: An exploratory study. Int J Action Meth. 2001;54(1):13–37. OVID-PsycINFO. Exclude: Not an eligible study design.
  303. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997;(4 Suppl):534–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9180827]
  304. Bower P, Byford S, Sibbald B, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: Cost effectiveness. Br Med J. 2000;321(7273):1389–92. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC27543] [PubMed: 11099285]
  305. Bowers WA. Treatment of depressed in-patients: Cognitive therapy plus medication, relaxation plus medication, and medication alone. Br J Psychiatr. 1990;156:73–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2404539]
  306. Bowman D, Scogin F, Lyrene B. The efficacy of self-examination therapy and cognitive bibliotherapy in the treatment of mild to moderate depression. Psychother Res. 1995;5(2):131–40. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  307. Bowman V, Ward LC, Bowman D, et al. Self-examination therapy as an adjunct treatment for depressive symptoms in substance abusing patients. Addict Behav. 1996;21(1):129–33. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8729714]
  308. Boyd GM. Effects of group therapy on levels of depression of family caregivers of patients with dementia residing in nursing homes. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  309. Bradley RH, Barkin RL, Jerome J, et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther. 2003;10(5):318–23. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12975715]
  310. Brajkovic L, Jevtovic S, Bilic V, et al. The efficacy of a brief supportive psychodynamic therapy in treating anxious-depressive disorder in Daily Hospital. Coll Antropol. 2009;33(1):245–51. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19408633]
  311. Bramesfeld A, Adler G, Brassen S, et al. Day-clinic treatment of late-life depression. Int J Geriatr Psychiatry. 2001;16(1):82–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11180490]
  312. Bransfield RC. Potential uses of modafinil in psychiatric disorders. J Appl Res. 2004;4(2):198–207. OVID-Embase. Exclude: Not an eligible study design.
  313. Brattstrom A. Long-term effects of St. John’s wort (Hypericum perforatum) treatment: A 1-year safety study in mild to moderate depression. Phytomed. 2009;16(4):277–83. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19299116]
  314. Brenes GA, Williamson JD, Messier SP, et al. Treatment of minor depression in older adults: A pilot study comparing sertraline and exercise. Aging Ment Health. 2007;11(1):61–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2885010] [PubMed: 17164159]
  315. Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther. 2000;22(4):411–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10823363]
  316. Brent D, Onorato M, Enrile A, et al. Treatment of resistant depression in adolescents (TORDIA) 2004. Wiley-CCTR. Exclude: Not an eligible guideline.
  317. Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatr. 1997;54(9):877–85. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9294380]
  318. Brent DA, Birmaher B. Adolescent depression. N Engl J Med. 2002;347(9):667–71. Exclude: Not an eligible guideline. [PubMed: 12200555]
  319. Brent DA. The treatment of SSRI-resistant depression in adolescents (TORDIA): In search of the best next step. Depress Anxiety. 2009;26(10):871–4. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC4083507] [PubMed: 19798756]
  320. Brent David A, Roth Claudia M, Holder Diane P, et al. Psychosocial interventions for treating adolescent suicidal depression: A comparison of three psychosocial interventions. 1996. pp. 187–206. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  321. Bressi C, Porcellana M, Marinaccio PM, et al. Short-term psychodynamic psychotherapy versus treatment as usual for depressive and anxiety disorders: A randomized clinical trial of efficacy. J Nerv Ment Dis. 2010;198(9):647–52. OVID-Embase. Exclude: Not an eligible population/treatment. [PubMed: 20823726]
  322. Bricker JB, Russo J, Stein MB, et al. Does occasional cannabis use impact anxiety and depression treatment outcomes? Results from a randomized effectiveness trial. Depress Anxiety. 2007;24(6):392–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17096386]
  323. Bridge LR, Benson P, Pietroni PC, et al. Relaxation and imagery in the treatment of breast cancer. Br Med J. 1988;297(6657):1169–72. Wiley-CCTR. Exclude: Not an eligible population treatment. [PMC free article: PMC1835041] [PubMed: 3144333]
  324. Bristow M, Bright J. Group cognitive therapy in chronic depression: Results from two intervention studies. Behav Cognit Psychother. 1995;23(4):373–80. OVID-Embase. Exclude: Not an eligible study design.
  325. Brittle N, Patel S, Wright C, et al. An exploratory cluster randomized controlled trial of group exercise on mobility and depression in care home residents. Clin Rehabil. 2009;23(2):146–54. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19164402]
  326. Britton WB, Haynes PL, Fridel KW, et al. Polysomnographic and subjective profiles of sleep continuity before and after mindfulness-based cognitive therapy in partially remitted depression. Psychosom Med. 2010;72(6):539–48. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20467003]
  327. Brockman B, Poynton A, Ryle A, et al. Effectiveness of time-limited therapy carried out by trainees: Comparison of two methods. Br J Psychiatr. 1987;151:602–10. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 3446303]
  328. Brodie NH, McGhie RL, O’Hara H, et al. Once daily administration of a fluphenazine/nortriptyline preparation in the treatment of mixed anxiety/depressive states. Curr Med Res Opin. 1976;4(5):346–52. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 795608]
  329. Brody BL, Roch-Levecq AC, Kaplan RM, et al. Age-related macular degeneration: Self-management and reduction of depressive symptoms in a randomized, controlled study. J Am Geriatr Soc. 2006;54(10):1557–62. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 17038074]
  330. Brollier C, Hamrick N, Jacobson B. Aerobic exercise: A potential occupational therapy modality for adolescents with depression. Occup Ther Ment Health. 1993;12(4):19–29. OVID-Embase. Exclude: Not an eligible study design.
  331. Broota A, Dhir R. Efficacy of two relaxation techniques in depression. J Pers Clin Stud. 1990;6(1):83–90. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  332. Brothers BM, Yang HC, Strunk DR, et al. Cancer patients with major depressive disorder: Testing a biobehavioral/cognitive behavior intervention. J Consult Clin Psychol. 2011;79(2):253–60. OVID-PsycINFO. Exclude: Not an eligible study design. [PMC free article: PMC3752923] [PubMed: 21341891]
  333. Brown C, Schulberg HC, Madonia MJ, et al. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;(153):1293–300. Exclude: Not an eligible population treatment. [PubMed: 8831437]
  334. Brown C, Schulberg HC, Sacco D, et al. Effectiveness of treatments for major depression in primary medical care practice: A post hoc analysis of outcomes for African American and white patients. J Affect Disord. 1999;53(2):185–92. Exclude: Not an eligible population treatment. [PubMed: 10360414]
  335. Brown ES, Gan V, Jeffress J, et al. Antidepressant treatment of caregivers of children with asthma. Psychosom. 2008;49(5):420–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18794511]
  336. Brown JSL, Elliott SA, Boardman J, et al. Meeting the unmet need for depression services with psycho-educational self-confidence workshops: Preliminary report. Br J Psychiatr. 2004;185(6):511–5. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 15572743]
  337. Brown JSL, Elliott SA, Boardman J, et al. Can the effects of a 1-day CBT psychoeducational workshop on self-confidence be maintained after 2 years? A naturalistic study. Depress Anxiety. 2008;25(7):632–40. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17941095]
  338. Brown MA, Goldstein-Shirley J, Robinson J, et al. The effects of a multi-modal intervention trial of light, exercise, and vitamins on women’s mood. Women Health. 2001;34(3):93–112. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11708689]
  339. Brown MA, Shirley JL. Enhancing women’s mood and energy: A research-based program for subthreshold depression using light, exercise, and vitamins. Holist Nurs Pract. 2005;19(6):278–84. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16269947]
  340. Brown MA, Munford A. Rehabilitation of post MI depression and psychological invalidism: A pilot study. Int J Psychiatry Med. 1983;13(4):291–8. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 6142868]
  341. Brown RA, Evans DM, Miller IW, et al. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol. 1997;65(5):715–26. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1885208] [PubMed: 9337490]
  342. Brown RP, Frances A, Kocsis JH, et al. Psychotic vs. nonpsychotic depression: Comparison of treatment response. J Nerv Ment Dis. 1982;170(10):635–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6125562]
  343. Brown RA, Lewinsohn PM. A psychoeducational approach to the treatment of depression: Comparison of group, individual, and minimal contact procedures. J Consult Clin Psychol. 1984;52(5):774–83. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 6501663]
  344. Brown RA, Evans DM, Miller IW, et al. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol. 1997;65(5):715–26. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PMC free article: PMC1885208] [PubMed: 9337490]
  345. Brown SA, Glasner-Edwards SV, Tate SR, et al. Integrated cognitive behavioral therapy versus twelve-step facilitation therapy for substance-dependent adults with depressive disorders. J Psychoactive Drugs. 2006;38(4):449–60. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 17373561]
  346. Brown WH Jr. A cognitive-behavorial intervention to decrease symptoms of depression, anxiety and somatic complaints in adults diagnosed with Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) Brown. 2003. OVID-PsycINFO. Exclude: Not an eligible study design.
  347. Browne G, Steiner M, Roberts J, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord. 2002;68(2–3):317–30. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12063159]
  348. Browne M, Lapierre YD, Hrdina PD, et al. Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol. 1990;5(2):103–10. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2116474]
  349. Bruce ML, Ten Have TR, Reynolds CF III, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: A randomized controlled trial. JAMA. 2004;291(9):1081–91. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14996777]
  350. Bruijn JA, Moleman P, Mulder PG, et al. Comparison of 2 treatment strategies for depressed inpatients: Imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry. 1998;59(12):657–63. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9921699]
  351. Brunoni AR, Fraguas J, Fregni F. Pharmacological and combined interventions for the acute depressive episode: Focus on efficacy and tolerability. Therapeut Clin Risk Manag. 2009;5(1):897–910. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2781064] [PubMed: 19956554]
  352. Brunstein-Klomek A, Zalsman G, Mufson L. Interpersonal psychotherapy for depressed adolescents (IPT-A) Isr J Psychiatry Relat Sci. 2007;44(1):40–6. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17665810]
  353. Brunwasser SM, Gillham JE, Kim ES. A meta-analytic review of the Penn Resiliency Program’s effect on depressive symptoms. J Consult Clin Psychol. 2009;77(6):1042–54. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19968381]
  354. Bryan C, Songer T, Brooks MM, et al. The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry. 2010;32(1):33–41. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 20114126]
  355. Bschor T, Berghöfer A, Ströhle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol. 2002;22(4):427–30. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 12172345]
  356. Bschor T, Baethge C. No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy: Review. Acta Psychiatr Scand. 2010;121(3):174–9. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19703121]
  357. Bschor T, Adli M, Baethge C, et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacol. 2002;27(3):470–8. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 12225704]
  358. Bschor T, Baethge C, Adli M, et al. Association between responses to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiatr Res. 2003;37(2):135–43. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 12842167]
  359. Bschor T, Baethge C, Adli M, et al. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety. 2003;17(1):43–8. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 12577277]
  360. Bulloch AG, Patten SB. Non-remission of depression in the general population as assessed by the HAMD-7 scale. Depress Anxiety. 2008;25(5):393–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17948276]
  361. Bump GM, Reynolds CF III, Smith G, et al. Accelerating response in geriatric depression: A pilot study combining sleep deprivation and paroxetine. Depress Anxiety. 1997;6(3):113–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9442985]
  362. Bump GM, Mulsant BH, Pollock BG, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety. 2001;13(1):38–44. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11233459]
  363. Burnand Y, Andreoli A, Kolatte E, et al. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv. 2002;53(5):585–90. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11986508]
  364. Burton E, Stice E, Bearman SK, et al. Experimental test of the affect-regulation theory of bulimic symptoms and substance use: A randomized trial. Int J Eat Disord. 2007;40(1):27–36. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1761129] [PubMed: 16958129]
  365. Butler LD, Waelde LC, Hastings TA, et al. Mediation with Yoga, group therapy with hypnosis, and psychoeducation for long-term depressed mood: A randomized pilot trial. J Clin Psychiatry. 2008;64(7):806–20. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 18459121]
  366. Butler S, Agius M, Holt C, et al. An audit to identify factors that are more commonly associated with depressed patients on augmentation therapy under the Befordshire East Community Mental Health Team (BECMHT) Psychiatria Danubina. 2010;22 Suppl-9 OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 21057417]
  367. Buysse DJ, Reynolds CF III, Houck PR, et al. Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy? J Clin Psychiatry. 1997;58(10):426–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9375592]
  368. Byford S, Barrett B, Roberts C, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression. Br J Psychiatr. 2007;191:521–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18055956]
  369. Cabanero M, Laje G, Detera-Wadleigh S, et al. Association study of phosphodiesterase genes in the sequenced treatment alternatives to relieve depression sample. Pharmacogenetics Genom. 2009;19(3):235–8. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2819180] [PubMed: 19214142]
  370. Cabiya JJ, Padilla-Cotto L, Gonzalez K, et al. Effectiveness of a cognitive-behavioral intervention for Puerto Rican children. Revista Interamericana de Psicologia. 2008;42(2):195–202. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  371. Cahill J, Barkham M, Hardy G, et al. Outcomes of patients completing and not completing cognitive therapy for depression. Br J Clin Psychol. 2003;42(Pt:2):2–43. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12828803]
  372. Cain JW. Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a “therapeutic window” J Clin Psychiatry. 1992;53(8):272–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1500403]
  373. Calabrese C, Londborg PD, Shelton MD, et al. Citalopram treatment of paroxetine-intolerant depressed patients. J Clin Psychiatry. 2003;64:564–7. Exclude: Not an eligible study design.
  374. Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707–13. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3153866] [PubMed: 18611150]
  375. Calabrese JR, Londborg PD, Shelton MD, et al. Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry. 2003;64(5):562–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12755660]
  376. Calcedo Ordonez A, Arosamene X, Otero Perez FJ, et al. Clomipramine/bentazepam combination in the treatment of major depressive disorders. Hum Psychopharmacol Clin Exp. 1992;7(2):115–22. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  377. Calear AL, Christensen H, Mackinnon A, et al. The YouthMood Project: A cluster randomized controlled trial of an online cognitive behavioral program with adolescents. J Consult Clin Psychol. 2009;77(6):1021–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19968379]
  378. Calear AL, Christensen H. Review of internet-based prevention and treatment programs for anxiety and depression in children and adolescents. Med J Aust. 2010;192(11 Suppl):S12–4. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20528700]
  379. Calear AL, Christensen H. Systematic review of school-based prevention and early intervention programs for depression. J Adolesc. 2010;33(3):429–38. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19647310]
  380. Caliyurt O, Guducu F. Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. J Affect Disord. 2005;88(1):75–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15967511]
  381. Campbell JM. Treating depression in well older adults: Use of diaries in cognitive therapy. Issues Ment Health Nurs. 1992;13(1):19–29. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1737700]
  382. Candy B, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev. 2008;(2) Art No:CD006722. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18425966]
  383. Canna MA. Controlled evaluation of the effects of expressive writing on subsequent cognitive behavioral group treatment with an anxious/depressed sample. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  384. Cantor DS, Stevens E. QEEG correlates of auditory-visual entrainment treatment efficacy of refractory depression. J Neurother. 2009;13(2):100–8. OVID-Embase. Exclude: Not an eligible population treatment.
  385. Cao Y, Song L, Wang Z. Controlled study of venlafaxine combined with quetiapine in refractory depression. J Clin Psychosom Dis. 2005;11(2):129–30. Wiley-CCTR. Exclude: Not an eligible study design.
  386. Cape J, Whittington C, Buszewicz M, et al. Brief psychological therapies for anxiety and depression in primary care: Meta-analysis and meta-regression. BMC Med. 2010;8(Art No.:38) OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2908553] [PubMed: 20579335]
  387. Cappeliez P. Presentation of depression and response to group cognitive therapy with older adults. J Clin Gerontology. 2000;(6):165–74. Exclude: Not an eligible study design.
  388. Cappiello A, McDougle CJ, Malison RT, et al. Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study. Biol Psychiatr. 1995;38(11):765–7. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 8580232]
  389. Cappiello A, McDougle CJ, Delgado PL, et al. Lithium and desipramine versus desipramine alone in the treatment of severe major depression: A preliminary study. Int Clin Psychopharmacol. 1998;13(5):191–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9817623]
  390. Carney CE, Segal ZV, Edinger JD, et al. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry. 2007;68(2):254–60. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17335324]
  391. Carney MW, Edeh J, Bottiglieri T, et al. Affective illness and S-adenosyl methionine: A preliminary report. Clin Neuropharmacol. 1986;9(4):379–85. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2425961]
  392. Carney MW, Chary TK, Bottiglieri T, et al. Switch and S-adenosylmethionine. Ala J Med Sci. 1988;25(3):316–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3052141]
  393. Carney RM, McKevitt PM, Goldberg AP. Psychological effects of exercise training in hemodialysis patients. Nephron. 1983;33(3):179–81. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 6843745]
  394. Carney RM, Templeton B, Hong BA, et al. Exercise training reduces depression and increases the performance of pleasant activities in hemodialysis patients. Nephron. 1987;47(3):194–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3317091]
  395. Carney RM, Freedland KE, Rubin EH, et al. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: A randomized controlled trial. JAMA. 2009;302(15):1651–7. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3477788] [PubMed: 19843899]
  396. Carpenter KM, Aharonovich E, Smith JL, et al. Behavior therapy for depression in drug dependence (BTDD): Results of a stage Ia therapy development pilot. Am J Drug Alcohol Abuse. 2006;32(4):541–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17127541]
  397. Carpenter KM, Smith JL, Aharonovich E, et al. Developing therapies for depression in drug dependence: Results of a stage 1 therapy study. Am J Drug Alcohol Abuse. 2008;34(5):642–52. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18821458]
  398. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999;60(1):45–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 10074878]
  399. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. 2000. Wiley-CCTR. Exclude: Not an eligible study design.
  400. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory major depression: Preliminary findings. 2000. Wiley-CCTR. Exclude: Not an eligible study design.
  401. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatr. 2002;51(2):183–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11822997]
  402. Carpenter LL, Leon Z, Yasmin S, et al. Do obese depressed patients respond to topiramate? A retrospective chart review. J Affect Disord. 2002;69(1–3):251–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12103474]
  403. Carpenter LL, Milosavljevic N, Schecter JM, et al. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005;66(10):1234–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16259536]
  404. Carpenter LL, Bayat L, Moreno F, et al. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res. 2008;157(1–3):123–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17976740]
  405. Carr A. Depression in young people: Description, assessment and evidence-based treatment. Dev Neurorehabil. 2008;11(1):3–15. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17943506]
  406. Carrico AW, Antoni MH, Weaver KE, et al. Cognitive-behavioural stress management with HIV-positive homosexual men: Mechanisms of sustained reductions in depressive symptoms. Chronic Illn. 2005;1(3):207–15. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17152183]
  407. Carrico AW, Antoni MH, Duran RE, et al. Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. Ann Behav Med. 2006;31(2):155–64. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16542130]
  408. Carrieri PB, Indaco A, Gentile S, et al. S-Adenosylmethionine treatment of depression in patients with Parkinsons’s disease. A double-blind, crossover study versus placebo. Curr Ther Res Clin Exp. 1990;48(1):154–60. OVID-Embase. OVID-Embase. Exclude: Not an elligible population design.
  409. Carroll BJ, Mowbray RM, Davies B. Sequential comparison of L-tryptophan with E.C.T. in severe depression. Lancet. 1970;1(7654):967–9. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 4191934]
  410. Carroll KM, Nich C, Rounsaville BJ. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. J Nerv Ment Dis. 1995;183(4):251–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7714514]
  411. Carroll S, Hides L, Catania L, et al. Integrated cognitive behaviour therapy for co-occurring substance misuse and major depression: Lessons from a youth mental health service. Australas Psychiatr. 2009;17(5):365–70. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20455796]
  412. Carta MG, Zairo F, Mellino G, et al. Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage. Clin Pract Epidemiol Ment Health. 2007. Article Number: 28. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC2228281] [PubMed: 18039392]
  413. Caruso I, Fumagalli M, Boccassini L, et al. Treatment of depression in rheumatoid arthritic patients: A comparison of S-adenosylmethionine (Samyr) and placebo in a double-blind study. Clin Trials J. 1987;24(4):305–10. OVID-Embase. Exclude: Not an eligible study design.
  414. Carvalho AF, Cavalcante JL, Castelo MS, et al. Augmentation strategies for treatment-resistant depression: A literature review. J Clin Pharm Ther. 2007;32(5):415–28. ISI:000249450400001. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17875106]
  415. Casamassima F, Huang J, Fava M, et al. Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. Am J Med Genet. 2010;(1):303–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19388002]
  416. Casciano R, Arikian SR, Tarride J-E, et al. Antidepressant selection for major depressive disorder: The budgetary impact on managed care. Drug Benefit Trends. 2000;12(5):6BH–17BH. OVID-Embase. Exclude: Not an eligible study design.
  417. Case SC. The effects of group therapy and exercise on depression and self-esteem in college students. 2003. OVID-PsycINFO. Exclude: Not an eligible study design.
  418. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: An extended follow-up. Depress Anxiety. 2004;20(3):131–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15549689]
  419. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: A 16-week pilot study. Can J Psychiatr. 2005;50(6):357–60. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15999953]
  420. Castle D, Schweitzer I, Tiller J. STAR*D: Has it taught us anything about the management of depression? Australas Psychiatr. 2009;17(5):360–4. OVID-Medline. Exclude: Systematic Review before 2005. [PubMed: 20455795]
  421. Castonguay LG, Schut AJ, Aikens DE, et al. Integrative cognitive therapy for depression: A preliminary investigation. J Psychother Integrat. 2004;14(1):4–20. OVID-PsycINFO. Exclude: Not an eligible study design.
  422. Castro M. The treatment of depression with homeopathy. Alternative Compl Ther. 1997;3(4):300–5. EBSCO-CINAHL. Exclude: Not an eligible study design.
  423. Cavanagh K, Shapiro DA, Van Den BS, et al. The effectiveness of computerized cognitive behavioural therapy in routine care. Br J Clin Psychol. 2006;45(Pt:4):4–514. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17076960]
  424. Cayiroglu S, Holub U, Zapotoczky HG. The scientific dialogue: From basic research to clinical intervention. Lisse, Netherlands: Swets & Zeitlinger Publishers; 1990. The combination of cognitive behaviour therapy and antidepressants in the treatment of depressed patients: Does it share the additional or dependent model of interaction? OVID-PsycINFO. Exclude: Not an eligible study design.
  425. Ceskova E, Nahunek K, Rysanek R, et al. Clinical experience with parenteral clomipramine and desipramine in the treatment of drug-resistant endogenous depression. Act Nerv Super. 1981;23(3):212–4. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  426. Cevasco AM, Kennedy R, Generally NR. Comparison of movement-to-music, rhythm activities, and competitive games on depression, stress, anxiety, and anger of females in substance abuse rehabilitation. J Music Ther. 2005;42(1):64–80. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15839734]
  427. Chan EKH. Efficacy of cognitive-behavioral, pharmacological, and combined treatments of depression: A meta-analysis. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  428. Chan I, Kong P, Leung P, et al. Cognitive-behavioral group program for Chinese heterosexual HIV-infected men in Hong Kong. Patient Educ Couns. 2005;56(1):78–84. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15590226]
  429. Chan MF, Chan EA, Mok E, et al. Effect of music on depression levels and physiological responses in community-based older adults. Int J Ment Health Nurs. 2009;18(4):285–94. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 19594648]
  430. Chan MF, Chan EA, Mok E. Effects of music on depression and sleep quality in elderly people: A randomised controlled trial. Complement Ther Med. 2010;18(3–4):150–9. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PubMed: 20688261]
  431. Chang M, Chen C, Huang K. Effects of music therapy on psychological health of women during pregnancy. J Clin Nurs. 2008;17(19):2580–7. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 18298503]
  432. Chang SH, Fang MC, Yang YS. Effectiveness of transcutaneous electrical acupoint stimulation for improving depressive mood status among nursing home elders in Taiwan: A pilot study. Geriatr Nurs. 2010;31(5):324–30. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20933145]
  433. Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial. BMC Psychiatr. 2008;8:73. Wiley-CCTR. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC2553785] [PubMed: 18752690]
  434. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression: Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatr. 1986;43(12):1155–61. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3022664]
  435. Chaudhry HR, Najam N, Naqvi A. The value of amineptine in depressed patients treated with cognitive behavioural psychotherapy. Hum Psychopharmacol. 1998;13(6):419–24. OVID-Embase. Exclude: Not an eligible population treatment.
  436. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: Update and clinical perspective. Curr Opin Psychiatry. 2011;24(1):10–7. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 21088586]
  437. Chen K, Chen M, Chao H, et al. Sleep quality, depression state, and health status of older adults after silver yoga exercises: Cluster randomized trial. Int J Nurs Stud. 2009;46(2):154–63. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 18947826]
  438. Chen K, Chen M, Lin M, et al. Effects of yoga on sleep quality and depression in elders in assisted living facilities. J Nurs Res. 2010;18(1):53–61. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 20220611]
  439. Chen TH, Lu RB, Chang AJ, et al. The evaluation of cognitive-behavioral group therapy on patient depression and self-esteem. Arch Psychiatr Nurs. 2006;20(1):3–11. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16442469]
  440. Chen Y, Guo JJ, Zhan S, et al. Treatment effects of antidepressants in patients with post-stroke depression: A meta-analysis. Ann Pharmacother. 2006;40(12):2115–22. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17119102]
  441. Cherkezova M, Toteva S. Acupuncture in the treatment of alcoholics with a depressive syndrome. J Russ East Eur Psychol. 1993;26(1):28–30. OVID-PsycINFO. Exclude: Not an eligible study design.
  442. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatr Allied Discipl. 2005;46(7):735–54. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15972068]
  443. Child A, Sanders J, Sigel P, et al. Meeting the psychological needs of cardiac patients: An integrated stepped-care approach within a cardiac rehabilitation setting. Br J Cardiol. 2010;17(4):175–9. EBSCO-CINAHL. Exclude: Not an eligible population/treatment.
  444. Chilvers C, Dewey M, Fielding K, et al. Antidepressant drugs and generic counselling for treatment of major depression in primary care: Randomised trial with patient preference arms. Br Med J. 2001;322(7289):772–5. Exclude: Not an eligible population treatment. [PMC free article: PMC30555] [PubMed: 11282864]
  445. Cho YC, Tsay SL. The effect of acupressure with massage on fatigue and depression in patients with end-stage renal disease. J Nurs Res. 2004;12(1):51–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15136963]
  446. Choi AN, Lee MS, Lim HJ. Effects of group music intervention on depression, anxiety, and relationships in psychiatric patients: A pilot study. J Altern Complement Med. 2008;14(5):567–70. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 18564958]
  447. Chou KL, Lee PW, Yu EC, et al. Effect of Tai Chi on depressive symptoms amongst Chinese older patients with depressive disorders: A randomized clinical trial. Int J Geriatr Psychiatry. 2004;19(11):1105–7. Exclude: Not an eligible population treatment. [PubMed: 15497192]
  448. Chouinard G, Young SN, Annable L, et al. Tryptophan-nicotinamide, imipramine and their combination in depression: A controlled study. Acta Psychiatr Scand. 1979;59(4):395–414. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 155389]
  449. Christensen H, Griffiths KM, Korten A. Web-based cognitive behavior therapy: Analysis of site usage and changes in depression and anxiety scores. J Med Internet Res. 2002;4(1):e3. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC1761927] [PubMed: 11956035]
  450. Christensen H, Griffiths KM, Korten AE, et al. A comparison of changes in anxiety and depression symptoms of spontaneous users and trial participants of a cognitive behavior therapy website. J Med Internet Res. 2004;6(4):e46. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC1550629] [PubMed: 15631970]
  451. Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: Randomised controlled trial. Br Med J. 2004;328(7434):265. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC324455] [PubMed: 14742346]
  452. Christensen H, Griffiths KM, Mackinnon AJ, et al. Online randomized controlled trial of brief and full cognitive behaviour therapy for depression. Psychol Med. 2006;36(12):1737–46. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16938144]
  453. Chronis AM, Gamble SA, Roberts JE, et al. Cognitive-behavioral depression treatment for mothers of children with attention-deficit/hyperactivity disorder. Behav Ther. 2006;37(2):143–58. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16942968]
  454. Chu BC, Harrison TL. Disorder-specific effects of CBT for anxious and depressed youth: A meta-analysis of candidate mediators of change. Clin Child Fam Psychol Rev. 2007;10(4):352–72. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17985239]
  455. Chu I-H, Buckworth J, Kirby TE, et al. Effect of exercise intensity on depressive symptoms in women. Ment Health Phys Activ. 2009;2(1):37–43. OVID-Embase. Exclude: Not an eligible population treatment.
  456. Chu IH. Effect of exercise intensity during aerobic training on depressive symptoms in initially sedentary depressed women. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  457. Chun DS. An assessment of support group participation on depression and adherence in veterans with hepatitis C. 2002. OVID-PsycINFO. Exclude: Not an eligible study design.
  458. Chung L, Tsai P, Liu B, et al. Home-based deep breathing for depression in patients with coronary heart disease: A randomised controlled trial. Int J Nurs Stud. 2010;47(11):1346–53. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PubMed: 20462580]
  459. Church J. The application of cognitive-behavioural therapy for depression to people with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) Psychooncol. 1998;7(2):78–88. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 9589506]
  460. Ciarambino T, Ferrara N, Castellino P, et al. Effects of a 6-days-a-week low protein diet regimen on depressive symptoms in young-old type 2 diabetic patients. Nutr. 2011;27(1):46–9. OVID-Embase. Exclude: Not an eligible population/treatment. [PubMed: 20472399]
  461. Ciechanowski P, Wagner E, Schmaling K, et al. Community-integrated home-based depression treatment in older adults: A randomized controlled trial. JAMA. 2004;291(13):1569–77. Exclude: Not an eligible population treatment. [PubMed: 15069044]
  462. Cipher DJ, Clifford PA, Roper KD. The effectiveness of geropsychological treatment in improving pain, depression, behavioral disturbances, functional disability, and health care utilization in long-term care. Clin Gerontol. 2007;30(3):23–40. OVID-Embase. Exclude: Not an elligible population design.
  463. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: A review of the epidemiology, risk and treatment evidence. Med J Aust. 2009;190(7 Suppl):S54–60. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19351294]
  464. Clarke G, Reid E, Eubanks D, et al. Overcoming depression on the Internet (ODIN): A randomized controlled trial of an Internet depression skills intervention program. J Med Internet Res. 2002;4(3):E14. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1761939] [PubMed: 12554545]
  465. Clarke G, DeBar L, Lynch F, et al. A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. J Am Acad Child Adolesc Psychiatry. 2005;44(9):888–98. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16113617]
  466. Clarke G, Eubanks D, Reid E, et al. Overcoming Depression on the Internet (ODIN) (2): A randomized trial of a self-help depression skills program with reminders. J Med Internet Res. 2005;7(2):e16. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1550641] [PubMed: 15998607]
  467. Clarke GN, Hawkins W, Murphy M, et al. Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: A randomized trial of a group cognitive intervention. J Am Acad Child Adolesc Psychiatry. 1995;34(3):312–21. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7896672]
  468. Clarke GN, Rohde P, Lewinsohn PM, et al. Cognitive-behavioral treatment of adolescent depression: Efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry. 1999;38(3):272–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10087688]
  469. Clarke GN, Hornbrook M, Lynch F, et al. A randomized trial of a group cognitive intervention for preventing depression in adolescent offspring of depressed parents. Arch Gen Psychiatr. 2001;58(12):1127–34. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11735841]
  470. Clarke GN, Hornbrook M, Lynch F, et al. Group cognitive-behavioral treatment for depressed adolescent offspring of depressed parents in a health maintenance organization. J Am Acad Child Adolesc Psychiatry. 2002;41(3):305–13. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11886025]
  471. Clayton A, Guico-Pabia C. Recognition of depression among women presenting with menopausal symptoms. Menopause. 2008;15(4):758–67. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18709704]
  472. Clement K, Covertson CR, Johnson MJ, et al. St. John’s wort and the treatment of mild to moderate depression: A systematic review. Holist Nurs Pract. 2006;20(4):197–203. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16825922]
  473. Clunie F. Double blind randomised controlled trial comparing moclobemide and phenelzine in treatment resistant depression. 2001. Wiley-CCTR. Exclude: Not an eligible study design.
  474. Cocker KI, Bell DR, Kidman AD. Cognitive behaviour therapy with advanced breast cancer patients: A brief report of a pilot study. Psychooncol. 1994;3(3):233–7. OVID-Embase. Exclude: Not an eligible study design.
  475. Cockram A, McCall L, Judd F, et al. The development and pilot testing of a Focused Education and Psychotherapy Program (FEPP) for treatment of depression in general practice. Australas Psychiatr. 2002;10(3):268–74. Exclude: Not an eligible study design.
  476. Coelho HF, Boddy K, Ernst E. Massage therapy for the treatment of depression: A systematic review. Int J Clin Pract. 2008;62(2):325–33. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18081800]
  477. Cohen AJ. Treatment of anergic depression in Hashimoto’s thyroiditis with fluoxetine and d-amphetamine. Depression. 1993;1(2):110–4. OVID-PsycINFO. Exclude: Not an eligible study design.
  478. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16449615]
  479. Cohen S, O’Leary KD, Foran H. A randomized clinical trial of a brief, problem-focused couple therapy for depression. Behav Ther. 2010;41(4):433–46. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3536531] [PubMed: 21035609]
  480. Cole BS. Spiritually-focused psychotherapy for people diagnosed with cancer: A pilot outcome study. Ment Health Relig Cult. 2005;8(3):217–26. OVID-Embase. Exclude: Not an eligible population treatment.
  481. Cole JO, Schatzberg AF, Sniffen C. Trazodone in treatment resistant depression: An open study. J Clin Psychopharmacol. 1981;1(Suppl 6):49S–54S. Exclude: Not an eligible study design.
  482. Cole MG, McCusker J, Elie M, et al. Systematic detection and multidisciplinary care of depression in older medical inpatients: A randomized trial. CMAJ. 2006;174(1):38–44. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1319344] [PubMed: 16330624]
  483. Coleman E, Cesnik J, Moore AM, et al. An exploratory study of the role of psychotropic medications in the treatment of sex offenders. J Offender Rehabil. 1992;18(3–4):75–88. OVID-PsycINFO. Exclude: Not an eligible study design.
  484. Colle LM, Belair J-F, DiFeo M, et al. Extended open-label fluoxetine treatment of adolescents with major depression. J Child Adolesc Psychopharmacol. 1994;4(4):225–32. OVID-Embase. Exclude: Not an eligible study design.
  485. Collet L, Cottraux J, Ladouceur R. Cognitive therapy of depression and counterdemand effects: A pilot study. Psychol Rep. 1987;60(2):555–60. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 3588801]
  486. Collins J, Abou SMT. Rolipram: A new concept for the treatment of tricyclic resistant depression. J DRUG DEV. 1992;5(2):65–70. Wiley-CCTR. Exclude: Not an eligible population treatment.
  487. Collins RW. The treatment of depression: An integrative psychotherapy model. 1997. OVID-PsycINFO. Exclude: Not an eligible study design.
  488. Comas DL. Effects of cognitive and behavioral group treatment on the depressive symptomatology of Puerto Rican women. J Consult Clin Psychol. 1981;49(5):627–32. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 7287971]
  489. Comer EW. Integrating the health and mental health needs of the chronically ill: A group for individuals with depression and sickle cell disease. Soc Work Health Care. 2004;38(4):57–76. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15149906]
  490. Compas BE, Forehand R, Keller G, et al. Randomized controlled trial of a family cognitive-behavioral preventive intervention for children of depressed parents. J Consult Clin Psychol. 2009;77(6):1007–20. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2821830] [PubMed: 19968378]
  491. Compas BE, Champion JE, Forehand R, et al. Coping and parenting: Mediators of 12-month outcomes of a family group cognitive-behavioral preventive intervention with families of depressed parents. J Consult Clin Psychol. 2010;78(5):623–34. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3030923] [PubMed: 20873898]
  492. Congleton AB. The effect of a cognitive-behavioral group intervention on the locus of control, attributional style, and depressive symptoms of middle school students. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  493. Conn DK, Clarke D, van Reekum R. Depression in Holocaust survivors: Profile and treatment outcome in a geriatric day hospital program. Int J Geriatr Psychiatry. 2000;15(4):331–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 10767733]
  494. Conn DK, Steingart AB. Diagnosis and management of late life depression: A guide for the primary care physician. Int J Psychiatry Med. 1997;27(3):269–81. OVID-PsycINFO. Exclude: Not an eligible guideline. [PubMed: 9565728]
  495. Conn VS. Depressive symptom outcomes of physical activity interventions: Meta-analysis findings. Ann Behav Med. 2010;39(2):128–38. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2870716] [PubMed: 20422333]
  496. Connerley RC. Distant intercessory prayer as an adjunct to psychotherapy with depressed outpatients: A small-scale investigation. 2003. OVID-PsycINFO. Exclude: Not an eligible study design.
  497. Conradi HJ, de Jonge P, Kluiter H, et al. Enhanced treatment for depression in primary care: Long-term outcomes of a psycho-educational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy. Psychol Med. 2007;37(6):849–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17376257]
  498. Conradi HJ, de Jonge P, Ormel J. Cognitive-behavioural therapy v. usual care in recurrent depression. Br J Psychiatr. 2008;193(6):505–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19043158]
  499. Conradsson M, Littbrand H, Lindelof N, et al. Effects of a high-intensity functional exercise programme on depressive symptoms and psychological well-being among older people living in residential care facilities: A cluster-randomized controlled trial. Aging Ment Health. 2010;14(5):565–76. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20496181]
  500. Constantino MJ, Marnell ME, Haile AJ, et al. Integrative cognitive therapy for depression: A randomized pilot comparison. Psychother. 2008;45(2):122–34. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 22122413]
  501. Cook JW, Spring B, McChargue DE, et al. Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. Psychopharmacol. 2004;173(1–2):153–9. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1847574] [PubMed: 14727000]
  502. Cooke M, Moyle W, Shum D, et al. A randomized controlled trial exploring the effect of music on quality of life and depression in older people with dementia. J Health Psychol. 2010;15(5):765–76. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PubMed: 20603300]
  503. Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. J Clin Psychiatry. 1992;53(1):16–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1737734]
  504. Coon DW, Thompson L, Steffen A, et al. Anger and depression management: Psychoeducational skill training interventions for women caregivers of a relative with dementia. Gerontologist. 2003;43(5):678–89. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14570964]
  505. Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatr. 2007;64(6):679–88. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17548749]
  506. Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2008;11(5):685–99. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18047754]
  507. Cooper AJ, Datta SR. A placebo controlled evaluation of L-tryptophan in depression in the elderly. Can J Psychiatr. 1980;25(5):386–90. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7407745]
  508. Coppen A, Whybrow PC, Noguera R, et al. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatr. 1972;26(3):234–41. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4551048]
  509. Coppen A, Abou-Saleh MT. Lithium therapy: From clinical trials to practical management. Acta Psychiatr Scand. 1988;78(6):754–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3146892]
  510. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121–30. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10967371]
  511. Corey-Lisle PK, Birnbaum H, Greenberg P, et al. Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: A pilot study. Psychopharmacol Bull. 2003;37(3):90–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14608242]
  512. Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004;164(11):1197–204. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15197045]
  513. Corrado P, Gottlieb H. Alternative medicine. The effect of biofeedback and relaxation training on depression in chronic pain patients. Am J Pain Manage. 1999;9(1):18–21. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  514. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study. J Clin Psychiatry. 2003;64(11):1349–56. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14658950]
  515. Costa e Silva. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1998;59(7):352–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9714263]
  516. Costa Miranda V, Trufelli DC, Santos J, et al. Effectiveness of guarana (Paullinia cupana) for postradiation fatigue and depression: Results of a pilot double-blind randomized study. J Altern Compl Med. 2009;15(4):431–3. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 19388866]
  517. Courbasson CM, de Sorkin AA, Dullerud B, et al. Acupuncture treatment for women with concurrent substance use and anxiety/depression: An effective alternative therapy? Fam Community Health. 2007;30(2):112–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19241647]
  518. Coventry PA, Gellatly JL. Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: A systematic review of cognitive behavioural therapy. Br J Health Psychol. 2008;13(Pt:3):381–400. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17535503]
  519. Covi L, Lipman RS. Cognitive behavioral group psychotherapy combined with imipramine in major depression. Psychopharmacol Bull. 1987;23(1):173–6. Exclude: Not an eligible population treatment. [PubMed: 3602315]
  520. Covi L, Roth D, Lipman RS. Cognitive group psychotherapy of depression: The close-ended group. Am J Psychother. 1982;36(4):459–69. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 7158669]
  521. Cowen PJ, McCance SL, Cohen PR, et al. Lithium increases 5-HT-mediated neuroendocrine responses in tricyclic resistant depression. Psychopharmacol. 1989;99(2):230–2. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2508159]
  522. Cox AA. A description of a behavioral group treatment for depression. J Specialists Group Work. 1984;9(2):85–92. OVID-PsycINFO. Exclude: Not an eligible study design.
  523. Cox JG. Is exercise an evidence-based intervention for clinical depression in older adults: A meta-analysis of randomized studies 2000–2006. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  524. Coyle C, Denault V, Miller R, et al. Understanding systematic reviews and their implications for evidence-based practice by examining aerobic exercise as a recreational therapy intervention for individuals with major depressive disorders. Am J Rec Ther. 2008;7(3):13–22. EBSCO-CINAHL. Excluded - Systematic review - relevant topic, citations cross-matched.
  525. Craft LL, Freund KM, Culpepper L, et al. Intervention study of exercise for depressive symptoms in women. J Womens Health. 2007;16(10):1499–509. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18062765]
  526. Craft LL. Exercise and clinical depression: Examining two psychological mechanisms. Psychol Sport Exerc. 2005;6(2):151–71. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  527. Craig AR, Hancock K, Chang E, et al. Immunizing against depression and anxiety after spinal cord injury. Arch Phys Med Rehabil. 1998;79(4):375–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 9552101]
  528. Craigie MA, Nathan P. A nonrandomized effectiveness comparison of broad-spectrum group CBT to individual CBT for depressed outpatients in a community mental health setting. Behav Ther. 2009;40(3):302–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19647531]
  529. Crail-Melendez D, Herrera A, Ramfrez-Bermudez J, et al. Cognitive behavioral therapy for treatment of depression in patients with temporal lobe epilepsy. Clin Neuropsychiatr. 2010;7(1):22–7. OVID-Embase. Exclude: Not an eligible study design.
  530. Creed F, Guthrie E, Ratcliffe J, et al. Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust NZ J Psychiatr. 2005;39(9):807–15. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16168039]
  531. Criconia AM, Araquistain JM, Daffina N, et al. Results of treatment with s-adenosyl-l-methionine in patients with major depression and internal illnesses. Curr Ther Res Clin Exp. 1994;55(6):666–74. OVID-Embase. Exclude: Not an eligible study design.
  532. Crismon ML, Trivedi M, Pigott TA, et al. The Texas medication algorithm project: Report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry. 1999;60(3):142–56. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 10192589]
  533. Crits-Christoph P, Gibbons MBC, Temes CM, et al. Interpersonal accuracy of interventions and the outcome of cognitive and interpersonal therapies for depression. J Consult Clin Psychol. 2010;78(3):420–8. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC3135378] [PubMed: 20515217]
  534. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatr. 2007;68(6):935–40. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17592920]
  535. Crowley JJ, Lipsky RH, Lucki I, et al. Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. Psychiatr Genet. 2008;18(5):248–51. OVID-Medline. Exclude: For guideline, not a population of interest. [PubMed: 18797399]
  536. Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: A preliminary analysis. Ann NY Acad Sci. 2004;1033:168–76. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15591014]
  537. Cruess S, Antoni MH, Hayes A, et al. Changes in mood and depressive symptoms and related change processes during cognitive-behavioral stress management in HIV-infected men. Cognit Ther Res. 2002;26(3):373–92. OVID-Embase. Exclude: Not an eligible population treatment.
  538. Cuijpers P. Prevention of depression in chronic general medical disorders: A pilot study. Psychol Rep. 1998;82(3:Pt 1):t-8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9676483]
  539. Cuijpers P, van Lier PA, van Straten A, et al. Examining differential effects of psychological treatment of depressive disorder: An application of trajectory analyses. J Affect Disord. 2005;89(1–3):137–46. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16274750]
  540. Cuijpers P, Smit F, Voordouw I, et al. Outcome of cognitive behaviour therapy for minor depression in routine practice. Psychol Psychother. 2005;78(Pt:2):2–88. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16004697]
  541. Cuijpers P, van Straten A, Smit F. Psychological treatment of late-life depression: A meta-analysis of randomized controlled trials. Int J Geriatr Psychiatry. 2006;21(12):1139–49. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16955421]
  542. Cuijpers P, van Straten A, Smits N, et al. Screening and early psychological intervention for depression in schools: Systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2006;15(5):300–7. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16572276]
  543. Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of depression: A meta-analysis. Clin Psychol Rev. 2007;27(3):318–26. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17184887]
  544. Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: A meta-analysis. Eur Psychiatr. 2007;22(1):9–15. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17194572]
  545. Cuijpers P, Smit F, van Straten A. Psychological treatments of subthreshold depression: A meta-analytic review. Acta Psychiatr Scand. 2007;115(6):434–41. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17498154]
  546. Cuijpers P, van Straten A, Warmerdam L. Are individual and group treatments equally effective in the treatment of depression in adults? A meta-analysis. Eur J Psychiatr. 2008;22(1):38–51. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched.
  547. Cuijpers P, van Straten A, van Oppen P, et al. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry. 2008;69(11):1675–85. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18945396]
  548. Cuijpers P, van Straten A, Warmerdam L, et al. Characteristics of effective psychological treatments of depression: A metaregression analysis. Psychother Res. 2008;18(2):225–36. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18815968]
  549. Cuijpers P, van Straten A, Warmerdam L, et al. Psychological treatment of depression: A meta-analytic database of randomized studies. BMC Psychiatr. 2008;8 Art No.:36. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2408566] [PubMed: 18485191]
  550. Cuijpers P, van Straten A, Andersson G, et al. Psychotherapy for depression in adults: A meta-analysis of comparative outcome studies. J Consult Clin Psychol. 2008;76(6):909–22. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19045960]
  551. Cuijpers P. Review: Relaxation better than wait-list, minimal or no treatment for depression but not as good as psychological treatments. Evid Based Ment Health. 2009;12(3):76–7. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 19633244]
  552. Cuijpers P, Dekker J, Hollon SD, et al. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: A meta-analysis. J Clin Psychiatry. 2009;70(9):1219–29. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19818243]
  553. Cuijpers P, Munoz RF, Clarke GN, et al. Psychoeducational treatment and prevention of depression: The “Coping with Depression” course thirty years later. Clin Psychol Rev. 2009;29(5):449–58. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19450912]
  554. Cuijpers P, van Straten A, van Schaik A, et al. Psychological treatment of depression in primary care: A meta-analysis. Br J Gen Pract. 2009;59(559):e51–e60. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2629842] [PubMed: 19192368]
  555. Cuijpers P, van Straten A, Warmerdam L, et al. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis. Depress Anxiety. 2009;26(3):279–88. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19031487]
  556. Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: Meta-analytic study of publication bias. Br J Psychiatr. 2010;196:173–8. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20194536]
  557. Cuijpers P, van Straten A, Schuurmans J, et al. Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clin Psychol Rev. 2010;30(1):51–62. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19781837]
  558. Cuijpers P, van Straten A, Hollon SD, et al. The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: A meta-analysis. Acta Psychiatr Scand. 2010;121(6):415–23. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19922522]
  559. Cukrowicz KC, Joiner J. Computer-based intervention for anxious and depressive symptoms in a non-clinical population. Cognit Ther Res. 2007;31(5):677–93. OVID-Embase. Exclude: Not an eligible population treatment.
  560. Cukrowicz KC. Prevention of anxiety and depression. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  561. Cullen JM. Testing the effectiveness of behavioral activation therapy in the treatment of acute unipolar depression. 2003. OVID-PsycINFO. Exclude: Not an eligible study design.
  562. Cullen M, Mitchell P, Brodaty H, et al. Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry. 1991;52(11):472–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1744065]
  563. Cully JA, Stanley MA, Deswal A, et al. Cognitive-behavioral therapy for chronic cardiopulmonary conditions: Preliminary outcomes from an open trial. Prim Care Comp J Clin Psychiatr. 2010;12(4):e1–e6. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC2983462] [PubMed: 21085552]
  564. Cunningham J. The effects of exercise and relaxation training upon psychological variables in coronary heart patients. 1980. OVID-PsycINFO. Exclude: Not an eligible study design.
  565. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatr. 1997;9(3):157–64. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9339881]
  566. Curry JF, Wells KC, Lochman JE, et al. Cognitive-behavioral intervention for depressed, substance-abusing adolescents: Development and pilot testing. J Am Acad Child Adolesc Psychiatry. 2003;42(6):656–65. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12921473]
  567. Cyranowski JM, Frank E, Shear MK, et al. Interpersonal psychotherapy for depression with panic spectrum symptoms: A pilot study. Depress Anxiety. 2005;21(3):140–2. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15965998]
  568. d’Elia G, Hallstrom T, Nystrom C, et al. Zimelidine vs maprotiline in depressed outpatients: A preliminary report. Acta Psychiatr Scand Suppl. 1981;290:225–35. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 6452793]
  569. da Silva TL, Ravindran LN, Ravindran AV. Yoga in the treatment of mood and anxiety disorders: A review. Asian J Psychiatry. 2009;2(1):6–16. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 23051013]
  570. da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson’s disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111(2–3):351–9. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 18485485]
  571. Dadkhah A, Raoufi MG. A Japanese treatment used in major depressive disorder in adolescence. Percept Motor Skills. 2007;105(2):531–8. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 18065074]
  572. Dai Y, Zhang S, Yamamoto J, et al. Cognitive behavioral therapy of minor depressive symptoms in elderly Chinese Americans: A pilot study. Community Ment Health J. 1999;35(6):537–42. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10863990]
  573. Dalen J, Smith BW, Shelley BM, et al. Pilot study: Mindful Eating and Living (MEAL): Weight, eating behavior, and psychological outcomes associated with a mindfulness-based intervention for people with obesity. Complement Ther Med. 2010;18(6):260–4. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 21130363]
  574. Daley A. Exercise and depression: A review of reviews. J Clin Psychol Med Settings. 2008;15(2):140–7. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19104978]
  575. Dallal A, Fontaine R, Ontiveros A, et al. Lithium carbonate augmentation of desipramine in refractory depression. Can J Psychiatr. 1990;35(7):608–11. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2125237]
  576. Dalton EJ, Rotondi D, Levitan RD, et al. Use of slow-release melatonin in treatment-resistant depression. J Psychiatr Neurosci. 2000;25(1):48–52. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC1407707] [PubMed: 10721684]
  577. Dam J, Ryde L, Svejso J, et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatr. 1998;31(2):48–54. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9562208]
  578. Dana EC. A cognitive-behavioral intervention for conduct-disordered and concurrently conduct-disorded and depressed children. 1998. OVID-PsycINFO. Exclude: Not an eligible study design.
  579. Dang MT. Walking away the blues: Exercise for depression in older adults. Nurs. 2010;40(11):33–6. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PubMed: 20975427]
  580. Dannlowski U, Baune BT, Bockermann I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: Positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol. 2008;23(7):587–93. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18663773]
  581. Darbinyan V, Aslanyan G, Amroyan E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatr. 2007;61(5):343–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17990195]
  582. Darewych O. The effectiveness of art psychotherapy on self-esteem, self-concept, and depression in children with glaucoma. Can Art Ther Assoc J. 2009;22(2):2–17. EBSCO-CINAHL. Exclude: Not an eligible study design.
  583. Daughters SB, Braun AR, Sargeant MN, et al. Effectiveness of a brief behavioral treatment for inner-city illicit drug users with elevated depressive symptoms: The life enhancement treatment for substance use (LETS Act!) J Clin Psychiatry. 2008;69(1):122–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18312046]
  584. David-Ferdon C, Kaslow NJ. Evidence-based psychosocial treatments for child and adolescent depression. J Clin Child Adolesc Psychol. 2008;37(1):62–104. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18444054]
  585. David D, Szentagotai A, Lupu V, et al. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: A randomized clinical trial, posttreatment outcomes, and six-month follow-up. J Clin Psychiatry. 2008;64(6):728–46. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18473339]
  586. Davidson JR, Morrison RM, Shore J, et al. Homeopathic treatment of depression and anxiety. Altern Ther Health Med. 1997;3(1):46–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8997804]
  587. Davidson JR, Abraham K, Connor KM, et al. Effectiveness of chromium in atypical depression: A placebo-controlled trial. Biol Psychiatr. 2003;53(3):261–4. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 12559660]
  588. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: Coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170(7):600–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2882253] [PubMed: 20386003]
  589. Davidson O, King M, Sharpe D, et al. A pilot randomized trial evaluating GP registrar management of major depression following brief training in cognitive behaviour therapy. Educ Gen Pract. 1999;10(4):485–8. OVID-Embase. Exclude: Not an eligible study design.
  590. Davis GR, Armstrong HE, Donovan DM, et al. Cognitive-behavioral treatment of depressed affect among epileptics: Preliminary findings. J Clin Psychiatry. 1984;40(4):930–5. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 6434595]
  591. Davis LL, Wisniewski SR, Howland RH, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Dependence. 2010;107(2–3):161–70. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19945804]
  592. Davis L, Barlow DH, Smith L. Comorbidity and the treatment of principal anxiety disorders in a naturalistic sample. Behav Ther. 2010;41(3):296–305. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 20569779]
  593. de Carvalho MR, Sato EI, Tebexreni AS, et al. Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. ÿÿ 2005;53(6):838–44. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 16342102]
  594. De Cuyper S, Timbremont B, Braet C, et al. Treating depressive symptoms in schoolchildren: A pilot study. Eur Child Adolesc Psychiatry. 2004;13(2):105–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15103536]
  595. de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. Arch Phys Med Rehab. 2003;84(8):1154–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12917854]
  596. de Graaf LE, Gerhards SA, Evers SM, et al. Clinical and cost-effectiveness of computerised cognitive behavioural therapy for depression in primary care: Design of a randomised trial. BMC Pub Health. 2008;8:224. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2474681] [PubMed: 18590518]
  597. de Graaf LE, Gerhards SA, Arntz A, et al. Clinical effectiveness of online computerised cognitive-behavioural therapy without support for depression in primary care: Randomised trial. Br J Psychiatr. 2009;195(1):73–80. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19567900]
  598. de Graaf LE, Huibers MJ, Riper H, et al. Use and acceptability of unsupported online computerized cognitive behavioral therapy for depression and associations with clinical outcome. J Affect Disord. 2009;116(3):227–31. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19167094]
  599. de Graaf LE, Gerhards SA, Arntz A, et al. One-year follow-up results of unsupported online computerized cognitive behavioural therapy for depression in primary care: A randomized trial. J Behav Ther Exp Psychiatr. 2011;42(1):89–95. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20723885]
  600. De Groot M, Kushnick M, Doyle T, et al. A model of community-based behavioral intervention for depression in diabetes: Program ACTIVE. Diabetes Spectrum. 2010;23(1):18–25. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC3327507] [PubMed: 22514361]
  601. De Groot M, Kushnick M, Doyle T, et al. From research to practice/diabetes and depression: Challenges and some opportunities. A model of community-based behavioral intervention for depression in diabetes: Program ACTIVE. Appalachians Coming Together to Increase Vital Exercise. Diabetes Spectrum. 2010;23(1):18–25. EBSCO-CINAHL. Exclude: Not an eligible study design. [PMC free article: PMC3327507] [PubMed: 22514361]
  602. de Jong R, Treiber R, Henrich G. Effectiveness of two psychological treatments for inpatients with severe and chronic depression. Cognit Ther Res. 1986;(10):645–63. Exclude: Not an eligible population treatment.
  603. de Jonghe F, Kool S, van Aalst G, et al. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord. 2001;64(2–3):217–29. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11313088]
  604. de Jonghe F, Hendricksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. Br J Psychiatr. 2004;185:37–45. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15231554]
  605. De Leo D. S-adenosyl-L-methionine (SAMe) in clinical practice: Preliminary report on 75 minor depressives. Curr Ther Res Clin Exp. 1985;37(4):658–61. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  606. De Leo D. S-Adenosylmethionine as an antidepressant: A double-blind trial versus placebo. Curr Ther Res Clin Exp. 1987;41(6):865–70. OVID-Embase. Exclude: Not an eligible population treatment.
  607. de Maat S, Dekker J, Schoevers R, et al. Relative efficacy of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis. Psychother Res. 2006;16(5):566–78. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched.
  608. de Maat S, Dekker J, Schoevers R, et al. Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: A mega-analysis based on three randomized clinical trials. Depress Anxiety. 2008;25(7):565–74. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17557313]
  609. de Man-van Ginkel JM, Gooskens F, Schuurmans MJ, et al. A systematic review of therapeutic interventions for poststroke depression and the role of nurses. J Clin Nurs. 2010;19(23–24):3274–90. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 21083778]
  610. De Mello MF, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychother Pract Res. 2001;(10):117–23. Exclude: Not an eligible population treatment. [PMC free article: PMC3330639] [PubMed: 11264335]
  611. De Mello MF, de Jesus MJ, Bacaltchuk J, et al. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):75–82. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15812600]
  612. de Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatr. 1981;138:252–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7272619]
  613. de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatr. 1983;40(12):1327–34. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 6418109]
  614. de Montigny C, Elie R, Caille G. Rapid response to the addition of lithium in iprindole-resistant unipolar depression: A pilot study. Am J Psychiatry. 1985;142(2):220–3. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3918468]
  615. de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: A Canadian multicenter, open-label trial. J Clin Psychopharmacol. 1999;19(5):401–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10505581]
  616. de Piano FA, de Piano LC, Carter W, et al. Physical fitness training: Adjunctive treatment for the depressed, low self esteem and muscular tense patient. Psychother Private Pract. 1984;2(3):75–83. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  617. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res Clin Exp. 1992;52(3):478–85. OVID-Embase. Exclude: Not an eligible population treatment.
  618. De Zeeuw ELEJ, Tak ECPM, Dusseldorp E, et al. Workplace exercise intervention to prevent depression: A pilot randomized controlled trial. Ment Health Phys Activ. 2010;3(2):72–7. OVID-Embase. Exclude: Not an eligible population/treatment.
  619. de Zwaan M, Schonbeck G, Nutzinger D, et al. Fluvoxamine and behavior therapy in the treatment of depressed obese. Pharmacopsychiatr. 1989;22(5):223. OVID-Embase. Exclude: Not an eligible study design.
  620. de Zwaan M, Nutzinger DO, Schobeck G, et al. The scientific dialogue: From basic research to clinical intervention. Lisse, Netherlands: Swets & Zeitlinger Publishers; 1990. Pharmacotherapy in behavioral treatment for depressed obese. OVID-PsycINFO. Exclude: Not an eligible study design.
  621. Dean-Clower E, Doherty-Gilman AM, Keshaviah A, et al. Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr Canc Ther. 2010;9(2):158–67. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20483875]
  622. Deas D, Randall CL, Roberts JS, et al. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: A pilot study. Hum Psychopharmacol. 2000;15(6):461–9. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 12404308]
  623. DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24(1):87–90. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14709953]
  624. DeBattista C, Solomon A, Arnow B, et al. The efficacy of divalproex sodium in the treatment of agitation associated with major depression. J Clin Psychopharmacol. 2005;25(5):476–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16160625]
  625. DeBattista C, Kinrys G, Hoffman D, et al. Referenced-EEG (rEEG) efficacy compared to STAR*D for patients with depression treatment failure: A first look at final results. CNS Response, Inc. 2009. Excluded.
  626. DeBattista C, Kinrys G, Hoffman D, et al. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011;45(1):64–75. OVID-Embase. Exclude: Mixed antidepressants; some failed on SSRI. [PubMed: 20598710]
  627. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol. 2003;23(1):27–30. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 12544372]
  628. Deberry S, Davis S, Reinhard KE. A comparison of meditation-relaxation and cognitive/behavioral techniques for reducing anxiety and depression in a geriatric population. J Geriatr Psychiatry. 1989;22(2):231–47. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2701175]
  629. DeBerry S. The effects of meditation-relaxation on anxiety and depression in a geriatric population. Psychother Theory Res Pract. 1982;19(4):512–21. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  630. Dekker J, Molenaar PJ, Kool S, et al. Dose-effect relations in time-limited combined psycho-pharmacological treatment for depression. Psychol Med. 2005;35(1):47–58. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15842028]
  631. Dekker JJ, Koelen JA, Van HL, et al. Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. J Affect Disord. 2008;109(1–2):183–8. Exclude: Not an eligible population treatment. [PubMed: 18061276]
  632. Del Vecchio M, Amati A, Vacca L, et al. Monitoring S-adenosyl-methionine blood levels and antidepressant effect. Acta Neurol. 1980;2(6):488–95. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7027755]
  633. DelBello MP, Adler CM, Whitsel RM, et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry. 2007;68(5):789–95. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 17503991]
  634. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord. 1988;15(1):55–60. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 2970493]
  635. Delle CR, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenonsyl-L-methionine 1,4-butanedisulfonate (SAME) in the treatment of major depression: Comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002;76(5):1172S–6S. OVID-Medline. Excluded. [PubMed: 12418499]
  636. Deltito JA, Moline M, Pollak C, et al. Effects of phototherapy on non-seasonal unipolar and bipolar depressive spectrum disorders. J Affect Disord. 1991;23(4):231–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1791269]
  637. den Boer PC, Wiersma D, Ten VI, et al. Cognitive self-therapy for chronic depression and anxiety: A multi-centre randomized controlled study. Psychol Med. 2007;37(3):329–39. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17076917]
  638. Denko TC, Friedman ES. Augmentation strategies in Star*D: A review. Prim Psychiatr. 2007;14(1):46–50. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  639. DeRubeis RJ, Hollon SD, Evans MD, et al. Can psychotherapies for depression be descriminated? A systematic investigation of cognitive therapy and interpersonal therapy. J Consult Clin Psychol. 1982;50(5):744–56. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 7142549]
  640. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatr. 2005;62(4):409–16. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15809408]
  641. Descilo T, Vedamurtachar A, Gerbarg PL, et al. Effects of a yoga breath intervention alone and in combination with an exposure therapy for post-traumatic stress disorder and depression in survivors of the 2004 South-East Asia tsunami. Acta Psychiatr Scand. 2010;121(4):289–300. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19694633]
  642. Deshmukh AD, Sarvaiya AA, Nayak AS. Effect of Indian classical music on quality of sleep in depressed patients: a randomized controlled trial. Nord J Music Ther. 2009;18(1):70–8. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  643. Deslandes AC, Moraes H, Alves H, et al. Effect of aerobic training on EEG alpha asymmetry and depressive symptoms in the elderly: A 1-year follow-up study. Braz J Med Biol Res. 2010;43(6):585–92. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20464340]
  644. Dessauer M, Goetze U, Tolle R. Periodic sleep deprivation in drug-refractory depression. Neuropsychobiol. 1985;13(3):111–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3900797]
  645. Dessaulles A, Johnson SM, Denton WH. Emotion-focused therapy for couples in the treatment of depression: A pilot study. Am J Fam Ther. 2003;31(5):345–53. OVID-Embase. Exclude: Not an eligible population treatment.
  646. Dew MA, Reynolds CF III, Mulsant B, et al. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J Affect Disord. 2001;65(2):155–66. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11356239]
  647. Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry. 2007;164(6):892–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17541048]
  648. Dhooper SS, Green SM, Huff MB, et al. Efficacy of a group approach to reducing depression in nursing home elderly residents. J Gerontol Soc Work. 1993;(20):87–100. Exclude: Not an eligible population treatment.
  649. Di Giulio G. Therapist, client factors, and efficacy in cognitive behavioural therapy: A meta-analytic exploration of factors that contribute to positive outcome. 2010. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched.
  650. Di Palma C, Urani R, Agricola R, et al. Is methylfolate effective in relieving major depression in ceronic alcoholics? A hypothesis of treatment. Curr Ther Res Clin Exp. 1994;55(5):559–68. OVID-Embase. Exclude: Not an eligible study design.
  651. Di Rocco A, Rogers JD, Brown R, et al. S-Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord. 2000;15(6):1225–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11104210]
  652. Diamond G, Josephson A. Family-based treatment research: A 10-year update. J Am Acad Child Adolesc Psychiatry. 2005;44(9):872–87. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16113616]
  653. Diamond GS, Reis BF, Diamond GM, et al. Attachment-based family therapy for depressed adolescents: A treatment development study. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1190–6. Exclude: Not an eligible population treatment. [PubMed: 12364840]
  654. Diamond S, Baltes BJ. The office treatment of mixed anxiety and depression with combination therapy. Psychosom. 1969;10(6):360–5. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4907859]
  655. Dias RS, Kerr-Correa F, Moreno RA, et al. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: A double-blind controlled pilot study. Menopause. 2006;13(2):202–11. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16645534]
  656. Diaz A, Fouilloux C, Ortiz S. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients. Proc West Pharmacol Soc. 2002;45:154–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12434564]
  657. Diazgranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatr. 2010;71(12):1605–11. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC3012738] [PubMed: 20673547]
  658. Dichter GS, Felder JN, Smoski MJ. The effects of Brief Behavioral Activation Therapy for Depression on cognitive control in affective contexts: An fMRI investigation. J Affect Disord. 2010;126(1–2):236–44. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2929307] [PubMed: 20421135]
  659. Diego MA, Field T, Hernandez-Reif M, et al. HIV adolescents show improved immune function following massage therapy. Int J Neurosci. 2001;106(1–2):35–45. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 11264907]
  660. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(1):57–71. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8861177]
  661. Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: An open trial. Bipolar Disorders. 2000;2(1):65–70. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11254023]
  662. Dietz LJ, Mufson L, Irvine H, et al. Family-based interpersonal psychotherapy for depressed preadolescents: An open-treatment trial. Early Interv Psychiatr. 2008;2(3):154–61. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC3551579] [PubMed: 21352148]
  663. DiMascio A, Weissman MM, Prusoff BA, et al. Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatr. 1979;36(13):1450–6. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 518245]
  664. Dimeo F, Bauer M, Varahram I, et al. Benefits from aerobic exercise in patients with major depression: A pilot study. Br J Sports Med. 2001;35(2):114–7. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC1724301] [PubMed: 11273973]
  665. Dimidjian S. Behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of major depression. 2005. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 16881773]
  666. Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4):658–70. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16881773]
  667. Dimitriou EC, Logothetis JA, Paschalidou M. A double blind comparative study of mianserin and a fixed combination of amitriptyline plus chlordiazepoxide. Adv Biochem Psychopharmacol. 1982;32:213–22. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7046365]
  668. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol. 1998;18(6):465–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9864079]
  669. Dinan TG, Barry S. A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders. Acta Psychiatr Scand. 1989;80(1):97–100. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2504034]
  670. Dinan TG, Scott LV. Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors? J Serotonin Res. 1996;3(3):119–21. OVID-Embase. Exclude: Not an eligible study design.
  671. Dinan TG, Lavelle E, Cooney J, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand. 1997;95(1):58–61. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9051162]
  672. Ditzler K, Gessner B, Schatton WFH, et al. Clinical trial on Neurapas versus placebo in patients with mild to moderate depressive symptoms: A placebo-controlled, randomised double-blind study. Phase IV: Clinical trial. Complement Ther Med. 1994;2(1):5–13. OVID-Embase. Exclude: Not an eligible population treatment.
  673. Dixon M. Does ‘healing’ benefit patients with chronic symptoms? A quasi-randomized trial in general practice. J R Soc Med. 1998;91(4):183–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1296636] [PubMed: 9659302]
  674. Dixon R, Cohen J. Steady state plasma concentration profiles and therapeutic response in anxious-depressed outpatients after administration of a chlordiazepoxide-amitriptyline combination. J Clin Psychopharmacol. 1983;3(2):107–9. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 6404953]
  675. Dobbin A, Maxwell M, Elton R. A benchmarked feasibility study of a self-hypnosis treatment for depression in primary care. Int J Clin Exp Hypnosis. 2009;57(3):293–318. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19459090]
  676. Dobia B, McMurray NE. Applicability of learned helplessness to depressed women undergoing assertion training. Aust J Psychol. 1985;37(1):71–80. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  677. Dobkin RD, Menza M, Marin H, et al. Bupropion improves sexual functioning in depressed minority women: An open-label switch study. J Clin Psychopharmacol. 2006;26(1):21–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16415700]
  678. Dobkin RD, Allen LA, Alloy LB, et al. Adaptive inferential feedback partner training for depression: A pilot study. Cognit Behav Pract. 2007;14(4):350–63. OVID-Embase. Exclude: Not an eligible study design.
  679. Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson’s disease: A pilot study. Mov Disord. 2007;22(7):946–52. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 17377926]
  680. Dobson KS, Hollon SD, Dimidjian S, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol. 2008;76(3):468–77. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2648513] [PubMed: 18540740]
  681. Dobson KS, Hopkins JA, Fata L, et al. The prevention of depression and anxiety in a sample of high-risk adolescents: A randomized controlled trial. Can J School Psychol. 2010;25(4):291–310. OVID-PsycINFO. Exclude: Not an eligible population/treatment.
  682. Docherty JP, Sack DA, Roffman M, et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: Effect on carbohydrate craving. J Psychiatr Pract. 2005;11(5):302–14. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 16184071]
  683. Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord. 2005;(89):1–11. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16169088]
  684. Doggrell SA. Fluoxetine - Do the benefits outweigh the risks in adolescent major depression? Expert Opin Pharmacother. 2005;6(1):147–50. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 15709892]
  685. Dolezal-Wood S, Belar CD, Snibbe J. A comparison of computer-assisted psychotherapy and cognitive-behavioral therapy in groups. J Clin Psychol Med Settings. 1998;5(1):103–15. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  686. Dombrovski AY, Blakesley-Ball RE, Mulsant BH, et al. Speed of improvement in sleep disturbance and anxiety compared with core mood symptoms during acute treatment of depression in old age. Am J Geriatr Psychiatr. 2006;14(6):550–4. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16731725]
  687. Dombrovski AY, Lenze EJ, Dew MA, et al. Maintenance treatment for old-age depression preserves health-related quality of life: A randomized, controlled trial of paroxetine and interpersonal psychotherapy. J Am Geriatr Soc. 2007;55(9):1325–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17767673]
  688. Dominguez RA, Jacobson AF, Goldstein BJ, et al. Comparison of triazolam and placebo in the treatment of insomnia in depressed patients. Curr Ther Res Clin Exp. 1984;36(5I):856–65. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment.
  689. Domino ME, Burns BJ, Silva SG, et al. Cost-effectiveness of treatments for adolescent depression: Results from TADS. Am J Psychiatry. 2008;165(5):588–96. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18413703]
  690. Domino ME, Foster EM, Vitiello B, et al. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry. 2009;48(7):711–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19465880]
  691. Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor ( BDNF) gene: No major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 2010;13(1):93–101. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19236730]
  692. Dong JT. Research on the reduction of anxiety and depression with acupuncture. Am J Acupunc. 1993;21(4):327–30. OVID-Embase. Exclude: Not an eligible study design.
  693. Doree JP, Tourjman SV, Kunicki S, et al. Comparison of quetiapine versus lithium treatment of resistant depression. 2004. Wiley-CCTR. Exclude: Not an eligible study design.
  694. Dorée JP, Des RJ, Lew V, et al. Quetiapine augmentation of treatment-resistant depression: A comparison with lithium. Curr Med Res Opin. 2007;23(2):333–41. Wiley-CCTR. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17288688]
  695. Dornseif BE, Dunlop SR, Potvin JH, et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25(1):71–9. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 2672072]
  696. Dowrick C, Dunn G, Ayuso-Mateos JL, et al. Problem solving treatment and group psychoeducation for depression: Multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group. Br Med J. 2000;321(7274):1450–4. Exclude: Not an eligible population treatment. [PMC free article: PMC27549] [PubMed: 11110739]
  697. Doyne EJ, Ossip-Klein DJ, Bowman ED, et al. Running versus weight lifting in the treatment of depression. J Consult Clin Psychol. 1987;55(5):748–54. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3454786]
  698. Dozois DJ, Bieling PJ, Patelis-Siotis I, et al. Changes in self-schema structure in cognitive therapy for major depressive disorder: A randomized clinical trial. J Consult Clin Psychol. 2009;77(6):1078–88. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19968384]
  699. Drago F, Motta A, Grossi E. Intravenous maprotiline in severe and resistant primary depression: A double-blind comparison with clomipramine. J Int Med Res. 1983;11(2):78–84. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 6343154]
  700. Driessen E, Van HL, Schoevers RA, et al. Cognitive Behavioral Therapy versus Short Psychodynamic Supportive Psychotherapy in the outpatient treatment of depression: A randomized controlled trial. BMC Psychiatr. 2007;7:58. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2174932] [PubMed: 17963493]
  701. Driessen E, Cuijpers P, Hollon SD, et al. Does pretreatment severity moderate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis. J Consult Clin Psychol. 2010;78(5):668–80. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20873902]
  702. Driessen E, Cuijpers P, de Maat SCM, et al. The efficacy of short-term psychodynamic psychotherapy for depression: A meta-analysis. Clin Psychol Rev. 2010;30(1):25–36. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19766369]
  703. Driscoll HC, Basinski J, Mulsant BH, et al. Late-onset major depression: Clinical and treatment-response variability. Int J Geriatr Psychiatry. 2005;20(7):661–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16021664]
  704. Driver S, Ede A. Impact of physical activity on mood after TBI. Brain Inj. 2009;23(3):203–12. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19205956]
  705. Duan D-M, Tu Y, Jiao S, et al. The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with fluoxetine intervention - A randomized, controlled trial. Chin J Integrat Med. 2011;17(3):190–9. OVID-Embase. Exclude: Not an eligible population/treatment. [PubMed: 21359920]
  706. Duan DM, Tu Y, Chen LP, et al. Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine. J Tradit Chin Med. 2009;29(3):167–73. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19894377]
  707. Duarte PS, Miyazaki MC, Blay SL, et al. Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Kidney Int. 2009;76(4):414–21. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19455196]
  708. Dube S, Dube S, Andersen SW, et al. Olanzapine-fluoxetine for treatment-resistant depression. 2002. Wiley-CCTR. Exclude: Not an eligible study design.
  709. Dube S, Andersen SW, Paul S, et al. Meta-analysis of olanzapine-fluoxetine in treatment-resistant depression. 2002. Wiley-CCTR. Exclude: Not an eligible study design.
  710. Dubicka B, Elvins R, Roberts C, et al. Combined treatment with cognitive-behavioural therapy in adolescent depression: Meta-analysis. Br J Psychiatr. 2010;197(6):433–40. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 21119148]
  711. Dubovsky SL, Buzan R, Thomas M, et al. Nicardipine improves the antidepressant action of ECT but does not improve cognition. J ECT. 2001;17(1):3–10. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11281512]
  712. Dudley DL, Volberding N, Loebel P. Intravenous chlorimipramine and refractory depression. Gen Hosp Psychiatry. 1980;2(1):61–4. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7380252]
  713. Dudley M, Hadzi-Pavlovic D, Andrews D, et al. New-generation antidepressants, suicide and depressed adolescents: How should clinicians respond to changing evidence? Aust NZ J Psychiatr. 2008;42(6):456–66. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18465372]
  714. Duffy SA, Ronis DL, Valenstein M, et al. A tailored smoking, alcohol, and depression intervention for head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2203–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17119047]
  715. Dufresne RL, Kass DJ, Becker RE. Bupopropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia. Drug Dev Res. 1988;12(3–4):259–66. OVID-Embase. Exclude: Not an eligible population treatment.
  716. Dujovne VF. Comparison of cognitive-behavioral to pharmacological treatment of depression in prepubertal children. 1994. OVID-PsycINFO. Exclude: Not an eligible study design.
  717. Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(6):614–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18004129]
  718. Dunn AL, Trivedi MH, Kampert JB, et al. The DOSE study: A clinical trial to examine efficacy and dose response of exercise as treatment for depression. Control Clin Trials. 2002;23(5):584–603. Exclude: Not an eligible study design. [PubMed: 12392873]
  719. Dunn AL, Trivedi MH, Kampert JB, et al. Exercise treatment for depression: Efficacy and dose response. Am J Prev Med. 2005;28(1):1–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15626549]
  720. Dunn NJ, Rehm LP, Schillaci J, et al. A randomized trial of self-management and psychoeducational group therapies for comorbid chronic posttraumatic stress disorder and depressive disorder. J Trauma Stress. 2007;20(3):221–37. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 17598141]
  721. Dunner DL, Schmaling KB, Hendrickson H, et al. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression. 1996;4(1):34–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9160652]
  722. Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67(5):688–95. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16841617]
  723. Dunner DL, Blier P, Keller MB, et al. Preventing recurrent depression: Long-term treatment for major depressive disorder. Prim Care Comp J Clin Psychiatr. 2007;9(3):214–23. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC1911177] [PubMed: 17632654]
  724. Dunner DL. Venlafaxine in the treatment of unresolved symptoms of depression following antidepressant therapy. Prim Psychiatr. 2007;14(3):39–49. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched.
  725. Dursun SM, Devarajan S, Kutcher S. The ‘dalhousie serotonin cocktail’ for treatment-resistant major depressive disorder. J Psychopharmacol. 2001;15(2):136–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11448087]
  726. Earley W, McIntyre A, Bauer M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine extended release) as add-on to antidepressants in patients with major depressive disorder (MDD): Results from a double-blind, randomized phase III study. Am Coll Neuropsychopharmacol Ann Meeting Abst. 2007 [Abstract]
  727. Ebert D, Albert R, May A, et al. Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacol. 1995;119(3):342–4. Wiley-CCTR. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 7675971]
  728. Echeburua E, Salaberria K, De Corral P, et al. Treatment of mixed anxiety-depression disorder: Long-term outcome. Behav Cognit Psychother. 2006;34(1):95–101. OVID-Embase. Exclude: Not an eligible population treatment.
  729. Eckshtain D. Combined cognitive behavioral treatment plus caregiver sessions for childhood depression. 2009. OVID-PsycINFO. Exclude: Not an eligible study design.
  730. Edwards DR. A double- blind, placebo-controlled trial of lithium augmentation of antidepressants in treatment-resistant depression in elderly patients. 1998. Wiley-CCTR. Exclude: Not an eligible study design.
  731. Edwards N, Gardiner M, Ritchie DM, et al. Effect of exercise on negative affect in residents in special care units with moderate to severe dementia. Alzheimer Dis Assoc Disord. 2008;22(4):362–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18978600]
  732. Ehrensing RH, Kastin AJ, Wurzlow GF, et al. Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord. 1994;31(4):227–33. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 7989637]
  733. Eidelson JI. Cognitive group therapy for depression: ‘Why and what’ Int J Ment Health. 1985;13(3–4):54–66. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  734. Ekers D, Lovell K. Self-help for anxiety and depression in primary care: An audit of a pilot clinic. Clin Effect Nurs. 2002;6(3–4):129–33. EBSCO-CINAHL. Exclude: Not an eligible study design.
  735. Ekers D, Richards D, Gilbody S. A meta-analysis of randomized trials of behavioural treatment of depression. Psychol Med. 2008;38(5):611–23. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17903337]
  736. Ekers D, Richards D, McMillan D, et al. Behavioural activation delivered by the non-specialist: Phase II randomised controlled trial. Br J Psychiatr. 2011;198(1):66–72. OVID-Embase. Exclude: Not an eligible population/treatment. [PubMed: 21200079]
  737. Eksi A, Braun KL. Over-time changes in PTSD and depression among children surviving the 1999 Istanbul earthquake. Eur Child Adolesc Psychiatry. 2009;18(6):384–91. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19221855]
  738. El-Khalili N, Joyce M, Atkinson S, et al. Adjunctive extended-release quetiapine fumarate (quetiapine extended release) in patients with major depressive disorder and inadequate antidepressant response. Int J Neuropsychopharmacol. 2010. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 20175941]
  739. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917–32. OVID-Medline. Exclude: Mixed antidepressants; some failed on SSRI. [PubMed: 20175941]
  740. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health. Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatr. 1989;46(11):971–82. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2684085]
  741. Eller T, Vasar V, Shlik J, et al. Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. J Psychopharmacol. 2009;23(7):854–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18562403]
  742. Ellis PM, Smith DAR. Treating depression: The beyondblue guidelines for treating depression in primary care: “Not so much what you do but that you keep doing it” Med J Aust. 2002;176:S77–83. Exclude: Not an eligible guideline. [PubMed: 12065002]
  743. Ellis PM, Hickie IB, Smith DAR. Summary of guideline for the treatment of depression. Australas Psychiatr. 2003;11(1):34–8. OVID-PsycINFO. Exclude: Not an eligible guideline.
  744. Elmquist JM, Melton TK, Croarkin P, et al. A systematic overview of measurement-based care in the treatment of childhood and adolescent depression. J Psychiatr Pract. 2010;16(4):217–34. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20644357]
  745. Elsenga S, van den Hoofdakker RH. Clinical effects of sleep deprivation and clomipramine in endogenous depression. J Psychiatr Res. 1982;17(4):361–74. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 7187779]
  746. Emanuels-Zuurveen L, Emmelkamp PM. Individual behavioural-cognitive therapy v. marital therapy for depression in maritally distressed couples. Br J Psychiatr. 1996;169(2):181–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8871794]
  747. Emanuels-Zuurveen L, Emmelkamp PM. Spouse-aided therapy with depressed patients. Behav Modif. 1997;21(1):62–77. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8995042]
  748. Embling S. The effectiveness of cognitive behavioural therapy in depression. Nurs Stand. 2002;17(14–15):33–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12567797]
  749. Emrich HM, Berger M, Riemann D, et al. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: A double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatr. 1987;20(2):60–3. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 3108909]
  750. Emslie G, Clarke G, Wagner K, et al. The treatment of ssri-resistant depression in adolescents (tordia) World Psychiatr. 2009;8(Suppl 1):37. Wiley-CCTR. Exclude: Not an eligible study design.
  751. Engelhardt W, Carl G, Hartung E. Intra-individual open comparison of burst-suppression-isoflurane-anaesthesia versus electroconvulsive therapy in the treatment of severe depression. Eur J Anaesthesiol. 1993;10(2):113–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8462536]
  752. Enns MW, Cox BJ, Pidlubny SR. Group cognitive behaviour therapy for residual depression: Effectiveness and predictors of response. Cognit Behav Ther. 2002;31(1):31–40. OVID-Embase. Exclude: Not an eligible study design.
  753. Erfurth A, Ackenheil M, Moller HJ. Effects of pindolol in hastening response to serotoninergic antidepressants: An open study in severely depressed in-patients. Clin Neuropsychiatr. 2004;1(3):196–201. OVID-PsycINFO. Exclude: Not an eligible study design.
  754. Erlen JA, Mellors MP, Sereika SM, et al. The use of life review to enhance quality of life of people living with AIDS: A feasibility study. Qual Life Res. 2001;10(5):453–64. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 11763207]
  755. Ernst E. Herbal remedies for depression and anxiety. Adv Psychiatr Treatment. 2007;13(4):312–6. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched.
  756. Ernst E. Review: St John’s wort superior to placebo and similar to antidepressants for major depression but with fewer side effects. Evid Based Ment Health. 2009;12(3):78. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 19633246]
  757. Eskin M, Ertekin K, Demir H. Efficacy of a problem-solving therapy for depression and suicide potential in adolescents and young adults. Cognit Ther Res. 2008;32(2):227–45. OVID-Embase. Exclude: Not an eligible population treatment.
  758. Ettelson RG. The treatment of adolescent depression. 2003. OVID-PsycINFO. Exclude: Not an eligible study design.
  759. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9(12):819–25. OVID-Medline. Exclude: Not an eligible guideline. [PMC free article: PMC2743615] [PubMed: 18091431]
  760. Evans MD, Hollon SD, DeRubeis RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatr. 1992;49(10):802–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1417433]
  761. Evans ME. Depression in elderly physically ill in-patients: A 12-month prospective study. Int Clin Psychopharmacol. 1993;8(4):333–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8277159]
  762. Evans R, Connis R. Comparison of brief group therapies for depressed cancer patients receiving radiation treatment. Public Health Rep. 1995;(110):306–11. Exclude: Not an eligible population treatment. [PMC free article: PMC1382125] [PubMed: 7610222]
  763. Even C, Schroder CM, Friedman S, et al. Efficacy of light therapy in nonseasonal depression: A systematic review. J Affect Disord. 2008;108(1–2):11–23. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17950467]
  764. Evins AE, Culhane MA, Alpert JE, et al. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol. 2008;28(6):660–6. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3505846] [PubMed: 19011435]
  765. Fabbri S, Fava GA, Rafanelli C, et al. Family intervention approach to loss of clinical effect during long-term antidepressant treatment: A pilot study. J Clin Psychiatry. 2007;68(9):1348–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17915972]
  766. Fahlen T, Agren H, Edstrom A, et al. Buspiron augmentation of SSRI therapy in treatment-refractory depression. 1996. Wiley-CCTR. Exclude: Not an eligible study design.
  767. Fahlén T, Agren H, Edström A, et al. Buspirone in SSRI-refractory depression. 1996. Wiley-CCTR. Exclude: Not an eligible study design.
  768. Fahndrich E. Effects of sleep deprivation on depressed patients of different nosological groups. Psychiatry Res. 1981;5(3):277–85. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6948310]
  769. Fahy TJ. Side effects of moclobemide in depressed patients refractory to other treatments. Ir J Psychol Med. 1993;10(1):24–7. OVID-Embase. Exclude: Not an eligible study design.
  770. Fakhoury TA, Miller JM, Hammer AE, et al. Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: An open-label, multicentre, prospective study. Drugs Aging. 2008;25(11):955–62. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18947263]
  771. Falconnier L. Socioeconomic status in the treatment of depression. Am J Orthopsychiatry. 2009;79(2):148–58. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19485632]
  772. Fan L, Fu W, Xu N, et al. Meta-analysis of 20 clinical, randomized, controlled trials of acupuncture for depression. Neural Regen Res. 2010;5(24):1862–9. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched.
  773. Fang Y, Yuan C, Xu Y, et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: A double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol. 2010;30(4):357–64. OVID-Medline. Exclude: Mixed antidepressants; some failed on SSRI. [PubMed: 20571433]
  774. Farabaugh A, Locascio JJ, Yap L, et al. Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosom. 2010;51(2):124–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20332287]
  775. Faramarzi M, Kheirkhah F, Esmaelzadeh S, et al. Is psychotherapy a reliable alternative to pharmacotherapy to promote the mental health of infertile women? A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):49–53. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18848381]
  776. Faramarzi M, Alipor A, Esmaelzadeh S, et al. Treatment of depression and anxiety in infertile women: Cognitive behavioral therapy versus fluoxetine. J Affect Disord. 2008;108(1–2):159–64. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17936366]
  777. Faravelli C, Albanesi G, Sessarego A. Viqualine in resistant depression: A double-blind, placebo-controlled trial. Neuropsychobiol. 1988;20(2):78–81. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3075725]
  778. Farid FF, Wenger TL, Tsai SY, et al. Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants. J Clin Psychiatry. 1983;44(5:Pt 2):t-3. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6406451]
  779. Fasullo S, Vinci GG. Treatment of resistant depression with TRH. Psichiatria e Psicoterapia Analitica. 1991;10(3):241–6. Wiley-CCTR. Exclude: Not an eligible population treatment.
  780. Fava GA, Savron G, Grandi S, et al. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry. 283;58(6):278–82. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9228899]
  781. Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry. 1994;151(9):1295–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8067483]
  782. Fava GA, Grandi S, Zielezny M, et al. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1996;153(7):945–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8659620]
  783. Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: Preliminary findings. Arch Gen Psychiatr. 1998;55(9):816–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9736008]
  784. Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1998;155(10):1443–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9766780]
  785. Fava GA, Rafanelli C, Cazzaro M, et al. Well-being therapy. A novel psychotherapeutic approach for residual symptoms of affective disorders. Psychol Med. 1998;28(2):475–80. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9572104]
  786. Fava GA, Ruini C, Rafanelli C, et al. Cognitive behavior approach to loss of clinical effect during long-term antidepressant treatment: A pilot study. Am J Psychiatry. 2002;159(12):2094–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12450962]
  787. Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry. 2004;161(10):1872–6. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 15465985]
  788. Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. J Clin Psychiatr. 2005;66(11):1392–400. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16420076]
  789. Fava M, Rosenbaum JF, Cohen L, et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord. 1992;25(4):229–34. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1430659]
  790. Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res. 1995;56(3):295–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7568552]
  791. Fava M, Rappe SM, Pava JA, et al. Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose. J Clin Psychiatry. 1995;56(2):52–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7852252]
  792. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatr. 2003;15(1):17–22. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12839429]
  793. Fava M, McGrath PJ, Sheu WP, et al. Switching to reboxetine: An efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol. 2003;23(4):365–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12920412]
  794. Fava M, Alpert J, Nierenberg AA, et al. A double-blind, randomized trial of St John’s wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005;25(5):441–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16160619]
  795. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatr. 2006;59(11):1052–60. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16581036]
  796. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatr. 2007;19(3):153–9. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17729016]
  797. Fava M, Wisniewski SR, Thase ME, et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies. J Clin Psychopharmacol. 2009;29(4):362–7. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19593176]
  798. Fawcett J, Edwards JH, Kravitz HM, et al. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients. J Clin Psychopharmacol. 1987;7(5):295–310. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3316312]
  799. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11(2):127–32. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2056139]
  800. Feet PO, Larsen S, Robak OH. A double blind study in out-patients with primary non-agitated depression treated with imipramine in combination with placebo, diazepam or dixyrazine. Acta Psychiatr Scand. 1985;72(4):334–40. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 3907277]
  801. Feighner JP, Brauzer B, Gelenberg AJ, et al. A placebo-controlled multicenter trial of Limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness. Psychopharmacol. 1979;61(2):217–25. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 108739]
  802. Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry. 1990;51(6):222–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2347858]
  803. Feighner JP, Sverdlov L, Nicolau G, et al. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: Comparison of follow-up re-treatment with initial treatment. Int J Neuropsychopharmacol. 2003;6(3):207–13. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12974986]
  804. Feighner JP, Sverdlov L, Hlavka J, et al. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients. Int Clin Psychopharmacol. 2008;23(1):29–35. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18090505]
  805. Feijo DM, de Jesus MJ, Bacaltchuk J, et al. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):75–82. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15812600]
  806. Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116(1–2):4–11. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19007996]
  807. Feldman G, Harley R, Kerrigan M, et al. Change in emotional processing during a dialectical behavior therapy-based skills group for major depressive disorder. Behav Res Ther. 2009;47(4):316–21. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 19232571]
  808. Fenton L, Fasula M, Ostroff R, et al. Can cognitive behavioral therapy reduce relapse rates of depression after ECT? A preliminary study. J ECT. 2006;22(3):196–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16957536]
  809. Ferguson J, Cunningham L, Merideth C, et al. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatr. 1994;6(3):153–60. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7881495]
  810. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007;30(3):136–44. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17545748]
  811. Ferrando SJ, Freyberg Z. Treatment of depression in HIV positive individuals: A critical review. Int Rev Psychiatry. 2008;20(1):61–71. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18240063]
  812. Ferrucci R, Bortolomasi M, Vergari M, et al. Transcranial direct current stimulation in severe, drug-resistant major depression. J Affect Disord. 2009;118(1–3):215–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 19286265]
  813. Fetsch RJ, Sprinkle RL. Effects of running on depressed adults. Am Ment Health Couns Assoc J. 1983;5(2):75–84. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  814. Field T, Hernandez-Reif M, Hart S, et al. Effects of sexual abuse are lessened by massage therapy. J Bodywork Movement Ther. 1997;1(2):65–9. OVID-AMED. Exclude: Not an eligible population treatment.
  815. Finch EJL, Katona CLE. Lithium augmentation in the treatment of refractory depression in old age. Int J Geriatr Psychiatry. 1989;4(1):41–6. OVID-Embase. Exclude: Not an eligible study design.
  816. Findling RL, McNamara NK, O’Riordan MA, et al. An open-label pilot study of St. John’s wort in juvenile depression. J Am Acad Child Adolesc Psychiatry. 2003;42(8):908–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12874492]
  817. Findling RL, Lingler J, Rowles BM, et al. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. J Child Adolesc Psychopharmacol. 2008;18(6):615–21. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19108666]
  818. Finkelstein FO, Watnick S, Finkelstein SH, et al. The treatment of depression in patients maintained on dialysis. J Psychosom Res. 2002;53(4):957–60. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 12377309]
  819. Finucane A, Mercer SW. An exploratory mixed methods study of the acceptability and effectiveness of mindfulness-based cognitive therapy for patients with active depression and anxiety in primary care. BMC Psychiatr. 2006;6:14. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC1456957] [PubMed: 16603060]
  820. Firth-Cozens J, Brewin CR. Attributional change during psychotherapy. Br J Clin Psychol. 1988;27(1):47–54. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 3355907]
  821. Fischer P, Tauscher J, Kufferle B, et al. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol. 1998;13(2):83–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9669189]
  822. Flaugher M. The intervention of music on perceptions of chronic pain, depression, and anxiety in ambulatory individuals with cancer University of Alabama at Birmingham. 2002. EBSCO-CINAHL. Exclude: Not an eligible study design.
  823. Fleck MP, Horwath E. Pharmacologic management of difficult-to-treat depression in clinical practice. Psychiatr Serv. 2005;56(8):1005–11. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16088019]
  824. Fleck MP, Moreno R, Andrade AG, et al. Efficacy of milnacipran in outpatients experiencing major depression non respondent to SSRIs: A 12-week open study. Revista de Psiquiatria Clinica. 2010;37(6):241–50. OVID-Embase. Exclude: Not an eligible study design.
  825. Fleischhauer J, Glauser G, Hofstetter P. The influence of light therapy in depressive patients. Pharmacopsychiatr. 1988;21(6):414–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3244780]
  826. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57–90. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19752841]
  827. Flint AJ, Rifat SL. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J Clin Psychopharmacol. 1994;14(5):353–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7806693]
  828. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord. 1996;36(3–4):95–105. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8821312]
  829. Flint AJ, Rifat SL. Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatr. 1997;5(2):107–15. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9106374]
  830. Flint AJ, Rifat SL. The effect of treatment on the two-year course of late-life depression. Br J Psychiatr. 1997;170:268–72. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 9229035]
  831. Flint AJ, Rifat SL. Maintenance treatment for recurrent depression in late life. A four-year outcome study. Am J Geriatr Psychiatr. 2000;8(2):112–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10804071]
  832. Floyd M, Scogin F, McKendree-Smith NL, et al. Cognitive therapy for depression: a comparison of individual psychotherapy and bibliotherapy for depressed older adults. Behav Modif. 2004;28(2):297–318. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14997954]
  833. Floyd M, Rohen N, Shackelford JA, et al. Two-year follow-up of bibliotherapy and individual cognitive therapy for depressed older adults. Behav Modif. 2006;30(3):281–94. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16574815]
  834. Fombonne E, Zinck S. Handbook of depression in children and adolescents. New York, NY, US: Guilford Press; 2008. Psychopharmacological treatment of depression in children and adolescents. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched.
  835. Fontaine R, Ontiveros A, Elie R, et al. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. Biol Psychiatr. 1991;29(9):946–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 1904782]
  836. Fontaine R, Ontiveros A, Elie R, et al. “Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression”: Correction. Biol Psychiatr. 1992;31(3):322. OVID-PsycINFO. Exclude: Not an eligible study design.
  837. Forman EM, Herbert JD, Moitra E, et al. A randomized controlled effectiveness trial of acceptance and commitment therapy and cognitive therapy for anxiety and depression. Behav Modif. 2007;31(6):772–99. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17932235]
  838. Fornaro P, Giberti F, Albano C, et al. Lamotrigine in the treatment of major depression. Preliminary results from an open study on outpatients. Ital J Psychiatr Behav Sci. 1998;8(3):114–8. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI.
  839. Forstmeier S, Rueddel H. Improving volitional competence is crucial for the efficacy of psychosomatic therapy: A controlled clinical trial. Psychother Psychosom. 2007;76(2):89–96. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 17230049]
  840. Foster MA, Ragsdale K, Dunne B, et al. Detection and treatment of depression in a VA primary care clinic. Psychiatr Serv. 1999;50(11):1494–5. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 10543862]
  841. Foster RP. Treating depression in vulnerable urban women: A feasibility study of clinical outcomes in community service settings. Am J Orthopsychiatry. 2007;77(3):443–53. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17696673]
  842. Fournier JC, DeRubeis RJ, Shelton RC, et al. Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder. Br J Psychiatr. 2008;192(2):124–9. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2682552] [PubMed: 18245030]
  843. Fowler JC, Ackerman SJ, Speanburg S, et al. Personality and symptom change in treatment-refractory inpatients: Evaluation of the phase model of change using Rorschach, TAT, and DSM-IV Axis V. J Pers Assess. 2004;83(3):306–22. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15548467]
  844. Franchini L, Bongiorno F, Spagnolo C, et al. Psychoeducational group intervention in addition to antidepressant therapy as relapse preventive strategy in unipolar patients. Clin Neuropsychiatr. 2006;3(4):282–5. OVID-Embase. Exclude: Not an eligible population treatment.
  845. Franco C, Manas I, Cangas AJ, et al. Reducing teachers’ psychological distress through a mindfulness training program. Spanish J Psychol. 2010;13(2):655–66. OVID-Embase. Exclude: Not an eligible population/treatment. [PubMed: 20977015]
  846. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatr. 1990;47(12):1093–9. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 2244793]
  847. Frank E, Kupfer DJ, Levenson J. Combined pharmacotherapy and psychotherapy for depression. Washington, DC, US: American Psychiatric Association; 1990. Continuation therapy for unipolar depression: The case for combined treatment. OVID-PsycINFO. Exclude: Not an eligible study design.
  848. Frank E, Grochocinski VJ, Spanier CA, et al. Interpersonal psychotherapy and antidepressant medication: Evaluation of a sequential treatment strategy in women with recurrent major depression. J Clin Psychiatry. 2000;61(1):51–7. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 10695647]
  849. Frank E, Kupfer DJ, Buysse DJ, et al. Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry. 2007;164(5):761–7. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3579577] [PubMed: 17475735]
  850. Frank E, Stewart BD. Treating depression in victims of rape. Clin Psychol. 1983;36(4):95–8. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  851. Frankenburg JB. The effects of three experimental phenomenological techniques in treating dysthymic depression. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  852. Franzblau SH, Echevarria S, Smith M, et al. A preliminary investigation of the effects of giving testimony and learning yogic breathing techniques on battered women’s feelings of depression. J Interpersonal Violence. 2008;23(12):1800–8. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 18319369]
  853. Frazer CJ, Christensen H, Griffiths KM. Effectiveness of treatments for depression in older people. Med J Aust. 2005;182(12):627–32. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15963019]
  854. Frederick C. Pools and wellings: The resolution of refractory intermittent depressive symptoms with ego-state therapy. Hypnos. 1993;20(4):221–7. OVID-AMED. Exclude: Not an eligible study design.
  855. Frederick JT, Steinman LE, Prohaska T, et al. Community-based treatment of late life depression: An expert panel-informed literature review. Am J Prev Med. 2007;33(3):222–49. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17826584]
  856. Free ML, Oei TP, Sanders MR. Treatment outcome of a group cognitive therapy program for depression. Int J Group Psychother. 1991;41(4):533–47. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1938020]
  857. Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass surgery: A randomized controlled trial. Arch Gen Psychiatr. 2009;66(4):387–96. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 19349308]
  858. Freeman MP, Hibbeln JR, Wisner KL, et al. An open trial of Omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatr. 2006;18(1):21–4. OVID-Embase. Exclude: Not an eligible study design.
  859. Freeman MP, Hibbeln JR, Silver M, et al. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: A preliminary open trial. Menopause. 2011;18(3):279–84. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC3195360] [PubMed: 21037490]
  860. Fremont J, Wilcoxon CL. Aerobic exercise and cognitive therapy in the treatment of dysphoric moods. Cognit Ther Res. 1987;11(2):241–51. OVID-Embase. Exclude: Not an eligible population treatment.
  861. Friedberg F, Krupp LB. A comparison of cognitive behavioral treatment for chronic fatigue syndrome and primary depression. Clin Infect Dis. 1994;18(Suppl 1):S105–10. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8148435]
  862. Friedberg RD, McClure JM, Wilding L, et al. A cognitive-behavioral skills training group for children experiencing anxious and depressive symptoms: A clinical report with accompanying descriptive data. J Contemp Psychother. 2003;33(3):157–75. OVID-Embase. Exclude: Not an eligible study design.
  863. Friede M, Henneicke von Zepelin HH, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John’s wort. Pharmacopsychiatr. 2001;34 Suppl-41 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11518073]
  864. Friedman AS. Interaction of drug therapy with marital therapy in depressive patients. Arch Gen Psychiatr. 1975;32(5):619–37. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 1092282]
  865. Friedman ES, Wisniewski SR, Gilmer W, et al. Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: Results of the NIMH star*D trial. Depress Anxiety. 2009;26(7):612–21. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 19382183]
  866. Friedman ES, Thase ME, Wisniewski SR, et al. Cognitive therapy augmentation versus CT switch treatment: A STAR*D report. Int J Cognit Ther. 2009;2(1):66–87. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI.
  867. Friedman MA, Cardemil EV, Uebelacker LA, et al. The GIFT program for major depression: Integrating group, individual, and family treatment. J Psychother Integrat. 2005;15(2):147–68. OVID-Embase. Exclude: Not an eligible study design.
  868. Fristad MA, Verducci JS, Walters K, et al. Impact of multifamily psychoeducational psychotherapy in treating children aged 8 to 12 years with mood disorders. Arch Gen Psychiatr. 2009;66(9):1013–21. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19736358]
  869. Frothingham SS. The effects of an optimism-based cognitive behavioral intervention on mood and functioning in cardiac patients. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  870. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607–14. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 11106131]
  871. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;(61):9–15. Exclude: Not an eligible population treatment. [PubMed: 10695639]
  872. Fu Keung WD. Cognitive and health-related outcomes of group cognitive behavioural treatment for people with depressive symptoms in Hong Kong: Randomized wait-list control study. Aust NZ J Psychiatr. 2008;42(8):702–11. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18622778]
  873. Fu WB, Fan L, Zhu XP, et al. Depressive neurosis treated by acupuncture for regulating the liver: A report of 176 cases. J Tradit Chin Med. 2009;29(2):83–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19663089]
  874. Fukunishi I, Hosaka T, Matsumoto T, et al. Liaison psychiatry and HIV infection (II): Application of relaxation in HIV positive patients. Psychiatry Clin Neurosci. 1997;51(1):5–8. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 9076853]
  875. Furtado CP, Maller JJ, Fitzgerald PB. A magnetic resonance imaging study of the entorhinal cortex in treatment-resistant depression. Psychiatry Res. 2008;163(2):133–42. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18511243]
  876. Furtado VA, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2008;(1) Art No:CD005377. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC4171386] [PubMed: 18254078]
  877. Furukawa TA, Cipriani A, Barbui C, et al. Long-term treatment of depression with antidepressants: A systematic narrative review. Can J Psychiatry. 2007;52(9):545–52. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17953158]
  878. Furze G, Dumville JC, Miles JN, et al. “Prehabilitation” prior to CABG surgery improves physical functioning and depression. Int J Cardiol. 2009;132(1):51–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2643012] [PubMed: 18703241]
  879. Gabelic I, Moll E. Moclobemide (Ro 11–1163 versus desipramine in the treatment of endogenous depression. Acta Psychiatr Scand Suppl. 1990;360:44–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2248068]
  880. Gabelic I, Kuhn B. Moclobemide (Ro 11–1163 versus tranylcypromine in the treatment of endogenous depression. Acta Psychiatr Scand Suppl. 1990;82(360):63. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 2248076]
  881. Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: An open, descriptive study. Depress Anxiety. 2006;23(8):485–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16845646]
  882. Gagiano CA, Muller PG, Fourie J, et al. The therapeutic efficacy of paroxetine: (a) An open study in patients with major depression not responding to antidepressants; (b) A double-blind comparison with amitriptyline in depressed outpatients. Acta Psychiatr Scand Suppl. 1989;350:130–1. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2530765]
  883. Gaik FV. Merging east and west: A preliminary study applying spring forest qigong to depression as an alternative and complementary treatment. 2003. OVID-PsycINFO. Exclude: Not an eligible study design.
  884. Galecki P, Szemraj J, Bienkiewicz M, et al. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol. 2009;24(4):277–86. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19319921]
  885. Gallagher-Thompson D, Hanley-Peterson P, Thompson LW. Maintenance of gains versus relapse following brief psychotherapy for depression. Journal of Consulting and Clinical Psychology. 1990;58(3):371–4. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 2365900]
  886. Gallagher-Thompson D, Gray HL, Tang PC, et al. Impact of in-home behavioral management versus telephone support to reduce depressive symptoms and perceived stress in Chinese caregivers: Results of a pilot study. Am J Geriatr Psychiatr. 2007;15(5):425–34. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17463192]
  887. Gallagher-Thompson D, Gray HL, Dupart T, et al. Effectiveness of cognitive/behavioral small group intervention for reduction of depression and stress in non-Hispanic White and Hispanic/Latino women dementia family caregivers: Outcomes and mediators of change. J Rational-Emotive Cognit Behav Ther. 2008;26(4):286–303. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  888. Gallagher DE, Thompson LW. Treatment of major depressive disorder in older adult outpatients with brief psychotherapies. Psychother Theory Res Pract. 1982;19(4):482–90. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  889. Gallagher DE, Thompson LW. Effectiveness of psychotherapy for both endogenous and nonendogenous depression in older adult outpatients. J Gerontol. 1983;38(6):707–12. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 6630906]
  890. Gallagher SM, Allen JJ, Hitt SK, et al. Six-month depression relapse rates among women treated with acupuncture. Complement Ther Med. 2001;9(4):216–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12184348]
  891. Ganster DC, Mayes BT, Sime WE, et al. Managing organizational stress: A field experiment. J Appl Psychol. 1982;67(5):533–42. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 6754688]
  892. Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 2008;23(5):269–75. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18703936]
  893. Garcia-Lizana F, Munoz-Mayorga I. Telemedicine for depression: A systematic review. Perspect Psychiatr Care. 2010;46(2):119–26. EBSCO-CINAHL. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20377799]
  894. Garcia-Toro M, Segura C, Gonzalez A, et al. Inefficacy of burst-suppression anesthesia in medication-resistant major depression: A controlled trial. J ECT. 2001;17(4):284–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11731731]
  895. Gardner EA. Long-term preventive care in depression: The use of bupropion in patients intolerant of other antidepressants. J Clin Psychiatry. 1983;44(5:Pt 2):t-62. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6406449]
  896. Gariballa S, Forster S. Effects of dietary supplements on depressive symptoms in older patients: A randomised double-blind placebo-controlled trial. Clin Nutr. 2007;26(5):545–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17662509]
  897. Garriock HA, Delgado P, Kling MA, et al. Number of risk genotypes is a risk factor for major depressive disorder: A case control study. Behav Brain Func. 2006;2 2006. Article Number: 24. Date of Publication: 05 Jul 2006. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC1526442] [PubMed: 16822313]
  898. Garriock HA, Hamilton SP. Genetic studies of drug response and side effects in the STAR*D study, part 2. J Clin Psychiatry. 2009;70(9):1323–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19818256]
  899. Garriock HA, Hamilton SP. Genetic studies of drug response and side effects in the STAR*D study, part 1. J Clin Psychiatr. 2009;70(8):1186–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19758527]
  900. Garriock HA, Tanowitz M, Kraft JB, et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry. 2010;167(5):565–73. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2885766] [PubMed: 20194481]
  901. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatr. 2010;67(2):133–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2794921] [PubMed: 19846067]
  902. Gartlehner G, Hansen RA, Thieda P, et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. 2007. [PubMed: 20704050]
  903. Garvey MJ, DeRubeis RJ, Hollon SD, et al. Response of depression to very high plasma levels of imipramine plus desipramine. Biol Psychiatr. 1991;30(1):57–62. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 1892963]
  904. Gary RA, Sueta CA, Dougherty M, et al. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. Heart Lung. 2004;33(4):210–8. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 15252410]
  905. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Under Exp Clin Res. 1990;16(2):101–6. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 2205455]
  906. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatr. 2005;38(2):78–86. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15744631]
  907. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: A double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatr. 2006;39(2):66–75. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16555167]
  908. Gaszner P. About the menopausal depression. Neuropsychopharmacol Hungarica. 2005;7(4):208–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16496486]
  909. Gayle RC, Spitler DL, Karper WB, et al. Psychological changes in exercising COPD patients. Int J Rehabil Res. 1988;11(4):335–42. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 3269843]
  910. Gaynes BN, Rush AJ, Trivedi MH, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: Results from STAR*D. J Gen Intern Med. 2008;23(5):550–60. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC2324144] [PubMed: 18247097]
  911. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439–45. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19880458]
  912. Gaynor ST, Lawrence PS. Complementing CBT for depressed adolescents with Learning through In-Vivo Experience (LIVE): Conceptual analysis, treatment description, and feasibility study. Behav Cognit Psychother. 2002;30(1):79–101. OVID-Embase. Exclude: Not an eligible study design.
  913. Gecele M, Francesetti G, Meluzzi A. Acetyl-L-carnitine in aged subjects with major depression: Clinical efficacy and effects on the circadian rhythm of cortisol. Dement. 1991;2(6):333–7. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  914. Gelenberg AJ, Shelton RC, Crits-Christoph P, et al. The effectiveness of St. John’s Wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry. 2004;65(8):1114–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15323598]
  915. Gelhart RP, King HL. The influence of comorbid risk factors on the effectiveness of cognitive-behavioral treatment of depression. Cognit Behav Pract. 2001;8(1):18–28. OVID-Embase. Exclude: Not an eligible study design.
  916. Gelhart RP, Hand-Ronga N, King HL. Group cognitive-behavioral treatment of depression and the interaction of demographic variables. J Cognit Psychother. 2002;16(4):469–86. OVID-Embase. Exclude: Not an eligible study design.
  917. Geller B, Cooper TB, Graham DL, et al. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a “fixed plasma level” design. Psychopharmacol Bull. 1990;26(1):85–90. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 2196631]
  918. Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause. 2007;14(3 Pt 1):541–9. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17194961]
  919. Gelman CR, Lopez M, Foster RP. Evaluating the impact of a cognitive-behavioral intervention with depressed Latinas: A preliminary report. Soc Work Ment Health. 2005;4(2):1–16. EBSCO-CINAHL. Exclude: Not an eligible study design.
  920. Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–94. OVID-Embase. Exclude: Mixed antidepressants; some failed on SSRI. [PubMed: 17177199]
  921. Gensichen J, Petersen JJ, Karroum T, et al. Positive impact of a family practice-based depression case management on patient’s self-management. Gen Hosp Psychiatry. 2011;33(1):23–8. OVID-Embase. Exclude: Not an eligible population/treatment. [PubMed: 21353124]
  922. Genthner GC, Friedman HL, Studley CF. Improvement in depression following reduction of upper cervical vertebral subluxation using orthospinology technique. J Vertebral Sublux Res. 2005:1–4. EBSCO-CINAHL. Exclude: Not an eligible study design.
  923. George T, Theodoros MT, Chiu E, et al. An open study of sertraline in patients with major depression who failed to respond to moclobemide. Aust NZ J Psychiatr. 1999;33(6):889–95. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10619217]
  924. Georgotas A, Friedman E, McCarthy M, et al. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatr. 1983;18(2):195–205. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6830930]
  925. Geretsegger C, Bitterlich W, Stelzig R, et al. Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients. Eur Neuropsychopharmacol. 2008;18(2):141–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18054209]
  926. Gerhards SA, de Graaf LE, Jacobs LE, et al. Economic evaluation of online computerised cognitive-behavioural therapy without support for depression in primary care: Randomised trial. Br J Psychiatr. 2010;196:310–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20357309]
  927. Gervasoni N, Aubry JM, Gex-Fabry M, et al. Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression? Pharmacol Res. 2009;59(3):202–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19073260]
  928. Gervasoni N, Legendre-Simon P, Aubry JM, et al. Early telephone intervention for psychiatric outpatients starting antidepressant treatment. Nord J Psychiatr. 2010;64(4):265–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20166864]
  929. Ghaemi SN, Katzow JJ, Desai SP, et al. Gabapentin treatment of mood disorders: A preliminary study. J Clin Psychiatry. 1998;59(8):426–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9721823]
  930. Ghaemi SN, Cherry EL, Katzow JA, et al. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disorders. 2000;2(3:Pt 1):t-9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11256687]
  931. Gharabawi G, Canuso C, Pandina G. A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Int J Neuropsychopharmacol. 2006;9(Supplement 1):S236. [Abstract]
  932. Ghaziuddin N, Naylor MW, King CA. Fluoxetine in tricyclic refractory depression in adolescents. Depression. 1995;2(6):287–91. OVID-Embase. Exclude: Not an eligible study design.
  933. Ghaziuddin N, Kutcher SP, Knapp P, et al. Summary of the practice parameter for the use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43(1):119–22. OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 14691369]
  934. Giannelli A, Rabboni M, Zarattini F, et al. A combination of hypothalamic phospholipid liposomes with trazodone for treatment of depression. An open controlled study. Acta Psychiatr Scand. 1989;79(1):52–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2648767]
  935. Gibbons CJ, Fournier JC, Stirman SW, et al. The clinical effectiveness of cognitive therapy for depression in an outpatient clinic. J Affect Disord. 2010;125(1–3):169–76. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2888955] [PubMed: 20080305]
  936. Gilbert G. Adults with both anxiety and depression respond poorly to treatment. J Natl Med Assoc. 2008;100(7):870–1. OVID-Embase. Exclude: Not an eligible study design.
  937. Gilbert J, Strong J. Dysfunctional attitudes in patients with depression: A study of patients admitted to a private psychiatric hospital. Br J Occup Ther. 1994;57(1):15–9. OVID-PsycINFO. Exclude: Not an eligible study design.
  938. Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: A cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006;166(21):2314–21. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17130383]
  939. Gill A, Womack R, Safranek S. Clinical Inquiries: Does exercise alleviate symptoms of depression? J Fam Pract. 2010;59(9):530–1. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20824231]
  940. Gillham JE, Hamilton J, Freres DR, et al. Preventing depression among early adolescents in the primary care setting: a randomized controlled study of the Penn Resiliency Program. J Abnorm Child Psychol. 2006;34(2):203–19. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16741684]
  941. Gilmer WS, Gollan JK, Wisniewski SR, et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry. 2008;69(8):1246–56. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18681756]
  942. Ginsberg DL. Chromium picolinate treatment of atypical depression. Prim Psychiatr. 2003;10(4):23–4. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  943. Ginsberg DL. Adjunctive ropinirole for treatment-resistant depression. Prim Psychiatr. 2005;12(8):26–7. OVID-PsycINFO. Exclude: Not an eligible study design.
  944. Ginsberg DL. Atomoxetine augmentation of antidepressants. Prim Psychiatr. 2005;12(3):19. OVID-PsycINFO. Exclude: Not an eligible study design.
  945. Gitlin MJ, Weiner H, Fairbanks L, et al. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord. 1987;13(3):267–72. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2960719]
  946. Given C, Given B, Rahbar M, et al. Does a symptom management intervention affect depression among cancer patients: Results from a clinical trial. Psychooncol. 2004;13(11):818–30. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15386790]
  947. Glassman AH, Platman SR. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res. 1969;7(2):83–8. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4917709]
  948. Glueckauf RL, Davis WS, Allen K, et al. Integrative cognitive-behavioral and spiritual counseling for rural dementia caregivers with depression. Rehabil Psychol. 2009;54(4):449–61. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19929127]
  949. Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1974941]
  950. Godfrin KA, van HC. The effects of mindfulness-based cognitive therapy on recurrence of depressive episodes, mental health and quality of life: A randomized controlled study. Behav Res Ther. 2010;48(8):738–46. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20462570]
  951. Goel N, Terman M, Terman JS, et al. Controlled trial of bright light and negative air ions for chronic depression. Psychol Med. 2005;35(7):945–55. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16045061]
  952. Goel N, Etwaroo GR. Bright light, negative air ions and auditory stimuli produce rapid mood changes in a student population: A placebo-controlled study. Psychol Med. 2006;36(9):1253–63. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16756690]
  953. Gold C, Solli HP, Kruger V, et al. Dose-response relationship in music therapy for people with serious mental disorders: Systematic review and meta-analysis. Clin Psychol Rev. 2009;29(3):193–207. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19269725]
  954. Goldberg B. Psychotropic drugs in children: A guide for the family physician. Can Fam Physician. 1989;35:2459–63. OVID-Embase. Exclude: Not an eligible guideline. [PMC free article: PMC2280178] [PubMed: 20469507]
  955. Gonul AS, Oguz A, Yabanoglu I, et al. Buspiron and pindolol in augmentation therapy of treatment-resistant depression. Eur Neuropsychopharmacol. 1999;9(Suppl 5):215. Wiley-CCTR. Exclude: Mixed antidepressants:some failed on SSRI.
  956. Gonul AS, Doksat K, Eker C, et al. Trends in serotonin uptake inhibitor research. Hauppauge, NY: Nova Biomedical Books; 2005. Managing treatment-resistant depression: Focusing on increasing serotonergic transmission. OVID-PsycINFO. Exclude: Not an eligible study design.
  957. Gonzalez-Pinto A, Gutierrez M, Gonzalez N, et al. Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression. J Neuropsychiatr Clin Neurosci. 2002;14(2):206–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11983797]
  958. Gonzalez GM, Munoz RF, Perez-Arce P, et al. Depression and HIV disease in injection drug users: A Spanish language feasibility study. Psychol Addict Behav. 1993;7(3):149–54. OVID-PsycINFO. Exclude: Not an eligible study design.
  959. Goodwin FK, Prange AJ Jr, Post RM, et al. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry. 1982;139(1):34–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7055275]
  960. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17(2):149–73. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 12870562]
  961. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: Randomised controlled trial. Br Med J. 2007;335(7611):142. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1925185] [PubMed: 17556431]
  962. Goodyer IM, Dubicka B, Wilkinson P, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess. 60 B.C.;12(14):iii–iiv. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18462573]
  963. Gordijn MCM, Beersma DGM, Korte HJ, et al. Testing the hypothesis of a circadian phase disturbance underlying depressive mood in nonseasonal depression. J Biol Rhythms. 1998;13(2):132–47. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 9554575]
  964. Gordon VC, Matwychuk AC, Sachs EG, et al. A 3-yr follow-up of a cognitive-behavioral therapy intervention. Arch Psychiatr Nurs. 1988;2(4):218–26. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 3178300]
  965. Gorgulu Y, Caliyurt O. Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. Brain Res Bull. 2009;80(3):158–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19576267]
  966. Gortner ET, Gollan JK, Dobson KS, et al. Cognitive-behavioral treatment for depression: Relapse prevention. J Consult Clin Psychol. 1998;66(2):377–84. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9583341]
  967. Gosney MA, Hammond MF, Shenkin A, et al. Effect of micronutrient supplementation on mood in nursing home residents. Gerontology. 2008;54(5):292–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18463429]
  968. Graf MC, Gaudiano BA, Geller PA. Written emotional disclosure: A controlled study of the benefits of expressive writing homework in outpatient psychotherapy. Psychother Res. 2008;18(4):389–99. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18815991]
  969. Gram LF, Rasmussen NA, Andersen PM, et al. Acute and continuation therapy in unipolar depression: Observations from the run-in phase of a maintenance trial. Acta Psychiatr Scand. 2008;118(2):123–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 18384466]
  970. Grant GM, Salcedo V, Hynan LS, et al. Effectiveness of quality of life therapy for depression. Psychol Rep. 1995;76(3:Pt 2):t-8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7480486]
  971. Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10–171 and amitriptyline in depressed patients. Acta Psychiatr Scand. 1987;75(5):478–86. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3300171]
  972. Gray N, Mays MZ, Wolf D, et al. Culturally focused wellness intervention for American Indian women of a small southwest community: Associations with alcohol use, abstinence self-efficacy, symptoms of depression, and self-esteem. Am J Health Promot. 2010;25(2):e1–10. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 21066905]
  973. Greden JF, Pande AC. Treatment of resistant depression with 5-HT uptake inhibitors. Clin Neuropharmacol. 1992;15 Suppl-443A OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1498908]
  974. Greden JF, Valenstein M, Spinner J, et al. Buddy-to-Buddy, a citizen soldier peer support program to counteract stigma, PTSD, depression, and suicide. Ann NY Acad Sci. 2010;1208:90–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20955330]
  975. Green BL, Krupnick JL, Chung J, et al. Impact of PTSD comorbidity on one-year outcomes in a depression trial. J Clin Psychiatry. 2006;62(7):815–35. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 16703602]
  976. Green TD, Reynolds CF III, Mulsant BH, et al. Accelerating antidepressant response in geriatric depression: A post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetine, nortriptyline, or placebo. J Geriatr Psychiatry Neurol. 1999;12(2):67–71. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10483927]
  977. Grenyer BF, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: A randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1393–6. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 17659823]
  978. Griffith PR. Is tryptophan useful in the treatment of depression? Employee Assist Q. 1986;2(1):23–30. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  979. Griffiths KM, Christensen H. Internet-based mental health programs: A powerful tool in the rural medical kit. Aust J Rural Health. 2007;15(2):81–7. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17441815]
  980. Griffiths L, Blignault I, Yellowlees P. Telemedicine as a means of delivering cognitive-behavioural therapy to rural and remote mental health clients. J Telemed Telecare. 2006;12(3):136–40. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16638234]
  981. Grigoriadis S, Kennedy SH, Srinivasan J, et al. SSRI augmentation with raloxifene for treatment-resistant depression. 2001. Wiley-CCTR. Exclude: Not an eligible study design.
  982. Grime PR. Computerized cognitive behavioural therapy at work: A randomized controlled trial in employees with recent stress-related absenteeism. Occup Med. 2004;54(5):353–9. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 15289593]
  983. Grof P, Joffe R, Kennedy S, et al. An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. Int Clin Psychopharmacol. 1993;8(3):167–72. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8263314]
  984. Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial. Neurology. 2010;75(13):1141–9. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PMC free article: PMC3463050] [PubMed: 20876468]
  985. Grunhaus L, Hirschman S, Dolberg OT, et al. Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT. J ECT. 2001;17(2):124–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11417923]
  986. Grunhaus LJ, Hirschmann S, Dolberg OT. Melatonin and fluoxetine in the prevention of depressive relapses after successful ECT treatment. 1997. Wiley-CCTR. Exclude: Not an eligible study design.
  987. Guaraldi GP, Fava M, Mazzi F, et al. An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatr. 1993;5(2):101–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8348200]
  988. Guelfi JD, Troy S. Sertraline in depressed patients resistant and/or intolerant to a previous treatment. May 15, 1999. 1999. Wiley-CCTR. Exclude: Not an eligible study design.
  989. Guétin S, Portet F, Picot MC, et al. Effect of music therapy on anxiety and depression in patients with Alzheimer’s type dementia: Randomised, controlled study. Dement Geriatr Cognit Disord. 2009;28(1):36–46. EBSCO-CINAHL. Exclude: Not an elligible population design. [PubMed: 19628939]
  990. Guirguis-Younger M, Cappeliez P, Younger A. A community-based intervention for treating depression in seniors. Can J Nurs Res. 2008;40(1):61–79. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18459272]
  991. Gum AM, Arean PA, Bostrom A. Low-income depressed older adults with psychiatric comorbidity: Secondary analyses of response to psychotherapy and case management. Int J Geriatr Psychiatry. 2007;22(2):124–30. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17096464]
  992. Gupta PK, Kumar M, Kumari R, et al. Anuloma-Viloma Pranayama and anxiety and depression among the aged. J Indian Acad Appl Psychol. 2010;36(1):159–64. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI.
  993. Gusi N, Reyes MC, Gonzalez-Guerrero JL, et al. Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: A randomised controlled trial. BMC Pub Health. 2008;8:231. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2491610] [PubMed: 18611277]
  994. Gutierrez RL, McKercher R, Galea J, et al. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectrums. 2005;10(10):800–5. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 16400242]
  995. Gwirtsman HE, Szuba MP, Toren L, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacol Bull. 1994;30(2):157–64. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7831449]
  996. Gyulai L, Bauer M, Garcia-Espana F, et al. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord. 2001;66(2–3):185–91. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11578671]
  997. Ha EH, Oh KJ. Effects of cognitive-behavioral group therapy for depressive mothers of children with behavior problems. Child Fam Behav Ther. 2006;28(2):1–13. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  998. Habib D, Seif ED. Effectiveness of cognitive behaviour therapy in schoolchildren with depressive symptoms in Alexandria, Egypt. East Mediterranean Health J. 2007;13(3):615–24. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17687835]
  999. Habukawa M, Uchimura N, Kakuma T, et al. Effect of CPAP treatment on residual depressive symptoms in patients with major depression and coexisting sleep apnea: Contribution of daytime sleepiness to residual depressive symptoms. Sleep Med. 2010;11(6):552–7. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20488748]
  1000. Hackett ML, Anderson CS, House AO. Management of depression after stroke: A systematic review of pharmacological therapies. Stroke. 2005;36(5):1092–7. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15802637]
  1001. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008;(4):CD003437. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18843644]
  1002. Hagen R, Nordahl HM, Kristiansen L, et al. A randomized trial of cognitive group therapy vs. waiting list for patients with co-morbid psychiatric disorders: Effect of cognitive group therapy after treatment and six and twelve months follow-up. Behav Cognit Psychother. 2005;33(1):33–44. OVID-Embase. Exclude: Not an eligible population treatment.
  1003. Hagen R, Nordahl HM, Grawe RW. Cognitive-behavioural group treatment of depression in patients with psychotic disorders. Clin Psychol Psychother. 2005;12(6):465–74. OVID-Embase. Exclude: Not an eligible study design.
  1004. Halford WK. Cognitive behavioural treatment of adjustment disorder with depressed mood following marital breakdown. Behav Change. 1987;4(1):28–33. OVID-Embase. Exclude: Not an eligible study design.
  1005. Hallert C, Astrom J, Walan A. Reversal of psychopathology in adult coeliac disease with the aid of pyridoxine (vitamin B6) Scand J Gastroenterol. 1983;18(2):299–304. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6369511]
  1006. Hamamci Z. Integrating psychodrama and cognitive behavioral therapy to treat moderate depression. Arts Psychother. 2006;33(3):199–207. OVID-Embase. Exclude: Not an eligible population treatment.
  1007. Hambridge JA, Turner A, Baker AL. BraveHeart begins: pilot results of group cognitive behaviour therapy for depression and anxiety in cardiac patients. Aust NZ J Psychiatr. 2009;43(12):1171–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20001417]
  1008. Hamdan-Mansour AM, Puskar K, Bandak AG. Effectiveness of cognitive-behavioral therapy on depressive symptomatology, stress and coping strategies among Jordanian university students. Issues Ment Health Nurs. 2009;30(3):188–96. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19291496]
  1009. Hampel P, Graef T, Krohn-Grimberghe B, et al. Effects of gender and cognitive-behavioral management of depressive symptoms on rehabilitation outcome among inpatient orthopedic patients with chronic low back pain: A 1 year longitudinal study. Eur Spine J. 2009;18(12):1867–80. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2899429] [PubMed: 19562387]
  1010. Hamre HJ, Witt CM, Glockmann A, et al. Anthroposophic therapy for chronic depression: A four-year prospective cohort study. BMC Psychiatr. 2006;6:57. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC1764730] [PubMed: 17173663]
  1011. Hamre HJ, Witt CM, Glockmann A, et al. Eurythmy therapy in chronic disease: A four-year prospective cohort study. BMC Pub Health. 2007;7 2007. Article Number: 61. Date of Publication: 2007. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC1868723] [PubMed: 17451596]
  1012. Hamre HJ, Witt CM, Glockmann A, et al. Rhythmical massage therapy in chronic disease: A 4-year prospective cohort study. J Altern Complement Med. 2007;13(6):635–42. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17718646]
  1013. Han C, Li X, Luo H, et al. Clinical study on electro-acupuncture treatment for 30 cases of mental depression. J Tradit Chin Med. 2004;24(3):172–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15510791]
  1014. Han P, Kwan M, Chen D, et al. A controlled naturalistic study on a weekly music therapy and activity program on disruptive and depressive behaviors in dementia. Dement Geriatr Cognit Disord. 2011;30(6):540–6. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PubMed: 21252549]
  1015. Hangen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. J Geriatr Psychiatry Neurol. 1994;7(Suppl):8. OVID-Medline. Excluded. [PubMed: 7857501]
  1016. Hannaford CP, Harrell EH, Cox K. Psychophysiological effects of a running program on depression and anxiety in a psychiatric population. Psychol Record. 1988;38(1):37–48. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1017. Hannan N, Hamzah Z, Akinpeloye HO, et al. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol. 2007;21(2):161–4. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17329295]
  1018. Hanser SB, Thompson LW. Effects of a music therapy strategy on depressed older adults. J Gerontology. 1994;49(6):265–9. Exclude: Not an eligible population treatment. [PubMed: 7963281]
  1019. Hanson LM. The efficacy of three treatments for depression: Morita psychotherapy, dietary brain-chemistry treatment, and the combination of morita psychotherapy/brain-chemistry treatment as compared to no-treatment control. 2002. OVID-PsycINFO. Exclude: Not an eligible study design.
  1020. Hansson M, Bodlund O, Chotai J. Patient education and group counselling to improve the treatment of depression in primary care: A randomized controlled trial. J Affect Disord. 2008;105(1–3):235–40. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 17509694]
  1021. Hantouche EG, Akiskal HS, Lancrenon S, et al. Mood stabilizer augmentation in apparently “unipolar” MDD: Predictors of response in the naturalistic French national EPIDEP study. J Affect Disord. 2005;84(2–3):243–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15708422]
  1022. Harden JAT. Effect of movement group therapy on depression, morale and self-esteem in aged women. University of Texas; Austin: 1989. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1023. Hardy GE, Cahill J, Stiles WB, et al. Sudden gains in cognitive therapy for depression: A replication and extension. J Consult Clin Psychol. 2005;73(1):59–67. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15709832]
  1024. Hare HP. Comparison of chlordiazepoxide-amitriptyline combination with amitriptyline alone in anxiety-depressive states. J Clin Pharmacol New Drugs. 1971;11(6):456–60. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4945123]
  1025. Haringsma R, Engels GI, Cuijpers P, et al. Effectiveness of the Coping With Depression (CWD) course for older adults provided by the community-based mental health care system in the Netherlands: A randomized controlled field trial. Int Psychogeriatr. 2006;18(2):307–25. Exclude: Not an eligible population treatment. [PubMed: 16255838]
  1026. Harley R, Sprich S, Safren S, et al. Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression. J Nerv Ment Dis. 2008;196(2):136–43. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 18277222]
  1027. Harner H, Hanlon AL, Garfinkel M. Effect of Iyengar yoga on mental health of incarcerated women: A feasibility study. Nurs Res. 2010;59(6):389–99. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20842067]
  1028. Harrer G, Hubner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: A multicenter double-blind study. J Geriatr Psychiatry Neurol. 1994;7 Suppl-8 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7857503]
  1029. Harrer G, Schmidt U, Kuhn U, et al. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetine. Arzneim-Forsch. 1999;49(4):289–96. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10337446]
  1030. Harris T, Brown GW, Robinson R. Befriending as an intervention for chronic depression among women in an inner city. 1: Randomised controlled trial. Br J Psychiatr. 1999;174:219–24. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10448446]
  1031. Hart S, Fonareva I, Merluzzi N, et al. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res. 2005;14(3):695–703. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16022063]
  1032. Hartley DE, Elsabagh S, File SE. Gincosan (a combination of Ginkgo biloba and Panax ginseng): The effects on mood and cognition of 6 and 12 weeks’ treatment in post-menopausal women. Nutr Neurosci. 2004;7(5–6):325–33. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 15682929]
  1033. Harvey AT, Silkey BS, Kornstein SG, et al. Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: Differences by sex and menopausal status. J Clin Psychiatry. 2007;68(6):951–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17592923]
  1034. Hauenstein EJ. Testing innovative nursing care: Home intervention with depressed rural women. Issues Ment Health Nurs. 1996;17(1):33–50. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 8682665]
  1035. Hautzinger M, Jong-Meyer R. Cognitive-behavioural therapy versus pharmacotherapy in depression. 1996. pp. 329–40. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  1036. Hawkins WE, Latkin C, Green DL. Depression therapy with injection drug users: Results of a pilot study. Am J Drug Alcohol Abuse. 2005;31(2):243–51. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15912714]
  1037. Hawley C, Sivakumaran T, Huber TJ, et al. Combination therapy with nefazodone and lithium: Safety and tolerability in fourteen patients. Int J Psychiatr Clin Pract. 1998;2(4):251–4. OVID-Embase. Exclude: Not an eligible study design.
  1038. Hawley CJ, Quick SJ, Ratnam S, et al. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. Int Clin Psychopharmacol. 1996;11(3):187–91. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8923097]
  1039. Hawley CJ, Pattinson HA, Quick SJ, et al. A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype. J Affect Disord. 1998;47(1–3):87–96. OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 9476748]
  1040. Hayward LM, Sullivan AC, Libonati JR. Group exercise reduces depression in obese women without weight loss. Percept Motor Skills. 2000;90(1):204–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10769900]
  1041. He Q, Zhang J, Tang Y. A controlled study on treatment of mental depression by acupuncture plus TCM medication. J Tradit Chin Med. 2007;27(3):166–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17955648]
  1042. He Y, Wang X, Xiao C, et al. Paroxetine with psychotherapy on post-stroke depression patients, a random placebo-controlled study. Neurol Ment Health. 2005;(5):6–9. Exclude: Not an eligible population treatment.
  1043. Hebenstreit GF, Fellerer K, Zochling R, et al. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand Suppl. 1989;350:81–4. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2530795]
  1044. Hejazi S, Ashayeri H, Mahmoodi M, et al. Effects of music on depression in students of Iran University of Medical Sciences, Tehran 2004. SBMU Faculty Nurs Midwif Q. 2005;14(47):56. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  1045. Hellerstein DJ, Little S, Batchelder S, et al. Dysthymia: An outcome study of combined group therapy and medication treatment versus medication treatment alone. 1997. Wiley-CCTR. Exclude: Not an eligible study design.
  1046. Hellerstein DJ, Little SA, Samstag LW, et al. Adding group psychotherapy to medication treatment in dysthymia: A randomized prospective pilot study. J Psychother Pract Res. 2001;10(2):93–103. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3330638] [PubMed: 11264333]
  1047. Hellerstein DJ, Batchelder S, Hyler S, et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):744–50. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18164528]
  1048. Hemmeter U, Hatzinger M, Brand S, et al. Effect of flumazenil-augmentation on microsleep and mood in depressed patients during partial sleep deprivation. J Psychiatr Res. 2007;41(10):876–84. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16978648]
  1049. Hendrickx B, Floris M. A controlled pilot study of the combination of fluvoxamine and lithium. Curr Ther Res Clin Exp. 1991;49(1):106–10. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  1050. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch Gen Psychiatr. 1983;40(12):1335–42. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 6418110]
  1051. Henken T, Huibers Marcus JH, Churchill R, et al. Family therapy for depression. Cochrane Database Syst Rev. 2007;(3):CD006728. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17636850]
  1052. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2009;43(3):215–29. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18586274]
  1053. Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93(1–3):239–43. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16677714]
  1054. Hermens ML, van Hout HP, Terluin B, et al. Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: A randomized equivalence trial. BMC Med. 2007;5:36. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2234409] [PubMed: 18067659]
  1055. Hernandez-Avila CA, Modesto-Lowe V, Feinn R, et al. Nefazodone treatment of comorbid alcohol dependence and major depression. Alcoholism Clin Exp Res. 2004;28(3):433–40. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 15084901]
  1056. Hernandez-Reif M, Ironson G, Field T, et al. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. J Psychosom Res. 2004;57(1):45–52. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15256294]
  1057. Herrington RN, Bruce A, Johnstone EC, et al. Comparative trial of L-tryptophan and amitriptyline in depressive illness. Psychol Med. 1976;6(4):673–8. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 794897]
  1058. Herwig U, Fallgatter AJ, Hoppner J, et al. Antidepressant effects of augmentative transcranial magnetic stimulation: Randomised multicentre trial. Br J Psychiatr. 2007;191:441–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17978325]
  1059. Hesse M. Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature. BMC Psychiatr. 2009;9(Art No.:6) OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2657780] [PubMed: 19232121]
  1060. Hewett K, Chrzanowski W, Schmitz M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol. 2009;23(5):531–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18635695]
  1061. Hickman SE, Barrick AL, Williams CS, et al. The effect of ambient bright light therapy on depressive symptoms in persons with dementia. J Am Geriatr Soc. 2007;55(11):1817–24. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 17944896]
  1062. Hides L, Carroll S, Catania L, et al. Outcomes of an integrated cognitive behaviour therapy (CBT) treatment program for co-occurring depression and substance misuse in young people. J Affect Disord. 2010;121(1–2):169–74. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19604584]
  1063. Hides L, Samet S, Lubman DI. Cognitive behaviour therapy (CBT) for the treatment of co-occurring depression and substance use: Current evidence and directions for future research. Drug Alcohol Rev. 2010;29(5):508–17. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20887574]
  1064. Hilsenroth MJ, Ackerman SJ, Blagys MD, et al. Short-term psychodynamic psychotherapy for depression: An examination of statistical, clinically significant, and technique-specific change. J Nerv Ment Dis. 2003;191(6):349–57. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12826915]
  1065. Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: A systematic review and meta-analysis. Aids Patient Care STDS. 2005;19(12):813–22. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16375613]
  1066. Himelhoch S, Mohr D, Maxfield J, et al. Feasibility of telephone-based cognitive behavioral therapy targeting major depression among urban dwelling African-American people with co-occurring HIV. Psychol Health Med. 2011;16(2):156–65. OVID-PsycINFO. Exclude: Not an eligible study design. [PMC free article: PMC3189854] [PubMed: 21328144]
  1067. Hirose S, Ashby CR Jr. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry. 2002;63(8):733–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12197455]
  1068. Hirsch C, Jolley S, Williams R. A study of outcome in a clinical psychology service and preliminary evaluation of cognitive-behavioural therapy in real practice. J Ment Health. 2000;9(5):537–49. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1069. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatr. 2002;51(2):123–33. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11822991]
  1070. Hirschfeld RMA, Nemeroff CB, Dunner DL, et al. Guidelines for the long-term treatment of depression. J Clin Psychiatr. 1994;55(12 SUPPL):61–9. OVID-Embase. Exclude: Not an eligible guideline.
  1071. Hitt RA. An evidence-based group treatment for depressed female adolescents and their mothers. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  1072. Hobi V, Gastpar M, Gastpar G, et al. Driving ability of depressive patients under antidepressants. J Int Med Res. 1982;10(2):65–81. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6121737]
  1073. Hodgkiss AD, McCarthy PT, Sulke AN, et al. High dose tertiary amine tricyclic antidepressants in the treatment of severe refractory depression: The central role of plasma concentration estimations. Hum Psychopharmacol. 1995;10(5):407–15. OVID-Embase. Exclude: Not an eligible study design.
  1074. Hoencamp E, Haffmans PM, Dijken WA. Lithium addition versus brofaromine in refractory, depressed patients. Clin Neuropharmacol. 1992;15(1 Pt B):325. Wiley-CCTR. Exclude: Not an eligible study design.
  1075. Hoencamp E, Haffmans PM, Dijken WA, et al. Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients. J Affect Disord. 1994;30(3):219–27. OVID-Medline. Excluded. [PubMed: 8006248]
  1076. Hoencamp E, Haffmans J, Dijken WA, et al. Lithium augmentation of venlafaxine: An open-label trial. J Clin Psychopharmacol. 2000;20(5):538–43. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11001238]
  1077. Hoffman BM, Babyak MA, Sherwood A, et al. Effects of aerobic exercise on sexual functioning in depressed adults. Ment Health Phys Activ. 2009;2(1):23–8. OVID-Embase. Exclude: Not an eligible population treatment.
  1078. Hoffman BM, Babyak MA, Craighead WE, et al. Exercise and pharmacotherapy in patients with major depression: One-year Follow-Up of the SMILE study. Psychosom Med. 2011;73(2):127–33. OVID-Embase. Exclude: Not an eligible population/treatment. [PMC free article: PMC3671874] [PubMed: 21148807]
  1079. Hoffman JM, Bell KR, Powell JM, et al. A randomized controlled trial of exercise to improve mood after traumatic brain injury. Pm & R. 2010;2(10):911–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20970760]
  1080. Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol. 2010;78(2):169–83. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2848393] [PubMed: 20350028]
  1081. Hogg JA, Deffenbacher JL. A comparison of cognitive and interpersonal-process group therapies in the treatment of depression among college students. J Couns Psychol. 1988;35(3):304–10. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1082. Hojaij CR. Reconsidering antidepressants infusions for resistant depressions in out-patient service. Neurol Psychiatr Brain Res. 1995;3(2):129–32. OVID-Embase. Exclude: Not an eligible study design.
  1083. Hollinghurst S, Peters TJ, Kaur S, et al. Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: Randomised controlled trial. Br J Psychiatr. 2010;197(4):297–304. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20884953]
  1084. Hollister LE, Overall JE, Shelton J, et al. Drug therapy of depression. Amitriptyline, perphenazine, and their combination in different syndromes. Arch Gen Psychiatr. 1967;17(4):486–93. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4861381]
  1085. Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatr. 1992;49(10):774–81. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1417429]
  1086. Hollon SD, DeRubeis RJ, Evans MD. Cognitive therapy in the treatment and prevention of depression. 1996. pp. 293–317. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  1087. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatr. 2005;62(4):417–22. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15809409]
  1088. Hollon SD, Jarrett RB, Nierenberg AA, et al. Psychotherapy and medication in the treatment of adult and geriatric depression: Which monotherapy or combined treatment? J Clin Psychiatr. 2005;66(4):455–68. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15816788]
  1089. Hollon SD, Shelton RC. Treatment guidelines for major depressive disorder. Behav Ther. 2001;32(2):235–58. OVID-PsycINFO. Exclude: Not an eligible guideline.
  1090. Holmgren E, Gosman-Hedstrom G, Lindstrom B, et al. What is the benefit of a high-intensive exercise program on health-related quality of life and depression after stroke? A randomized controlled trial. Adv Physiother. 2010;12(3):125–33. OVID-Embase. Exclude: Not an eligible population/treatment. [PMC free article: PMC2956448] [PubMed: 21037954]
  1091. Holroyd S, Durgee J. Venlafaxine in treatment refractory geriatric depression. Clin Gerontol. 1998;18(3):39–50. OVID-Embase. Exclude: Not an eligible study design.
  1092. Holsboer-Trachsler E, Ernst K. Sustained antidepressive effect of repeated partial sleep deprivation. Psychopathol. 1986;19 Suppl-6 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3575621]
  1093. Holtzheimer PE III, Meeks TW, Kelley ME, et al. A double-blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry. 2008;23(6):625–31. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC4407281] [PubMed: 18058832]
  1094. Honore P, Moller SE, Jorgensen A. Lithium + L-tryptophan compared with amitriptyline in endogenous depression. J Affect Disord. 1982;4(1):79–82. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6461690]
  1095. Hopko DR, Bell JL, Armento M, et al. Cognitive-behavior therapy for depressed cancer patients in a medical care setting. Behav Ther. 2008;39(2):126–36. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18502246]
  1096. Hopwood SE, Bogle S, Wildgust HJ. The combination of fluoxetine and lithium in clinical practice. Int Clin Psychopharmacol. 1993;8(4):325–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8277157]
  1097. Hornig-Rohan M, Amsterdam JD. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):585–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11999912]
  1098. Horowitz A, Reinhardt JP, Boerner K. The effect of rehabilitation on depression among visually disabled older adults. Aging Ment Health. 2005;9(6):563–70. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16214704]
  1099. Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacol. 2010;35(3):727–40. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC3055621] [PubMed: 19924111]
  1100. Hosaka T, Sugiyama Y. Structured intervention in family caregivers of the demented elderly and changes in their immune function. Psychiatry Clin Neurosci. 2003;57(2):147–51. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 12667160]
  1101. Hou WH, Chiang PT, Hsu TY, et al. Treatment effects of massage therapy in depressed people: A meta-analysis. J Clin Psychiatr. 2010;71(7):894–901. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20361919]
  1102. Hou Y-M, Kang B, Lin J-D, et al. Combined cognitive therapy with fluoxetine hydrochloride on patients with senile depressive neurosis in open wards: A randomized controlled study. Chin J Clin Rehab. 2003;7(30):4105–7. OVID-Embase. Exclude: Not an elligible population design.
  1103. Houghton S, Curran J, Saxon D. An uncontrolled evaluation of group behavioural activation for depression. Behav Cognit Psychother. 2008;36(2):235–9. OVID-Embase. Exclude: Not an eligible study design.
  1104. Howell CA, Turnbull DA, Beilby JJ, et al. Preventing relapse of depression in primary care: A pilot study of the “Keeping the blues away” program. Med J Aust. 2008;188(12:Suppl) Suppl-41 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18558915]
  1105. Howland RH. Sequenced treatment alternatives to relieve depression (STAR*D) - Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv. 2008;46(10):21–4. ISI:000259780300009. Exclude: Not an eligible population treatment. [PubMed: 18935932]
  1106. Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug Alcohol Dependence. 2009;99(1–3):248–60. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18986774]
  1107. Høstmaelingen HJ, Asskilt O, Austad SG, et al. Primary care treatment of depression in the elderly: A double-blind, multi-centre study of flupenthixol (‘Fluanxol’) and sustained-release amitriptyline. Curr Med Res Opin. 1989;11(9):593–9. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 2692973]
  1108. Hsu W, Lai H. Effects of music on major depression in psychiatric inpatients. Arch Psychiatr Nurs. 2004;18(5):193–9. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 15529285]
  1109. Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatr. 2007;64(7):783–92. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17606812]
  1110. Huang Y, Chen J, Zou J. Effect of scalp electro-acupuncture on post-stroke depression. Chin J Clin Rehab. 2005;9(40):172–3. OVID-Embase. Exclude: Not an elligible population design.
  1111. Hubner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. J Geriatr Psychiatry Neurol. 1994;7 Suppl-4 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7857500]
  1112. Hughes CW, Emslie GJ, Lynn CM, et al. The Texas children’s medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry. 1999;38(11):1442–54. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 10560232]
  1113. Hughes S, Cohen D. A systematic review of long-term studies of drug treated and non-drug treated depression. J Affect Disord. 2009;118(1–3):9–18. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19249104]
  1114. Huibers Marcus JH, Beurskens A, Bleijenberg G, et al. Psychosocial interventions by general practitioners. Cochrane Database Syst Rev. 2007;(3):CD003494. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17636726]
  1115. Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med. 2000;9(8):700–8. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 10927707]
  1116. Hunkeler EM, Katon W, Tang L, et al. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. Br Med J. 2006;332(7536):259–63. Exclude: Not an eligible population treatment. [PMC free article: PMC1360390] [PubMed: 16428253]
  1117. Husain MM, Rush JA, Wisniewski SR, et al. Family history of depression and therapeutic outcome: Findings from STAR*D. J Clin Psychiatry. 2009;70(2):185–95. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19192454]
  1118. Huskamp HA, Azzone V, Frank RG. Carve-outs, women, and the treatment of depression. Women’s Health Issues. 1998;8(5):267–82. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 9793457]
  1119. Huskamp HA, Busch AB, Domino ME, et al. Antidepressant reformulations: Who uses them, and what are the benefits? Health Aff. 2009;28(3):734–45. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2752284] [PubMed: 19414882]
  1120. Hvas AM, Juul S, Lauritzen L, et al. No effect of vitamin B-12 treatment on cognitive function and depression: A randomized placebo controlled study. J Affect Disord. 2004;81(3):269–73. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15337331]
  1121. Hyer L, Yeager CA, Hilton N, et al. Group, individual, and staff therapy: An efficient and effective cognitive behavioral therapy in long-term care. Am J Alzheimer’s Dis Other Dementias. 2008;23(6):528–39. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19001352]
  1122. Hynninen MJ, Bjerke N, Pallesen S, et al. A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respir Med. 2010;104(7):986–94. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20346640]
  1123. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: A randomized controlled trial. JAMA. 2002;287(14):1807–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11939866]
  1124. Hyun M, Chung HC, Lee Y. The effect of cognitive-behavioral group therapy on the self-esteem, depression, and self-efficacy of runaway adolescents in a shelter in South Korea. Appl Nurs Res. 2005;18(3):160–6. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 16106334]
  1125. Ianniello A, Ostuni PA, Sfriso P, et al. S-adenosyl-L-methionine in Sjogren’s syndrome and fibromyalgia. Curr Ther Res Clin Exp. 1994;55(6):699–706. OVID-PsycINFO. Exclude: Not an eligible study design.
  1126. Ilhan YL, Corapcioglu A, Kocabasoglu N, et al. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psychiatr Clin Pract. 2004;8(4):205–11. OVID-Embase. Exclude: Not an eligible population treatment.
  1127. Ille R, Spona J, Zickl M, et al. “Add-On”-therapy with an individualized preparation consisting of free amino acids for patients with a major depression. Eur Arch Psychiatry Clin Neurosci. 2007;257(4):222–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17401733]
  1128. Inoue T, Nakagawa S, Kitaichi Y, et al. Long-term outcome of antidepressant-refractory depression: the relevance of unrecognized bipolarity. J Affect Disord. 2006;95(1–3):61–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16797078]
  1129. Inoue T, Kitaichi Y, Masui T, et al. Pramipexole for stage 2 treatment-resistant major depression: An open study. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1446–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20708060]
  1130. Inoue T, Abekawa T, Nakagawa S, et al. Long-term naturalistic follow-up of lithium augmentation: Relevance to bipolarity. J Affect Disord. 2011;129(1–3):64–7. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20837361]
  1131. Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatr. 1996;40(2):151–3. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 8793048]
  1132. Insel TR, Wang PS. The STAR*D trial: Revealing the need for better treatments. Psychiatr Serv. 2009;60(11):1466–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19880463]
  1133. Interian A, Allen LA, Gara MA, et al. A pilot study of culturally adapted cognitive behavior therapy for Hispanics with major depression. Cognit Behav Pract. 2008;15(1):67–75. OVID-Embase. Exclude: Not an eligible study design.
  1134. Ioannidis JPA, Evans SJW, Gotzsche PC, et al. Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–8. ISI:000225206900005. Exclude: Not an eligible guideline. [PubMed: 15545678]
  1135. Iosifescu DV, Nierenberg AA, Mischoulon D, et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005;66(8):1038–42. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16086620]
  1136. Iosifescu DV, Bolo NR, Nierenberg AA, et al. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatr. 2008;63(12):1127–34. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18206856]
  1137. Iqbal S, Bassett M. Evaluation of perceived usefulness of activity scheduling in an inpatient depression group. J Psychiatr Ment Health Nurs. 2008;15(5):393–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18454825]
  1138. Irene R, Luis MA, Helena D-C, et al. Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample. Int J Psychiatr Clin Pract. 2009;13(2):100–8. OVID-Embase. Exclude: Not an eligible study design.
  1139. Isaac MT, Isaac MB, Gallo F, et al. Milnacipran and pindolol: A randomized trial of reduction of antidepressant latency. Hum Psychopharmacol. 2003;18(8):595–601. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14696018]
  1140. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatr. 2009;66(9):966–75. OVID-Medline. Exclude: For Mixed antidepressants; some failed on SSRI. [PubMed: 19736353]
  1141. Itil TM, Michael ST, Baccari S. Antidepressant effects of fluotracen, a long-acting potent thymoleptic (a double-blind controlled trial) Curr Ther Res Clin Exp. 1984;35(6):1014–32. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment.
  1142. Ivkovic M, Damjanovic A, Jovanovic A, et al. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: Efficacy and tolerability. Psychiatria Danubina. 2009;21(2):187–93. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 19556947]
  1143. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord. 2000;61(1–2):127–32. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11099751]
  1144. Jacobs MK, Christensen A, Snibbe JR, et al. A comparison of computer-based versus traditional individual psychotherapy. Prof Psychol Res Pract. 2001;32(1):92–6. Exclude: Not an eligible population treatment.
  1145. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52(5):217–20. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2033029]
  1146. Jacobson AF. Doctor-patient concordance in a placebo-controlled trial of limbitrol versus its components. Psychopharmacol Bull. 1978;14(3):61–3. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 353872]
  1147. Jacobson NS, Dobson K, Fruzzetti AE, et al. Marital therapy as a treatment for depression. J Consult Clin Psychol. 1991;59(4):547–57. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1918559]
  1148. Jacobson NS, Fruzzetti AE, Dobson K, et al. Couple therapy as a treatment for depression: II. The effects of relationship quality and therapy on depressive relapse. J Consult Clin Psychol. 1993;61(3):516–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8326054]
  1149. Jahn H, Schick M, Kiefer F, et al. Metyrapone as additive treatment in major depression: A double-blind and placebo-controlled trial. Arch Gen Psychiatr. 2004;61(12):1235–44. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15583115]
  1150. James AC, Winmill L, Anderson C, et al. A preliminary study of an extension of a community dialectic behaviour therapy (DBT) programme to adolescents in the looked after care system. Child Adolesc Ment Health. 2011;16(1):9–13. OVID-Embase. Exclude: Not an eligible study design.
  1151. James RT, Dean BC. A comparison of a single night-time and a divided daily dosage regimen of a chlordiazepoxide/amitriptyline combination. Curr Med Res Opin. 1980;6(8):573–5. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 7389390]
  1152. James RT, Dean BC. Comparison of limbitrol (chlordiazepoxide/amitriptyline) and amitriptyline alone as a single night-time dose for the treatment of depression with anxiety. J Int Med Res. 1985;13(2):84–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3888730]
  1153. Jamison C, Scogin F. The outcome of cognitive bibliotherapy with depressed adults. J Consult Clin Psychol. 1995;63(4):644–50. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7673542]
  1154. Jamison CS. Outcome, process, and client variables in cognitive bibliotherapy with depressed adults. 1994. OVID-PsycINFO. Exclude: Not an eligible study design.
  1155. Janakiramaiah N, Gangadhar BN, Murthy PJN, et al. Therapeutic efficacy of Sudarshan Kriya Yoga (SKY) in dysthymic disorder. Nimhans J. 1998;16(1):21–8. OVID-PsycINFO. Exclude: Not an eligible study design.
  1156. Janakiramaiah N, Gangadhar BN, Naga Venkatesha, Murthy PJ, et al. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: A randomized comparison with electroconvulsive therapy (ECT) and imipramine. J Affect Disord. 2000;57(1–3):255–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10708840]
  1157. Jansen IH, Olde Rikkert MG, Hulsbos HA, et al. Toward individualized evidence-based medicine: five “N of 1” trials of methylphenidate in geriatric patients. J Am Geriatr Soc. 2001;49(4):474–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11347795]
  1158. Januel D, Galinowski A, Poirier MF, et al. Prospective study of antidepressants combined with lithium in unipolar depression: Preliminary results. Lithium. 1994;5(4):253–7. OVID-PsycINFO. Exclude: Not an eligible study design.
  1159. Januel D, Poirier MF, D’alche-Biree F, et al. Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. J Affect Disord. 2003;76(1–3):191–200. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 12943949]
  1160. Jarrett RB, Basco MR, Risser R, et al. Is there a role for continuation phase cognitive therapy for depressed outpatients? J Consult Clin Psychol. 1998;66(6):1036–40. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9874918]
  1161. Jarrett RB, Schaffer M, McIntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: A double-blind, placebo-controlled trial. Arch Gen Psychiatr. 1999;56(5):431–7. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1475805] [PubMed: 10232298]
  1162. Jarrett RB, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase: A randomized clinical trial. Arch Gen Psychiatr. 2001;58(4):381–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1307495] [PubMed: 11296099]
  1163. Javnbakht M, Kenari RH, Ghasemi M. Effects of yoga on depression and anxiety of women. Complement Ther Clin Pract. 2009;15(2):102–4. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 19341989]
  1164. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust NZ J Psychiatr. 2008;42(3):192–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18247193]
  1165. Jefferson JW. Treating affective disorders in the presence of cardiovascular disease. Psychiatr Clin North Am. 1983;6(1):141–55. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6889170]
  1166. Jensen C. Psychosocial treatment of depression in women: Nine single-subject evaluations. Res Soc Work Pract. 1994;4(3):267–82. OVID-PsycINFO. Exclude: Not an eligible study design.
  1167. Jensen HV, Olafsson K, Lykke-Olesen L, et al. Combining nortriptyline and lithium in elderly depressed patients: A double-blind, placebo-controlled study. Lithium. 1992;3(4):259–62. OVID-Embase. Exclude: Not an eligible population treatment.
  1168. Ji Y, Hebbring S, Zhu H, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Therapeut. 2011;89(1):97–104. OVID-Medline. Exclude: Systematic Review before 2005. [PMC free article: PMC3034442] [PubMed: 21107318]
  1169. Jiahui Z, Peng S. Clinical observation on acupuncture treatment of depressive neurosis in 30 cases. J Tradit Chin Med. 2006;26(3):191–2. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17078447]
  1170. Joanne L, Jim M, Constance L, et al. Cognitive-behavioral and psychodynamic group psychotherapy in treatment of geriatric depression. J Consult Clin Psychol. 1984;52(2):180–9. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 6715645]
  1171. Joffe H, Groninger H, Soares C, et al. An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. J Womens Health Gender Based Med. 2001;10(10):999–1004. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 11788110]
  1172. Joffe H, Petrillo LF, Viguera AC, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: A preliminary report. J Clin Psychiatry. 2007;68(12):1954–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18162029]
  1173. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 1990;32(3):241–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2201988]
  1174. Joffe RT, Singer W. Thyroid hormone use to enhance the effects of drugs. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:389A–90A. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 1498887]
  1175. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatr. 1993;50(5):387–93. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 8489327]
  1176. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54(7):269–71. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8335654]
  1177. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry. 1994;55(1):24–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8294388]
  1178. Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57(3):114–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8617695]
  1179. Joffe RT, Levitt AJ. Relationship between antidepressant partial and nonresponse and subsequent response to antidepressant augmentation. J Affect Disord. 1999;52(1–3):257–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10357043]
  1180. Joffe RT, Sawka AM, Marriott MJ, et al. Does substitution of T4 with T3 plus T4 for T4 replacement improve depressive symptoms in patients with hypothyroidism? Ann NY Acad Sci. 2004;1032:287–8. Wiley-CCTR. Exclude: Not an elligible population design. [PubMed: 15677430]
  1181. Johnson JE, Zlotnick C. A pilot study of group interpersonal psychotherapy for depression in substance-abusing female prisoners. J Subst Abuse Treat. 2008;34(4):371–7. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 17629441]
  1182. Johnston GA. Megavitamins and psychotherapy: Effective, economical and time-saving treatment: A three year study. J Orthomolecular Med. 1993;8(2):104–20. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1183. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatr. 1991;52(11):450–6. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 1744061]
  1184. Johnstone EC, Owens DG, Lambert MT, et al. Combination tricyclic antidepressant and lithium maintenance medication in unipolar and bipolar depressed patients. J Affect Disord. 1990;20(4):225–33. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2149728]
  1185. Joliat MJ, Brown EB, Miner CM. Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine. J Clin Psychopharmacol. 2004;24(4):464–7. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 15232349]
  1186. Jones ID, Karapiperis V, Bowman L, et al. Does formal psychoeducational support influence anxiety and depression levels in cardiac patients and their relatives? A pilot study. J Cardpulm Rehabil. 2006;26(3):172–5. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 16738457]
  1187. Joo JH, Lenze EJ, Mulsant BH, et al. Risk factor for falls during treatment of late-life depression. J Clin Psychiatry. 2002;63(10):936–41. Exclude: Not an eligible study design. [PubMed: 12416604]
  1188. Jorde R, Sneve M, Figenschau Y, et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: Randomized double blind trial. J Intern Med. 2008;264(6):599–609. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18793245]
  1189. Jorm AF, Allen NB, O’Donnell CP, et al. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust. 2006;185(7):368–72. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17014404]
  1190. Jorm AF, Morgan AJ, Hetrick SE. Relaxation for depression. Cochrane Database Syst Rev. 2008;(4):CD007142. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18843744]
  1191. Judd FK, Piterman L, Cockram AM, et al. A comparative study of venlafaxine with a focused education and psychotherapy program versus venlafaxine alone in the treatment of depression in general practice. Hum Psychopharmacol. 2001;16(5):423–8. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 12404563]
  1192. Jungkunz G, Nedopil N, Ruther E. Acute effects of the synthetic analogue of methionine enkephalin FK 33–824 on depressive symptoms. Pharmacopsychiatria. 1983;16(3):90–2. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 6351118]
  1193. Juruena MF, Pariante CM, Papadopoulos AS, et al. Prednisolone suppression test in depression: Prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatr. 2009;194(4):342–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19336786]
  1194. Justine M, Hamid TA. A multicomponent exercise program for institutionalized older adults. J Gerontol Nurs. 2010;36(10):32–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20438009]
  1195. Kaas MJ, Lewis ML. Cognitive behavioral group therapy for residents in assisted-living facilities. J Psychosoc Nurs Ment Health Serv. 1999;37(10):9–15. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10529958]
  1196. Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosylmethionine in depression: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 1990;147(5):591–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2183633]
  1197. Kahan JS, Mitchell JM, Kemp BJ, et al. The results of a 6-month treatment for depression on symptoms, life satisfaction, and community activities among individuals aging with a disability. Rehabil Psychol. 2006;51(1):13–22. OVID-Embase. Exclude: Not an eligible population treatment.
  1198. Kahn JS, Kehle TJ, Jenson WR, et al. Comparison of cognitive-behavioral, relaxation, and self-modeling interventions for depression among middle-school students. School Psychol Rev. 1990;19(2):196–211. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1199. Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatr. 2001;34(3):96–103. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11434406]
  1200. Kallepalli BR, Bhatara VS, Fogas BS, et al. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J Child Adolesc Psychopharmacol. 1997;7(2):97–107. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9334895]
  1201. Kaltenthaler E, Parry G, Beverley C, et al. Computerised cognitive-behavioural therapy for depression: Systematic review. Br J Psychiatr. 2008;193(3):181–4. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18757972]
  1202. Kamlet MS, Wade M, Kupfer DJ, et al. Economics and mental health. Baltimore, MD, US: Johns Hopkins University Press; 1992. Cost-utility analysis of maintenance treatment for recurrent depression: A theoretical framework and numerical illustration. OVID-PsycINFO. Exclude: Not an eligible study design.
  1203. Kamlet MS, Paul N, Greenhouse J, et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials. 1995;16(1):17–40. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7743786]
  1204. Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: A prospective, placebo-controlled comparison. Arch Gen Psychiatr. 1982;39(9):1065–9. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 6810839]
  1205. Kang HS, Sok SR, Kang JS. Effects of Meridian acupressure for stroke patients in Korea. J Clin Nurs. 2009;18(15):2145–52. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19583646]
  1206. Kannappan R, Lakshmi Bai R. Cognitive behaviour therapy as an adjunct to drug therapy in the treatment of dsythymic disorder. J Indian Acad Appl Psychol. 2007;33(2):195–200. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1207. Kannappan R. Intervention as an adjunct to drug therapy for childhood depression. J Indian Acad Appl Psychol. 2009;35(1):57–62. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1208. Kantor D, McNevin S, Leichner P, et al. The benefit of lithium carbonate adjunct in refractory depression: Fact or fiction? Can J Psychiatr. 1986;31(5):416–8. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 3089576]
  1209. Kaplan EM’. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study. Clin Ther. 2002;24(7):1194–200. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 12182262]
  1210. Kaplan K, Mendelson LB, Ploener DM. The effect of a jogging program on psychiatric inpatients with symptoms of depression. Occup Ther J Res. 1983;3(3):173–5. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  1211. Karavidas MK, Lehrer PM, Vaschillo E, et al. Preliminary results of an open label study of heart rate variability biofeedback for the treatment of major depression. Appl Psychophysiol Biofeedback. 2007;32(1):19–30. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17333315]
  1212. Karp JF, Whyte EM, Lenze EJ, et al. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: Outcome and tolerability. J Clin Psychiatry. 2008;69(3):457–63. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2846083] [PubMed: 18251622]
  1213. Karp JF, Weiner DK, Dew MA, et al. Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: Results of an open-label pilot study. Int J Geriatr Psychiatry. 2010;25(6):633–42. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2872036] [PubMed: 19750557]
  1214. Kasckow JW, Mohamed S, Thallasinos A, et al. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry. 2001;16(12):1163–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11748776]
  1215. Kashner TM, Henley SS, Golden RM, et al. Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. J Affect Disord. 2007;104(1–3):251–61. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17509693]
  1216. Kashner TM, Trivedi MH, Wicker A, et al. The impact of nonclinical factors on care use for patients with depression: A STAR*D report. CNS Neurosci Therapeut. 2009;15(4):320–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19712127]
  1217. Kashner TM, Trivedi MH, Wicker A, et al. Release bias in accessing medical records in clinical trials: A STAR*D report. Int J Meth Psychiatr Res. 2009;18(3):147–58. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19701922]
  1218. Kaslow NJ, Leiner AS, Reviere S, et al. Suicidal, abused African American women’s response to a culturally informed intervention. J Consult Clin Psychol. 2010;78(4):449–58. OVID-PsycINFO. Exclude: Not an eligible population/treatment. [PubMed: 20658802]
  1219. Kasper S, Yieira A. Stimulation with dl-fenfluramine and antidepressive medication in major depressed inpatients. Pharmacopsychiatr. 1989;22(5):201. OVID-Embase. Exclude: Not an eligible study design.
  1220. Kasper S, Voll G, Vieira A, et al. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression: Results of a double-blind study. Pharmacopsychiatr. 1990;23(3):135–42. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2115680]
  1221. Kasper S, Anghelescu IG, Szegedi A, et al. Superior efficacy of St John’s wort extract WS 5570 compared to placebo in patients with major depression: A randomized, double-blind, placebo-controlled, multi-center trial. BMC Med. 2006;4:14. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1538611] [PubMed: 16796730]
  1222. Kasper S, Anghelescu IG, Szegedi A, et al. Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode. Wien Med Wochenschr. 2007;157(13–14):362–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17704988]
  1223. Kasper S, Gastpar G, Muller WE, et al. Efficacy of St. John’s wort extract WS 5570 in acute treatment of mild depression: A reanalysis of data from controlled clinical trials. Eur Arch Psychiatry Clin Neurosci. 2011;258(1):59–63. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18084790]
  1224. Kataoka SH, Stein BD, Jaycox LH, et al. A school-based mental health program for traumatized Latino immigrant children. J Am Acad Child Adolesc Psychiatry. 2003;42(3):311–8. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 12595784]
  1225. Katona CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatr. 1995;166(1):80–6. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 7894881]
  1226. Katzelnick DJ, Simon GE, Pearson SD, et al. Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med. 2000;9(4):345–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10776363]
  1227. Kaufmann MW, Cassem NH, Murray GB, et al. Use of psychostimulants in medically ill patients with neurological disease and major depression. Can J Psychiatr. 1984;29(1):46–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6704886]
  1228. Kay-Lambkin FJ, Baker AL, Lewin TJ, et al. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: A randomized controlled trial of clinical efficacy. Addiction. 2009;104(3):378–88. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19207345]
  1229. Kay-Lambkin FJ, Baker AL, McKetin R, et al. Stepping through treatment: Reflections on an adaptive treatment strategy among methamphetamine users with depression. Drug Alcohol Rev. 2010;29(5):475–82. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20887570]
  1230. Keller M. Cross-over study of sertraline versus imipramine in chronic depression. 1996. 1996. Wiley-CCTR. Exclude: Not an eligible study design.
  1231. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462–70. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10816183]
  1232. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: A multisite study from the consortium for research in electroconvulsive therapy (CORE) Arch Gen Psychiatr. 2006;63(12):1337–44. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC3708140] [PubMed: 17146008]
  1233. Kelly AC, Zuroff DC, Shapira LB. Soothing oneself and resisting self-attacks: The treatment of two intrapersonal deficits in depression vulnerability. Cognit Ther Res. 2009;33(3):301–13. OVID-Embase. Exclude: Not an eligible population treatment.
  1234. Kelly FD, Dowd ET, Duffey DK. A comparison of cognitive and behavioural intervention strategies in the treatment of depression. Br J Cognit Psychother. 1983;1(2):51–8. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI.
  1235. Kelly JA, Murphy DA, Bahr GR, et al. Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. Am J Psychiatry. 1993;150(11):1679–86. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8214177]
  1236. Kelly TF, Lieberman DZ. Long term augmentation with T3 in refractory major depression. J Affect Disord. 2009;115(1–2):230–3. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19108898]
  1237. Kemp BJ, Kahan JS, Krause JS, et al. Treatment of major depression in individuals with spinal cord injury. J Spinal Cord Med. 2004;27(1):22–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15156933]
  1238. Kemp BJ, Corgiat M, Gill C. Effects of brief cognitive-behavioral group psychotherapy on older persons with and without disabling illness. Behav Health Aging. 1991;2(1):21–8. OVID-PsycINFO. Exclude: Not an eligible study design.
  1239. Kendrick T, Simons L, Mynors-Wallis L, et al. A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study. Health Technol Assess. 2005;9(37):iii-59. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16153354]
  1240. Kendrick T, Chatwin J, Dowrick C, et al. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: The THREAD (THREshold for AntiDepressant response) study. Health Technol Assess. 2009;13(22):1–159. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19401066]
  1241. Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS) J Am Acad Child Adolesc Psychiatry. 2006;45(12):1404–11. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17135985]
  1242. Kennard BD, Emslie GJ, Mayes TL, et al. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(12):1395–404. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2826176] [PubMed: 18978634]
  1243. Kennard BD, Stewart SM, Hughes JL, et al. Developing cognitive behavioral therapy to prevent depressive relapse in youth. Cognit Behav Pract. 2008;15(4):387–99. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC2882305] [PubMed: 20535241]
  1244. Kennard BD, Silva SG, Mayes TL, et al. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry. 2009;166(3):337–44. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2823118] [PubMed: 19147693]
  1245. Kennard BD, Silva SG, Tonev S, et al. Remission and recovery in the treatment for adolescents with depression study (TADS): Acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry. 2009;48(2):186–95. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2843506] [PubMed: 19127172]
  1246. Kennard BD, Clarke GN, Weersing VR, et al. Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: Preliminary findings. J Consult Clin Psychol. 2009;77(6):1033–41. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3705725] [PubMed: 19968380]
  1247. Kennedy N, Paykel ES. Treatment and response in refractory depression: results from a specialist affective disorders service. J Affect Disord. 2004;81(1):49–53. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15183599]
  1248. Kennedy P, Duff J, Evans M, et al. Coping effectiveness training reduces depression and anxiety following traumatic spinal cord injuries. Br J Clin Psychol. 2003;42(1):41–52. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 12675978]
  1249. Kennedy SH, Eisfeld BS, Meyer JH, et al. Antidepressants in clinical practice: Limitations of assessment methods and drug response. Hum Psychopharmacol. 2001;16(1):105–14. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 12404605]
  1250. Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatr. 2001;46 Suppl-58S OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 11441771]
  1251. Kennedy SH, Cohen NL, Lam RW, et al. Combining psychotherapy and pharmacotherapy. Can J Psychiatr. 2001;46(SUPPL 1):59S–62S. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 11441772]
  1252. Kennedy SH, Lam RW, Cohen NL, et al. Medications and other biological treatments. Can J Psychiatr. 2001;46(SUPPL 1):38S–58S. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 11441771]
  1253. Kennedy SH, Srinivasan J, Fulton K. SSRI augmentation with raloxifene for treatment-resistant depression sophie grigoriadis In 2001. Wiley-CCTR. Exclude: Not an eligible study design.
  1254. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63(3):181–6. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11926715]
  1255. Kennedy SH, Lam RW, Cohen NL, et al. Reboxetine: a preliminary report on its use through the Special Access Program. J Psychiatr Neurosci. 2002;27(6):418–22. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC161714] [PubMed: 12491574]
  1256. Kennedy SH, Lam RW, Morris B. Clinical guidelines for depressive disorders: Summary of recommendations relevant to family physicians. Can Fam Physician. 2003;49:489–91. OVID-Embase. Exclude: Not an eligible guideline. [PMC free article: PMC2214213] [PubMed: 12729245]
  1257. Kennedy SH, Segal ZV, Cohen NL, et al. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. J Clin Psychiatry. 2003;64(4):439–44. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 12716247]
  1258. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16(2):93–100. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16249073]
  1259. Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry. 2007;164(5):778–88. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17475737]
  1260. Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord. 2009;117(Suppl 1):S44–53. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 19656575]
  1261. Kenny MA, Williams JM. Treatment-resistant depressed patients show a good response to Mindfulness-based Cognitive Therapy. Behav Res Ther. 2007;45(3):617–25. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2808477] [PubMed: 16797486]
  1262. Kerfoot M, Harrington R, Harrington V, et al. A step too far? Randomized trial of cognitive-behaviour therapy delivered by social workers to depressed adolescents. Eur Child Adolesc Psychiatry. 2004;13(2):92–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15103534]
  1263. Kerr J, Calfas KJ, Caparosa S, et al. A pilot study to assess the feasibility and acceptability of a community based physical activity intervention (involving internet, telephone, and pedometer support), integrated with medication and mood management for depressed patients. Ment Health Phys Activ. 2008;1(1):40–5. OVID-Embase. Exclude: Not an eligible study design.
  1264. Kerse N, Hayman KJ, Moyes SA, et al. Home-based activity program for older people with depressive symptoms: DeLLITE--a randomized controlled trial. Ann Fam Med. 2010;8(3):214–23. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2866718] [PubMed: 20458104]
  1265. Kessler D, Lewis G, Kaur S, et al. Therapist-delivered Internet psychotherapy for depression in primary care: A randomised controlled trial. Lancet. 2009;374(9690):628–34. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19700005]
  1266. Ketter TA, Post RM, Parekh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: Preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry. 1995;56(10):471–5. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 7559374]
  1267. Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manage Care Pharm. 2008;14(5):426–41. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18597572]
  1268. Khullar A, Chokkha P, Fullerton Dl, et al. A double-blind, randomized, placebo-controlled study of quetiapine as augmentation therapy to SSRI/SNRI agents in the treatment of non-psychotic unipolar depression with residual symptoms. Am Psychiatr Assoc Ann Meeting: New Res Abst. 2006 [Abstract]
  1269. Khumar SS, Kaur P, Kaur S. Effectiveness of Shavasana on depression among university students. Indian J Clin Psychol. 1993;20(2):82–7. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1270. Kiloh LG, Moore G. An open trial of zimelidine in patients with endogenous depression. Int Pharmacopsychiatry. 1982;17(1):28–35. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6211416]
  1271. Kim KB, Cohen SM, Oh HK, et al. The effects of meridian exercise on anxiety, depression, and self-esteem of female college students in Korea. Holist Nurs Pract. 2004;18(5):230–4. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 15497601]
  1272. Kim SW, Shin IS, Kim JM, et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1504–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17692448]
  1273. Kim W, Lim S-K, Chung E-J, et al. The effect of cognitive behavior therapy-based psychotherapy applied in a forest environment on physiological changes and remission of major depressive disorder. Psychiatr Investig. 2009;6(4):245–54. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2808793] [PubMed: 20140122]
  1274. Kim Y, Bowers J. Efficacy of acupuncture for treating depression. Altern Ther Womens Health. 2007;9(7):49–53. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1275. Kinder LS, Katon WJ, Ludman E, et al. Improving depression care in patients with diabetes and multiple complications. J Gen Intern Med. 2006;21(10):1036–41. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1831638] [PubMed: 16836628]
  1276. King C, Kennedy P. Coping effectiveness training for people with spinal cord injury: Preliminary results of a controlled trial. Br J Clin Psychol. 1999;38(Pt 1):5–14. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 10212733]
  1277. King DJ. Drug management of depression. Ir Med J. 1983;76(1):44–50. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 6826341]
  1278. King M, Sibbald B, Ward E, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health Technol Assess. 2000;4(19):1–83. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11086269]
  1279. Kingston T, Dooley B, Bates A, et al. Mindfulness-based cognitive therapy for residual depressive symptoms. Psychol Psychother. 2007;80(Pt:2):2–203. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17535594]
  1280. Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with Multiple Sclerosis. Neuropsychology. 2010;24(5):573–80. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2933087] [PubMed: 20804245]
  1281. Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis. 1989;177(9):546–50. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2769247]
  1282. Kiosses DN, Arean PA, Teri L, et al. Home-delivered problem adaptation therapy (PATH) for depressed, cognitively impaired, disabled elders: A preliminary study. Am J Geriatr Psychiatr. 2010;18(11):988–98. OVID-Embase. Exclude: Not an eligible population/treatment. [PMC free article: PMC2962702] [PubMed: 20808092]
  1283. Kirkham MA. Two-year follow-up of skills training with mothers of children with disabilities. Am J Ment Retard. 1993;97(5):509–20. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 7681675]
  1284. Kirstein L. Neuroendocrine dysfunction and response to tricyclic antidepressants. J Clin Psychiatry. 1984;45(9):385–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6432772]
  1285. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial. Psychooncol. 2007;16(4):277–86. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17385190]
  1286. Kitsumban V, Thapinta D, Sirindharo PB, et al. Effect of cognitive mindfulness practice program on depression among elderly Thai women. Thai J Nurs. 2009;13(2):95–107. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  1287. Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatr. 1979;36(5):550–4. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 219802]
  1288. Klausner EJ, Clarkin JF, Spielman L, et al. Late-life depression and functional disability: The role of goal-focused group psychotherapy. Int J Geriatr Psychiatry. 1998;13(10):707–16. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9818307]
  1289. Kleber HD, Weissman MM, Rounsaville BJ, et al. Imipramine as treatment for depression in addicts. Arch Gen Psychiatr. 1983;40(6):649–53. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6342564]
  1290. Klein DN, Santiago NJ, Vivian D, et al. Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Psychol. 2004;72(4):681–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15301653]
  1291. Klein DN, Arnow BA, Barkin JL, et al. Early adversity in chronic depression: Clinical correlates and response to pharmacotherapy. Depress Anxiety. 2009;26(8):701–10. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC3528400] [PubMed: 19434623]
  1292. Klein JB, Jacobs RH, Reinecke MA. Cognitive-behavioral therapy for adolescent depression: A meta-analytic investigation of changes in effect-size estimates. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1403–13. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2270481] [PubMed: 18049290]
  1293. Klein MH, Greist JH, Gurman AS. A comparative outcome study of group psychotherapy vs. exercise treatments for depression. Int J Ment Health. 1985;13(3–4):148–77. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment.
  1294. Klein RA. Expectancy enhancement as a precursor to cognitive therapy for depression: A pilot investigation. 2009. OVID-PsycINFO. Exclude: Not an eligible study design.
  1295. Klieser E, Lehmann E. Experimental comparison between the effect of standardized trazodone-amitriptyline and placebo treatment in vitalized depressive patients. Psychopharmacol. 1988;95 Suppl-5 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3133710]
  1296. Kline NS, Shah BK. Comparable therapeutic efficacy of tryptophan and imipramine: Average therapeutic ratings versus “true” equivalence. An important difference. Curr Ther Res Clin Exp. 1973;15(7):484–7. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 4198311]
  1297. Knapen J, Van dV, van Coppenolle H, et al. Comparison of changes in physical self-concept, global self-esteem, depression and anxiety following two different psychomotor therapy programs in nonpsychotic psychiatric inpatients. Psychother Psychosom. 2005;74(6):353–61. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16244511]
  1298. Knapen J, Sommerijns E, Vancampfort D, et al. State anxiety and subjective well-being responses to acute bouts of aerobic exercise in patients with depressive and anxiety disorders. Br J Sports Med. 2009;43(10):756–9. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19019899]
  1299. Knoth RL, Bolge SC, Kim E, et al. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16(8):e188–e196. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20690785]
  1300. Knowlton L. Investigating SAM-e for depression. Psychiatr Times. 2001;18(5):10. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1301. Knubben K, Reischies FM, Adli M, et al. A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depression. Br J Sports Med. 2007;41(1):29–33. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2465130] [PubMed: 17062659]
  1302. Kobayashi N, Sawamura T, Yoshida T, et al. The effectiveness of lithium augmentation of milnacipran: Preliminary data using the modified Japanese Psychopharmacology Algorithm. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004;24(5):279–81. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15658504]
  1303. Koch JM, Hinze-Selch D, Stingele K, et al. Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression. Psychother Psychosom. 2009;78(3):187–92. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19321972]
  1304. Kocsis JH, Friedman RA, Markowitz JC, et al. Maintenance therapy for chronic depression: A controlled clinical trial of desipramine. Arch Gen Psychiatr. 1996;53(9):769–76. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 8792753]
  1305. Kocsis JH, Rush AJ, Markowitz JC, et al. Continuation treatment of chronic depression: A comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol Bull. 2003;37(4):73–87. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15131518]
  1306. Koertge J, Janszky I, Sundin O, et al. Effects of a stress management program on vital exhaustion and depression in women with coronary heart disease: A randomized controlled intervention study. J Intern Med. 2008;263(3):281–93. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18067552]
  1307. Kohlenberg RH, Kanter JW, Bolling MY, et al. Enhancing cognitive therapy for depression with functional analytic psychotherapy: Treatment guidelines and empirical findings. Cognit Behav Pract. 2002;9(3):213–29. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1308. Kohler WK, Pelzer A, Schmidt K-P, et al. Bright light and dim light in the therapy of depression: Effects on the circadian system and clinical results. Pharmacopsychiatr. 1989;22(5):202. OVID-Embase. Exclude: Not an eligible study design.
  1309. Kohn-Wood Laura, Hudson Glenetta, Graham Erin T. Ethnic minorities. 2008:351–72. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  1310. Kohn CS, Petrucci RJ, Baessler C, et al. The effect of psychological intervention on patients' long-term adjustment to the ICD: A prospective study. Pacing Clin Electrophysiol. 2000;23(4:Pt 1):t-6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10793433]
  1311. Koike K, Ohno S, Takahashi N, et al. Efficacy of the herbal medicine Unkei-to as an adjunctive treatment to hormone replacement therapy for postmenopausal women with depressive symptoms. Clin Neuropharmacol. 2004;27(4):157–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15319700]
  1312. Kojima R, Fujisawa D, Tajima M, et al. Efficacy of cognitive behavioral therapy training using brief e-mail sessions in the workplace: A controlled clinical trial. Ind Health. 2010;48(4):495–502. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20720342]
  1313. Kok RM, Vink D, Heeren TJ, et al. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: An open, randomized, controlled trial. J Clin Psychiatry. 2007;68(8):1177–85. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 17854241]
  1314. Kok RM, Nolen WA, Heeren TJ. Outcome of late-life depression after 3 years of sequential treatment. Acta Psychiatr Scand. 2009;119(4):274–81. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19053970]
  1315. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;12:CD008121. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 21154393]
  1316. Konarski JZ, Kennedy SH, Segal ZV, et al. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatr Neurosci. 2009;34(3):175–80. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2674969] [PubMed: 19448846]
  1317. Kong S. Day treatment programme for patients with eating disorders: Randomized controlled trial. J Adv Nurs. 2005;51(1):5–14. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 15941455]
  1318. Koniak-Griffin D. Aerobic exercise, psychological well-being, and physical discomforts during adolescent pregnancy. Res Nurs Health. 1994;17(4):253–63. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 8036273]
  1319. Konig F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatr. 1997;30(3):93–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9211570]
  1320. Konuk N, Atasoy N, Atik L, et al. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Adv Ther. 2006;23(4):646–54. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17050507]
  1321. Koo JR, Yoon JY, Joo MH, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci. 2005;329(1):1–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15654172]
  1322. Kool S, Dekker J, Duijsens IJ, et al. Changes in personality pathology after pharmacotherapy and combined therapy for depressed patients. J Personal Disord. 2003;17(1):60–72. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12659547]
  1323. Kool S, Dekker J, Duijsens IJ, et al. Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry. 2003;11(3):133–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12893503]
  1324. Kopecek M, Bares M, Svarc J, et al. Hyperprolactinemia after low dose of amisulpride. Neuroendocrinol Lett. 2004;25(6):419–22. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15665803]
  1325. Kopecek M, Bares M, Horacek J, et al. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. Neuroendocrinol Lett. 2006;27(6):803–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17187006]
  1326. Koran LM, Aboujaoude EN, Gamel NN. Duloxetine treatment of dysthymia and double depression: An open-label trial. J Clin Psychiatry. 2007;68(5):761–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17503986]
  1327. Korn L, Logsdon RG, Polissar NL, et al. A randomized trial of a cam therapy for stress reduction in American Indian and Alaskan native family caregivers. Gerontologist. 2009;49(3):368–77. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2682170] [PubMed: 19377083]
  1328. Kornstein SG, Dunner DL, Meyers AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry. 2008;69(9):1383–92. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19193339]
  1329. Koszycki D, Lafontaine S, Frasure-Smith N, et al. An open-label trial of interpersonal psychotherapy in depressed patients with coronary disease. Psychosom. 2004;45(4):319–24. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 15232046]
  1330. Kouidi E, Karagiannis V, Grekas D, et al. Depression, heart rate variability, and exercise training in dialysis patients. Eur J Cardiovasc Prev Rehab. 2010;17(2):160–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19745744]
  1331. Koutra A, Katsiadrami A, Diakogiannis G. The effect of group psychological counselling in Greek university students' anxiety, depression, and self-esteem. Eur J Psychother Counsell. 2010;12(2):101–11. OVID-PsycINFO. Exclude: Not an eligible study design.
  1332. Kovac SH, Range LM. Does writing about suicidal thoughts and feelings reduce them? Suicide Life Threat Behav. 2002;32(4):428–40. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 12501967]
  1333. Kovach-Anta CM. The effects of physical activity on levels of depression, anxiety, and hypochondriasis in the elderly. 1998. OVID-PsycINFO. Exclude: Not an eligible study design.
  1334. Kowalenko N, Rapee RM, Simmons J, et al. Short-term effectiveness of a school-based early intervention program for adolescent depression. Clin Child Psychol Psychiatry. 2005;10(4):493–507. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  1335. Kozel FA, Trivedi MH, Wisniewski SR, et al. Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatr. 2008;16(1):58–64. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18165462]
  1336. Kraaij V, van EA, Garnefski N, et al. Effects of a cognitive behavioral self-help program and a computerized structured writing intervention on depressed mood for HIV-infected people: a pilot randomized controlled trial. Patient Educ Couns. 2010;80(2):200–4. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19781889]
  1337. Kramer MM. The effects of exercise on psychological well-being in women recovering from breast cancer. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  1338. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch Gen Psychiatr. 1989;46(10):922–8. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 2679483]
  1339. Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatr. 1989;46(9):794–800. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 2505730]
  1340. Krampen G. Long-term evaluation of the effectiveness of additional autogenic training in the psychotherapy of depressive disorders. Eur Psychol. 1999;4(1):11–8. Exclude: Not an eligible population treatment.
  1341. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152(3):391–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7864265]
  1342. Kratochvil C, Emslie G, Silva S, et al. Acute time to response in the Treatment for Adolescents with Depression Study (TADS) J Am Acad Child Adolesc Psychiatry. 2006;45(12):1412–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17135986]
  1343. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915–24. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16113620]
  1344. Kraus RP, Diaz P, McEachran A. Managing rapid metabolizers of antidepressants. Depress Anxiety. 1996;4(6):320–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9166660]
  1345. Kravitz HM, Sabelli HC, Fawcett J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. J Am Osteopath Assoc. 1984;84(1 SUPPL):119–23. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 6490415]
  1346. Kripke DF, Mullaney DJ, Klauber MR, et al. Controlled trial of bright light for nonseasonal major depressive disorders. Biol Psychiatr. 1992;31(2):119–34. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1737074]
  1347. Krishna M, Jauhari A, Lepping P, et al. Is group psychotherapy effective in older adults with depression? A systematic review. Int J Geriatr Psychiatry. 2011;26(4):331–40. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20973096]
  1348. Krishnamurthy MN, Telles S. Assessing depression following two ancient Indian interventions. J Gerontol Nurs. 2007;33(2):17–23. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 17310659]
  1349. Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: A randomized controlled trial. JAMA. 2009;301(20):2099–110. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2884224] [PubMed: 19470987]
  1350. Krogh J, Saltin B, Gluud C, et al. The DEMO trial: A randomized, parallel-group, observer-blinded clinical trial of strength versus aerobic versus relaxation training for patients with mild to moderate depression. J Clin Psychiatry. 2009;70(6):790–800. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19573478]
  1351. Kroll L, Harrington R, Jayson D, et al. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry. 1996;35(9):1156–61. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8824059]
  1352. Kronsnoble KM. Psychological effects of habitual aerobic exercise on cardiac patients. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  1353. Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med. 2007;3(1):48–55. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17557453]
  1354. Kua EH. Pharmacotherapy and psychotherapy in the treatment of depression in the elderly. Singapore Med J. 2000;41(3 SUPPL):35–6. OVID-Embase. Exclude: Not an eligible population treatment.
  1355. Kudoh A, Ishihara H, Matsuki A. Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: A trial of off-on-off-on design. Clin J Pain. 1998;14(1):61–5. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 9535315]
  1356. Kuehner C. An evaluation of the 'Coping with Depression Course' for relapse prevention with unipolar depressed patients. Psychother Psychosom. 2005;74(4):254–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15947516]
  1357. Kufferle B, Grunberger J. Early clinical double-blind study with S-adenosyl-L-methionine: A new potential antidepressant. Adv Biochem Psychopharmacol. 1982;32:175–80. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7046363]
  1358. Kuhner C, Angermeyer MC, Veiel HOF. Cognitive-behavioral group intervention as a means of tertiary prevention in depressed patients: Acceptance and short-term efficacy. Cognit Ther Res. 1996;20(4):391–409. OVID-PsycINFO. Exclude: Not an eligible study design.
  1359. Kuhs H, Färber D, Borgstädt S, et al. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. J Affect Disord. 1996;37(1):31–41. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 8682976]
  1360. Kuhs H, Kemper B, Lippe-Neubauer U, et al. Repeated sleep deprivation once versus twice a week in combination with amitriptyline. J Affect Disord. 1998;47(1–3):97–103. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 9476749]
  1361. Kuk AY, Li J, Rush AJ. Recursive subsetting to identify patients in the STAR*D: A method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. J Clin Psychiatr. 2010;71(11):1502–8. OVID-Medline. Exclude: Systematic Review before 2005. [PubMed: 21114950]
  1362. Kulcu DG, Kurtais Y, Tur BS, et al. The effect of cardiac rehabilitation on quality of life, anxiety and depression in patients with congestive heart failure. A randomized controlled trial, short-term results. Eur Medicophys. 2007;43(4):489–97. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 18084172]
  1363. Kumagai R, Ichimiya Y. Efficacy of blonanserin in combination therapy for treatment-resistant depression. Psychiatry Clin Neurosci. 2009;63(4):593–4. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19659567]
  1364. Kundermann B, Hemmeter-Spernal J, Huber MT, et al. Effects of total sleep deprivation in major depression: Overnight improvement of mood is accompanied by increased pain sensitivity and augmented pain complaints. Psychosom Med. 2008;70(1):92–101. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18158380]
  1365. Kundermann B, Strate P, Hemmeter-Spernal J, et al. Mid-term effects of serial sleep deprivation therapy implemented in cognitive-behavioral treatment on the neuroendocrine response to clomipramine in patients with major depression. J Psychiatr Res. 2009;43(7):711–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18930473]
  1366. Kunik ME, Pollock BG, Perel JM, et al. Clomipramine in the elderly: Tolerance and plasma levels. J Geriatr Psychiatry Neurol. 1994;7(3):139–43. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7916936]
  1367. Kunik ME, Braun U, Stanley MA, et al. One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. Psychol Med. 2001;31(4):717–23. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11352373]
  1368. Kunik ME, Veazey C, Cully JA, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: A randomized controlled trial. Psychol Med. 2008;38(3):385–96. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17922939]
  1369. Kupfer DJ, Spiker DG. Refractory depression: Prediction of non-response by clinical indicators. J Clin Psychiatry. 1981;42(8):307–12. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7251567]
  1370. Kupfer DJ, Perel JM, Frank E. Adequate treatment with imipramine in continuation treatment. J Clin Psychiatry. 1989;50(7):250–5. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2661546]
  1371. Kurland AA, Nagaraju A. Viloxazine and the depressed schizophrenic: Methodological issues. J Clin Pharmacol. 1981;21(1):37–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7012190]
  1372. Kush FR, Fleming LM. An innovative approach to short-term group cognitive therapy in the combined treatment of anxiety and depression. Group Dynam. 2000;4(2):176–83. OVID-Embase. Exclude: Not an eligible study design.
  1373. Kutcher S, LeBlanc J, Maclaren C, et al. A randomized trail of a specific adherence enhancement program in setraline-treated adults with major depressive disorder in a primary care setting. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):591–6. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11999913]
  1374. Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol. 2008;76(6):966–78. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19045965]
  1375. Kvist J, Kirkegaard C. Effect of repeated sleep deprivation on clinical symptoms and the TRH test in endogenous depression. Acta Psychiatr Scand. 1980;62(5):494–502. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6782834]
  1376. Kwamie Y, Persad E, Stancer H. The use of carbamazepine as an adjunctive medication in the treatment of affective disorders: A clinical report. Can J Psychiatr. 1984;29(7):605–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6150757]
  1377. Laakmann G, Schule C, Baghai T, et al. St. John's wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy. Pharmacopsychiatr. 1998;31 Suppl-9 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9684948]
  1378. Labbé EE, Welsh MC, Delaney D. Effects of consistent aerobic exercise on the psychological functioning of women. Percept Motor Skills. 1988;67(3):919–25. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 3226848]
  1379. Lafferman J, Solomon K, Ruskin P. Lithium augmentation for treatment-resistant depression in the elderly. J Geriatr Psychiatry Neurol. 1988;1(1):49–52. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3150926]
  1380. Lai SM, Studenski S, Richards L, et al. Therapeutic exercise and depressive symptoms after stroke. J Am Geriatr Soc. 2006;54(2):240–7. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 16460374]
  1381. Lai Y. Effects of music listening on depressed women in Taiwan. Issues Ment Health Nurs. 1999;20(3):229–46. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 10633642]
  1382. Laidlaw K, Davidson K, Toner H, et al. A randomised controlled trial of cognitive behaviour therapy vs treatment as usual in the treatment of mild to moderate late life depression. Int J Geriatr Psychiatry. 2008;23(8):843–50. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18311844]
  1383. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007;164(10):1530–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17898344]
  1384. Laje G, Allen AS, Akula N, et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenetics Genom. 2009;19(9):666–74. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2819190] [PubMed: 19724244]
  1385. Laje G, Perlis RH, Rush AJ, et al. Pharmacogenetics studies in STAR*D: Strengths, limitations, and results. Psychiatr Serv. 2009;60(11):1446–57. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3775610] [PubMed: 19880459]
  1386. Lam JY, Freeman MK, Cates ME. Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Ann Pharmacother. 2007;41(6):1005–12. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17519297]
  1387. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: Combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004;65(3):337–40. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15096072]
  1388. Lam RW, Lonn SL, Despiegel N. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: A pooled analysis. Int Clin Psychopharmacol. 2010;25(4):199–203. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20357664]
  1389. Lam RW, Lutz K, Preece M, et al. Telephone-administered cognitive-behavioral therapy for clients with depressive symptoms in an employee assistance program: A pilot study. Ann Clin Psychiatr. 2011;23(1):11–6. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 21318191]
  1390. Lamers F, Jonkers CC, Bosma H, et al. A minimal psychological intervention in chronically ill elderly patients with depression: A randomized trial. Psychother Psychosom. 2010;79(4):217–26. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20424499]
  1391. Lamers F, Jonkers CCM, Bosma H, et al. Improving quality of life in depressed COPD patients: Effectiveness of a minimal psychological intervention. J Chron Obstruct Pulmonary Dis. 2010;7(5):315–22. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 20854045]
  1392. Lancer R. The effect of aerobic exercise on obsessive compulsive disorder, anxiety, and depression. 2005. OVID-PsycINFO. Exclude: Not an eligible study design.
  1393. Landaas JA. The effect of aerobic exercise on self-efficacy perceptions body-esteem, anxiety and depression. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  1394. Landreville P. Cognitive bibliotherapy for depression in older adults with a disability. Clin Gerontol. 1998;19(3):69–75. OVID-Embase. Exclude: Not an eligible population treatment.
  1395. Landreville P, Bissonnette L. Effects of cognitive bibliotherapy for depressed older adults with a disability. Clinical Gerontologist: The Journal of Aging and Mental Health. 1997;17(4):35–55. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1396. Lane AM, Lovejoy DJ. The effects of exercise on mood changes: The moderating effect of depressed mood. J Sports Med Phys Fitness. 2001;41(4):539–45. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 11687775]
  1397. Lane DA, Chong AY, Lip Gregory YH. Psychological interventions for depression in heart failure. Cochrane Database Syst Rev. 2005;(1):CD003329. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15674906]
  1398. Langer G, Karazman R, Neumark J, et al. Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. A double-blind comparison with electroconvulsive treatment. Neuropsychobiol. 1995;31(4):182–94. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7659199]
  1399. Lantz JE. Depression and social interest tasks. J Individ Psychol. 1981;37(1):113–6. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1400. Laperriere A, Ironson GH, Antoni MH, et al. Decreased depression up to one year following CBSM+ intervention in depressed women with AIDS: The smart/EST women's project. J Health Psychol. 2005;10(2):223–31. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2587455] [PubMed: 15723892]
  1401. Larcombe NA, Wilson PH. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Br J Psychiatr. 1984;145:366–71. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 6487909]
  1402. Larsen JK, Rafaelsen OJ. Long-term treatment of depression with isocarboxazide. Acta Psychiatr Scand. 1980;62(5):456–63. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7211430]
  1403. Larun L, Nordheim LV, Ekeland E, et al. Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev. 2006;(3):CD004691. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16856055]
  1404. Latour D, Cappeliez P. Pretherapy training for group cognitive therapy with depressed older adults. Can J Aging. 1994;13(2):221–35. OVID-Embase. Exclude: Not an eligible population treatment.
  1405. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: A 16-week naturalistic study. Bipolar Disorders. 2002;4(5):307–14. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12479663]
  1406. Lauritzen L, Clemmesen L, Klysner R, et al. Combined treatment with imipramine and mianserin. A controlled pilot study. Pharmacopsychiatr. 1992;25(4):182–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1528957]
  1407. Lauritzen L, Bendsen BB, Vilmar T, et al. Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study. Psychopharmacol. 1994;114(1):119–22. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 7846193]
  1408. Lauterbach E, Felber W, Muller-Oerlinghausen B, et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: A randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand. 2008;118(6):469–79. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18808400]
  1409. Laux G, Koenig W, Pfaff G. Antidepressant combination therapy of endogenous depressions with benzodiazepines or neuroleptics: A study comparing adjuvant treatment with oxazolam versus chlorprothixene. Pharmacopsychiatr. 1988;21(2):87–92. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2899329]
  1410. Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatr. 1998;55(7):645–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9672056]
  1411. Lavertue NE, Kumar VK, Pekala RJ. The effectiveness of a hypnotic ego-strengthening procedure for improving self-esteem and depression. Aust J Clin Exp Hypnosis. 2002;30(1):1–23. Exclude: Not an eligible population treatment.
  1412. Lavie CJ, Milani RV, Cassidy MM, et al. Effects of cardiac rehabilitation and exercise training programs in women with depression. Am J Cardiol. 1999;83(10):1480–3. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 10335766]
  1413. Lavretsky H, Kim MD, Kumar A, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: An open trial. J Clin Psychiatry. 2003;64(12):1410–4. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14728100]
  1414. Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatr. 2006;14(2):181–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16473984]
  1415. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatr. 2001;9(3):298–303. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 11481139]
  1416. Layne CM, Saltzman WR, Poppleton L, et al. Effectiveness of a school-based group psychotherapy program for war-exposed adolescents: A randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2008;47(9):1048–62. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18664995]
  1417. Learmonth D, Rai S. Taking computerized CBT beyond primary care. Br J Clin Psychol. 2008;47(Pt:1):1–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17939879]
  1418. Learmonth D, Trosh J, Rai S, et al. The role of computer-aided psychotherapy within an NHS CBT specialist service. Couns Psychother Res. 2008;8(2):117–23. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1419. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: Consensus statement update. JAMA. 1997;278(14):1186–90. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 9326481]
  1420. Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St. John's wort extract WS 5570 in major depression: A double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159(8):1361–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12153829]
  1421. Lee MR, Cohen L, Hadley SW, et al. Cognitive-behavioral group therapy with medication for depressed gay men with AIDS or symptomatic HIV infection. Psychiatr Serv. 1999;50(7):948–52. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10402618]
  1422. Lee MS, Jang J, Jang H, et al. Effects of Qi-therapy on blood pressure, pain and psychological symptoms in the elderly: A randomized controlled pilot trial. Complement Ther Med. 2003;11(3):159–64. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 14659379]
  1423. Leff J, Vearnals S, Brewin CR, et al. The London depression intervention trial. Randomised controlled trial of antidepressants v. couple therapy in the treatment and maintenance of people with depression living with a partner: Clinical outcome and costs. Br J Psychiatr. 2000;177:95–100. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 11026946]
  1424. Legrand FD, Mille CR. The effects of 60 minutes of supervised weekly walking (in a single vs. 3–5 session format) on depressive symptoms among older women: Findings from a pilot randomized trial. Ment Health Phys Activ. 2009;2(2):71–5. OVID-Embase. Exclude: Not an eligible population treatment.
  1425. Legrand F, Heuze JP. Antidepressant effects associated with different exercise conditions in participants with depression: A pilot study. J Sport Exerc Psychol. 2007;29(3):348–64. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 17876971]
  1426. Leibenluft E, Moul DE, Schwartz PJ, et al. A clinical trial of sleep deprivation in combination with antidepressant medication. Psychiatry Res. 1993;46(3):213–27. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 8493292]
  1427. Leinonen E, Niemi H. The influence of educational information on depressed outpatients treated with escitalopram: A semi-naturalistic study. Nord J Psychiatr. 2007;61(2):109–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17454725]
  1428. Leite JR, FL, Amemiya TM, et al. Effect of progressive self-focus meditation on attention, anxiety, and depression scores. Percept Motor Skills. 2010;110(3 Part 1):840–8. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PubMed: 20681336]
  1429. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response: An association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatr. 2008;63(12):1103–10. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC2587308] [PubMed: 18191112]
  1430. Lemmens GM, Eisler I, Buysse A, et al. The effects on mood of adjunctive single-family and multi-family group therapy in the treatment of hospitalized patients with major depression. A 15-month follow-up study. Psychother Psychosom. 2009;78(2):98–105. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19218828]
  1431. Lemon K. An assessment of treating depression and anxiety with aromatherapy. Int J Aromather. 2004;14(2):63–9. OVID-Embase. Exclude: Not an eligible population treatment.
  1432. Lenoir S, Degenring FH, Saller R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L. Phytomed. 1999;6(3):141–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10439477]
  1433. Lenox-Smith AJ, Schaeffer P, Willard L. A double-blind study of venlafaxine XR versus citalopram in patients with treatment-resistant depression. Presented at the Annual Meeting of the British Association for Psychopharmacology; July 2001; Harrogate, Yorkshire, England, UK. 2001. [Abstract]
  1434. Lenze EJ, Dew MA, Mazumdar S, et al. Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: Effects on social adjustment. Am J Psychiatry. 2002;159(3):466–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11870013]
  1435. Lenze EJ, Sheffrin M, Driscoll HC, et al. Incomplete response in late-life depression: Getting to remission. Dialog Clin Neurosci. 2008;10(4):419–30. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC3181898] [PubMed: 19170399]
  1436. Leo RJ, Ligot J. A systematic review of randomized controlled trials of acupuncture in the treatment of depression. J Affect Disord. 2007;97(1–3):13–22. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16899301]
  1437. Leppamaki S, Haukka J, Lonnqvist J, et al. Drop-out and mood improvement: A randomised controlled trial with light exposure and physical exercise. BMC Psychiatr. 2004;4:22. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC514552] [PubMed: 15306031]
  1438. Lerber-Good WF. Neurotransmitter precursor therapies in affective disorders. Int J Vitam Nutr Res. 1986;56(SUPPL 29):69–82. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 2871118]
  1439. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297(4):367–79. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17244833]
  1440. Lesser I, Rosales A, Zisook S, et al. Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D. Psychiatr Serv. 2008;59(11):1273–84. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18971403]
  1441. Lesser IM, Castro DB, Gaynes BN, et al. Ethnicity/race and outcome in the treatment of depression: Results from STAR*D. Med Care. 2007;45(11):1043–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18049344]
  1442. Lett HS, Davidson J, Blumenthal JA. Nonpharmacologic treatments for depression in patients with coronary heart disease. Psychosom Med. 2005;67(Suppl 1):S58–62. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15953803]
  1443. Leucht S, Hackl HJ, Steimer W, et al. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacol. 2000;147(4):378–83. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10672631]
  1444. Leuchter AF, Lesser IM, Trivedi MH, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract. 2008;14(5):271–80. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2778329] [PubMed: 18832958]
  1445. Leuchter AF, Husain MM, Cook IA, et al. Painful physical symptoms and treatment outcome in major depressive disorder: A STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med. 2010;40(2):239–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19493369]
  1446. Leung SN, Orrell MW. A brief cognitive behavioural therapy group for the elderly: Who benefits? Int J Geriatr Psychiatry. 1993;8(7):593–8. OVID-PsycINFO. Exclude: Not an eligible study design.
  1447. Levendoglu F, Altintepe L, Okudan N, et al. A twelve week exercise program improves the psychological status, quality of life and work capacity in hemodialysis patients. J Nephrol. 2004;17(6):826–32. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 15593058]
  1448. Levesque M, Savard J, Simard S, et al. Efficacy of cognitive therapy for depression among women with metastatic cancer: A single-case experimental study. J Behav Ther Exp Psychiatr. 2004;35(4):287–305. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15530844]
  1449. Levin A, Schlebusch L. Mianserin is better tolerated and more effective in depression than a nomifensine-clobazam combination: A double-blind study. Acta Psychiatr Scand Suppl. 1985;320:75–80. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3863470]
  1450. Levine J, Gonsalves M, Babur I, et al. Inositol 6 g daily may be effective in depression but not in schizophrenia. Hum Psychopharmacol. 1993;8(1):49–53. OVID-Embase. Exclude: Not an eligible study design.
  1451. Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997;7(2):147–55. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 9169302]
  1452. Levine J, Mishori A, Susnosky M, et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatr. 1999;45(3):270–3. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10023500]
  1453. Levitan RD, Shen JH, Jindal R, et al. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: Antidepressant and hypnotic effects. J Psychiatr Neurosci. 2000;25(4):337–46. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1407729] [PubMed: 11022398]
  1454. Levitt AJ, Joffe RT, Kennedy SH. Bright light augmentation in antidepressant nonresponders. J Clin Psychiatry. 1991;52(8):336–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1869495]
  1455. Lewinsohn PM, Clarke GN, Hops H, et al. Cognitive-behavioral treatment for depressed adolescents. Behav Ther. 1990;21(4):385–401. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment.
  1456. Lewinsohn Peter M, Clarke Gregory N, Paul Rohde, et al. A course in coping: A cognitive-behavioral approach to the treatment of adolescent depression. 1996. pp. 109–35. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  1457. Lewis CC, Simons AD, Silva SG, et al. The role of readiness to change in response to treatment of adolescent depression. J Consult Clin Psychol. 2009;77(3):422–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2822468] [PubMed: 19485584]
  1458. Lewis FM, Cochrane BB, Fletcher KA, et al. Helping Her Heal: A pilot study of an educational counseling intervention for spouses of women with breast cancer. Psychooncol. 2008;17(2):131–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17429834]
  1459. Leykin Y, Amsterdam JD, DeRubeis RJ, et al. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol. 2007;75(2):267–76. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17469884]
  1460. Li C, Huang Y, Li Y, et al. Treating post-stroke depression with mind-refreshing antidepressive acupuncture therapy. Int J Clin Acupunct. 1994;5(4):389–93. Exclude: Not an eligible population treatment.
  1461. Li LT, Wang SH, Ge HY, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. J Altern Complement Med. 2008;14(7):841–6. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 18721085]
  1462. Lichtenberg PA, Kimbarow ML, Morris P, et al. Behavioral treatment of depression in predominantly African-American medical patients. Clin Gerontol. 1996;17(2):15–33. Exclude: Not an eligible population treatment.
  1463. Lieber AL, Newbury ND. Diagnosis, treatment, and outcome in refractory depression. Ann Clin Psychiatr. 1991;3(2):119–24. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  1464. Lieverse R, Nielen MMA, Veltman DJ, et al. Bright light in elderly subjects with nonseasonal major depressive disorder: A double blind randomised clinical trial using early morning bright blue light comparing dim red light treatment. Trials. 2008;9(Article Number 48) OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC2553185] [PubMed: 18671864]
  1465. Lieverse R, Van Someren EJ, Nielen MM, et al. Bright light treatment in elderly patients with nonseasonal major depressive disorder: A randomized placebo-controlled trial. Arch Gen Psychiatr. 2011;68(1):61–70. OVID-Medline. Exclude: Not an eligible population/treatment. [PubMed: 21199966]
  1466. Lii YC, Tsay SL, Wang TJ. Group intervention to improve quality of life in haemodialysis patients. J Clin Nurs. 2007;16(11C):268–75. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17931320]
  1467. Lim HJ, Moon YI, Lee MS. Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int. 2005;25(3):225–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15650833]
  1468. Lim YM, Hong GR. Effect of 16-week Kouk-Sun-Do exercise on physical fitness, emotional state, and immunoglobulin A in community-dwelling elders in Korea. Appl Nurs Res. 2010;23(2):91–100. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20420996]
  1469. Limosin F, Loze JY, Zylberman-Bouhassira M, et al. The course of depressive illness in general practice. Can J Psychiatr. 2004;49(2):119–23. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 15065746]
  1470. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatr. 2007;68(7):1056–61. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17685742]
  1471. Lincoln NB, Flannaghan T, Sutcliffe L, et al. Evaluation of cognitive behavioural treatment for depression after stroke: A pilot study. Clin Rehabil. 1997;11(2):114–22. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9199863]
  1472. Lincoln NB, Flannaghan T. Cognitive behavioral psychotherapy for depression following stroke: A randomized controlled trial. Stroke. 2003;34(1):111–5. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 12511760]
  1473. Lindberg D, Ahlfors UG, Dencker SJ, et al. Symptom reduction in depression after treatment with L-tryptophan or imipramine. Item analysis of Hamilton rating scale for depression. Acta Psychiatr Scand. 1979;60(3):287–94. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 386715]
  1474. Linde K, Knuppel L. Large-scale observational studies of hypericum extracts in patients with depressive disorders--a systematic review. Phytomed. 2005;12(1–2):148–57. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15693723]
  1475. Linde K, Mulrow CD, Berner M, et al. St John's wort for depression. Cochrane Database Syst Rev. 2005;(2):CD000448. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15846605]
  1476. Linde K, Berner M, Egger M, et al. St John's wort for depression: Meta-analysis of randomised controlled trials. Br J Psychiatr. 2005;186:99–107. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15684231]
  1477. Lingjaerde O, Edlund AH, Gormsen CA, et al. The effects of lithium carbonate in combination with tricyclic antidepressants in endogenous depression. A double-blind, multicenter trial. Acta Psychiatr Scand. 1974;50(2):233–42. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4605253]
  1478. Lingjaerde O, Bratfos O, Bratlid T, et al. A double-blind comparison of zimelidine and desipramine in endogenous depression. Acta Psychiatr Scand. 1983;68(1):22–30. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 6225313]
  1479. Liou CP, Her JR. The effectiveness of psychotherapies on hospitalized depressive patients. Chin Med J. 1996;58(3):163–70. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8940787]
  1480. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry. 1984;141(3):448–50. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6367496]
  1481. Listman PJ. Cognitive therapy is effective in diabetic patients with depression. Am Fam Physician. 1997;56(2):566. OVID-Embase. Exclude: Not an eligible study design.
  1482. Little A, Hansen RA, Gartlehner G, et al. Impact of the STAR*D trial from the perspective of the payer. Psychiatr Serv. 2009;60(11):1463–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19880462]
  1483. Little SAS, Kligler B, Homel P, et al. Multimodal mind/body group therapy for chronic depression: A pilot study. Explore. 2009;5(6):330–7. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 19913759]
  1484. Liu C-F, Hedrick SC, Chaney EF, et al. Cost-effectiveness of collaborative care for depression in a primary care veteran population. Psychiatr Serv. 2003;54(5):698–704. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 12719501]
  1485. Liu ETH, Chen W-L, Li Y-H, et al. Exploring the efficacy of cognitive bibliotherapy and a potential mechanism of change in the treatment of depressive symptoms among the Chinese: A randomized controlled trial. Cognit Ther Res. 2009;33(5):449–61. OVID-Embase. Exclude: Not an eligible population treatment.
  1486. Liu P, He FF, Bai WP, et al. Menopausal depression: Comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. Chin Med J. 2004;117(2):189–94. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14975200]
  1487. Liu S-J, Lin C-J, Chen Y-M, et al. The effects of reminiscence group therapy on self-esteem, depression, loneliness and life satisfaction of elderly people living alone. Mid-Taiwan J Med. 2007;12(3):133–42. OVID-Embase. Exclude: Not an eligible population treatment.
  1488. Lobstein DD, Rasmussen CL. Decreases in resting plasma beta-endorphin and depression scores after endurance training. J Sports Med Phys Fitness. 1991;31(4):543–51. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 1806732]
  1489. Locca J-F, Bula CJ, Zumbach S, et al. Pharmacological treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in nursing homes: Development of practice recommendations in a Swiss canton. J Am Med Dir Assoc. 2008;9(8):611. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 18585647]
  1490. Lojko D, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord. 2007;103(1–3):253–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17289154]
  1491. Lolak S, Connors GL, Sheridan MJ, et al. Effects of progressive muscle relaxation training on anxiety and depression in patients enrolled in an outpatient pulmonary rehabilitation program. Psychother Psychosom. 2008;77(2):119–25. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18230945]
  1492. Lombardo NBE, Dresser MVB, Malivert M, et al. Acupuncture as treatment for anxiety and depression in persons with dementia: Results of a feasibility and effectiveness study. Alzheimers Care Q. 2001;2(4):28–41. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1493. Londborg PD, Smith WT, Glaudin V, et al. Short-term cotherapy with clonazepam and fluoxetine: Anxiety, sleep disturbance and core symptoms of depression. J Affect Disord. 2000;61(1–2):73–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11099743]
  1494. Lopez-Munoz F, Alamo C, Rubio G, et al. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatr. 2007;40(1):14–9. ISI:000244859800003. Exclude: Not an eligible study design. [PubMed: 17327955]
  1495. Lopez MA, Basco MR. Feasibility of dissemination of cognitive behavioral therapy to Texas community mental health centers. J Behav Health Serv Res. 2011;38(1):91–104. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20162373]
  1496. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at the end of life: A systematic review. Ann Intern Med. 2008;148(2):147–59. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18195339]
  1497. Louis M, Kowalski SD. Use of aromatherapy with hospice patients to decrease pain, anxiety, and depression and to promote an increased sense of well-being. Am J Hospice Palliat Care. 2002;19(6):381–6. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 12442972]
  1498. Loving RT, Kripke DF, Shuchter SR. Bright light augments antidepressant effects of medication and wake therapy. Depress Anxiety. 2002;16(1):1–3. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 12203667]
  1499. Loving RT, Kripke DF, Knickerbocker NC, et al. Bright green light treatment of depression for older adults. BMC Psychiatr. 2005;5:42. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1309618] [PubMed: 16283926]
  1500. Loving RT, Kripke DF, Elliot JA. Bright light treatment of depression for older adults. BMC Psychiatr. 2005;(5):41. Exclude: Not an eligible population treatment. [PMC free article: PMC1298312] [PubMed: 16283925]
  1501. Lowry F, Wachter K, Worcester S. Meta-analysis supports gabapentin/new antidepressants. Oncol Rep. 2008 Fall;:104. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched.
  1502. López J, Crespo M. Analysis of the efficacy of a psychotherapeutic program to improve the emotional status of caregivers of elderly dependent relatives. Aging Ment Health. 2008;12(4):451–61. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 18791892]
  1503. Lucas M, Asselin G, Merette C, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: A double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr. 2009;89(2):641–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19116322]
  1504. Luciano JS Jr. Neural network modeling of unipolar depression: Patterns of recovery and prediction of outcome. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  1505. Ludman EJ, Simon GE, Grothaus LC, et al. A pilot study of telephone care management and structured disease self-management groups for chronic depression. Psychiatr Serv. 2007;58(8):1065–72. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17664517]
  1506. Ludman EJ, Simon GE, Tutty S, et al. A randomized trial of telephone psychotherapy and pharmacotherapy for depression: Continuation and durability of effects. J Consult Clin Psychol. 2007;75(2):257–66. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 17469883]
  1507. Luo H, Meng F, Jia Y, et al. Clinical research on the therapeutic effect of the electro-acupuncture treatment in patients with depression. Psychiatry Clin Neurosci. 1998;52 Suppl-40 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9895187]
  1508. Luo HC, Jia YK, Li Z. Electro-acupuncture vs. amitriptyline in the treatment of depressive states. J Tradit Chin Med. 1985;5(1):3–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3849629]
  1509. Luo HC, Ureil H, Shen YC, et al. Comparative study of electroacupuncture and fluoxetine for treatment of depression. Chin J Psychiatry. 2003;(36):215–9. Exclude: Paper cannot be located.
  1510. Lustman PJ, Griffith LS, Freedland KE, et al. The course of major depression in diabetes. Gen Hosp Psychiatry. 1997;19(2):138–43. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 9097068]
  1511. Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;129(8):613–21. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9786808]
  1512. Lustman PJ, Clouse RE. Depression in diabetic patients: The relationship between mood and glycemic control. J Diabetes Complications. 2005;19(2):113–22. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15745842]
  1513. Luty SE, Carter JD, McKenzie JM, et al. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatr. 2007;190:496–502. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17541109]
  1514. Lydecker KP, Tate SR, Cummins KM, et al. Clinical outcomes of an integrated treatment for depression and substance use disorders. Psychol Addict Behav. 2010;24(3):453–65. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3609717] [PubMed: 20853931]
  1515. Lykouras L, Avgoustides D, Papakostas Y, et al. Medication response to ECT-resistant melancholic patients. Acta Psychiatr Belg. 1995;95(3):113–21. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8525854]
  1516. Lynch D, Laws KR, McKenna PJ. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol Med. 2010;40(1):9–24. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19476688]
  1517. Lynch DJ, Tamburrino MB, Nagel R. Telephone counseling for patients with minor depression: Preliminary findings in a family practice setting. J Family Pract. 1997;44(3):293–8. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 9071250]
  1518. Lynch TR, Morse JQ, Mendelson T, et al. Dialectical behavior therapy for depressed older adults: A randomized pilot study. Am J Geriatr Psychiatr. 2003;11(1):33–45. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12527538]
  1519. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: Replication and exploration of differential relapse prevention effects. J Consult Clin Psychol. 2004;72(1):31–40. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14756612]
  1520. Maag John W, Swearer Susan M, Toland Michael D. Cognitive-behavioral interventions for depression in children and adolescents: Meta-analysis, promising programs, and implications for school personnel. 2009. pp. 235–65. 2009. OVID-PsycINFO. Exclude: Not an eligible study design.
  1521. Macaskill ND, Macaskill A. Rational-emotive therapy plus pharmacotherapy versus pharmacotherapy alone in the treatment of high cognitive dysfunction depression. Cognit Ther Res. 1996;20(6):575–92. Exclude: Not an eligible population treatment.
  1522. MacEwan GW, Remick RA. Treatment resistant depression: A clinical perspective. Can J Psychiatr. 1988;33(9):788–92. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3214826]
  1523. Mackert A, Volz H-P, Stieglitz R-D, et al. Light treatment of non-seasonal affective disorder. Pharmacopsychiatr. 1989;22(5):206. OVID-Embase. Exclude: Not an eligible study design.
  1524. Mackert A, Volz HP, Stieglitz RD, et al. Effect of bright white light on non-seasonal depressive disorder. Pharmacopsychiatr. 1990;23(3):151–4. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2374772]
  1525. Mackert A, Volz HP, Stieglitz RD, et al. Phototherapy in nonseasonal depression. Biol Psychiatr. 1991;30(3):257–68. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1912117]
  1526. Mackin RS, Arean PA. Evidence-based psychotherapeutic interventions for geriatric depression. Psychiatr Clin North Am. 2005;28(4):805–20. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16325730]
  1527. Mackinnon A, Griffiths KM, Christensen H. Comparative randomised trial of online cognitive-behavioural therapy and an information website for depression: 12-month outcomes. Br J Psychiatr. 2008;192(2):130–4. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18245031]
  1528. Macrodimitris S, Wershler J, Hatfield M, et al. Group cognitive-behavioral therapy for patients with epilepsy and comorbid depression and anxiety. Epilepsy Behav. 2011;20(1):83–8. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 21131237]
  1529. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord. 1996;41(3):201–10. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 8988452]
  1530. Maes M, Vandoolaeghe E, van Hunsel F, et al. Immune disturbances in treatment-resistant depression: Modulation by antidepressive treatments. Hum Psychopharmacol. 1997;12(2):153–62. OVID-Embase. Exclude: Not an eligible study design.
  1531. Maes M, Verkerk R, Vandoolaeghe E, et al. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: Modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998;97(4):302–8. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 9570492]
  1532. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999;19(2):177–82. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 10211920]
  1533. Mahoney SH. Depression, anxiety, and stress among the elderly: A comparison of treatment outcome between two cognitive-behavioral interventions. 1998. OVID-PsycINFO. Exclude: Not an eligible study design.
  1534. Maina G, Rosso G, Crespi C, et al. Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: A pilot study. Psychother Psychosom. 2007;76(5):298–305. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17700050]
  1535. Maina G, Rosso G, Bogetto F. Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: Long-term results. J Affect Disord. 2009;114(1–3):200–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18728001]
  1536. Maina G, Rosso G, Rigardetto S, et al. No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression. Psychother Psychosom. 2010;79(5):295–302. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20616624]
  1537. Malhi GS, Ng F, Berk M. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust NZ J Psychiatr. 2008;42(4):346–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18330778]
  1538. Malison RT, Anand A, Pelton GH, et al. Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol. 1999;19(5):466–70. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 10505589]
  1539. Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J Manage Care Pharm. 2007;13(6 Suppl A):S8–18. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17874482]
  1540. Malt UF, Robak OH, Madsbu HP, et al. The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: Randomised double blind study. Br Med J. 1999;318(7192):1180–4. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC34546] [PubMed: 10221945]
  1541. Malyszczak K, Frydecka D, Pawlowski T, et al. Mixed anxiety and depressive disorder before and after psychodynamic group psychotherapy: A 1-year follow-up study. Int J Psychiatr Clin Pract. 2010;14(4):298–302. OVID-Embase. Exclude: Not an eligible study design.
  1542. Manassis K, Wilansky-Traynor P, Farzan N, et al. The feelings club: Randomized controlled evaluation of school-based CBT for anxious or depressive symptoms. Depress Anxiety. 2010;27(10):945–52. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20602433]
  1543. Manber R, Arnow B, Blasey C, et al. Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. Psychol Med. 2003;33(4):693–702. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12785471]
  1544. Manber R, Schnyer RN, Allen JJ, et al. Acupuncture: A promising treatment for depression during pregnancy. J Affect Disord. 2004;83(1):89–95. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15546651]
  1545. Manber R, Edinger JD, Gress JL, et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008;31(4):489–95. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2279754] [PubMed: 18457236]
  1546. Manber R, Kraemer HC, Arnow BA, et al. Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. J Consult Clin Psychol. 2008;76(3):459–67. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3694578] [PubMed: 18540739]
  1547. Manber R, Rush AJ, Thase ME, et al. The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep J Sleep Sleep Disord Res. 2003;26(2):130–6. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 12683470]
  1548. Mancini C, Van Ameringen M, Farvolden P. Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder? J Affect Disord. 2002;68(1):59–65. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11869783]
  1549. Mancini M, Gianni W, Rossi A, et al. Duloxetine in the management of elderly patients with major depressive disorder: An analysis of published data. Expert Opin Pharmacother. 2009;10(5):847–60. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19351233]
  1550. Maneeton N, Thongkam A, Maneeton B. Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study. J Med Assoc Thai. 2010;93(3):337–42. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20420109]
  1551. Manger TA, Motta RW. The impact of an exercise program on posttraumatic stress disorder, anxiety, and depression. Int J Emerg Ment Health. 2005;7(1):49–57. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15869081]
  1552. Mannel M, Kuhn U, Schmidt U, et al. St. John's wort extract LI160 for the treatment of depression with atypical features: A double-blind, randomized, and placebo-controlled trial. J Psychiatr Res. 2010;44(12):760–7. OVID-PsycINFO. Exclude: Not an eligible population/treatment. [PubMed: 20181361]
  1553. Manschreck TC, Redmond DA, Beaudette SM. Clozapine in the back wards. Ann Clin Psychiatr. 1994;6(4):215–25. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 7647831]
  1554. Manson SM. Mashkiki: Old medicine nourishing the new. Lanham, MD, England: University Press of America; 1992. Depression and related mental illnesses among American Indians: The current state of the art in treatment. OVID-PsycINFO. Exclude: Not an eligible study design.
  1555. Marangell LB, George MS, Callahan AM, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatr. 1997;54(3):214–22. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9075462]
  1556. Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003;160(5):996–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12727707]
  1557. Maratos AS, Gold C, Wang X, et al. Music therapy for depression. Cochrane Database Syst Rev. 2008;(1) OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18254052]
  1558. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15315995]
  1559. March J, Silva S, Vitiello B, et al. The Treatment for Adolescents with Depression Study (TADS): Methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry. 2006;45(12):1393–403. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17135984]
  1560. March JS, Silva S, Petrycki S, et al. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder. Evid Based Med. 2005;10(2):46. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 15830418]
  1561. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): Long-term effectiveness and safety outcomes. Arch Gen Psychiatr. 2007;64(10):1132–43. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17909125]
  1562. March JS, Vitiello B. Clinical messages from the Treatment for Adolescents with Depression Study (TADS) Am J Psychiatry. 2009;166(10):1118–23. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 19723786]
  1563. Marchand E, Ng J, Rohde P, et al. Effects of an indicated cognitive-behavioral depression prevention program are similar for Asian American, Latino, and European American adolescents. Behav Res Ther. 2010;48(8):821–5. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2918730] [PubMed: 20537319]
  1564. Marchioro G, Azzarello G, Checchin F, et al. The impact of a psychological intervention on quality of life in non-metastatic breast cancer. Eur J Canc. 1996;32A(9):1612–5. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 8911127]
  1565. Marco EJ, Wolkowitz OM, Vinogradov S, et al. Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: A pilot study. World J Biol Psychiatr. 2002;3(3):156–61. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 12478881]
  1566. Marcus AC, Garrett KM, Cella D, et al. Can telephone counseling post-treatment improve psychosocial outcomes among early stage breast cancer survivors? Psychooncol. 2010;19(9):923–32. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2891611] [PubMed: 19941285]
  1567. Marcus SC, Hassan M, Olfson M. Antidepressant switching among adherent patients treated for depression. Psychiatr Serv. 2009;60(5):617–23. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 19411348]
  1568. Marcus SM, Young EA, Kerber KB, et al. Gender differences in depression: Findings from the STAR*D study. J Affect Disord. 2005;87(2–3):141–50. Exclude: Not an eligible population treatment. [PubMed: 15982748]
  1569. Markopoulou K, Papadopoulos A, Juruena MF, et al. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinol. 2009;34(1):19–26. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18805642]
  1570. Markowitz JC, Klerman GL, Clougherty KF, et al. Individual psychotherapies for depressed HIV-positive patients. Am J Psychiatry. 1995;152(10):1504–9. Exclude: Not an eligible population treatment. [PubMed: 7573591]
  1571. Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatr. 1998;55(5):452–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9596048]
  1572. Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatr. 1998;55(5):452–7. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 9596048]
  1573. Markowitz JC, Spielman LA, Sullivan M, et al. An exploratory study of ethnicity and psychotherapy outcome among HIV-positive patients with depressive symptoms. J Psychother Pract Res. 2000;9(4):226–31. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC3330614] [PubMed: 11069135]
  1574. Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Disord. 2005;89(1–3):167–75. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16263177]
  1575. Markowitz John C, Klerman Gerald L, Perry Samuel W, et al. Interpersonal psychotherapy for depressed HIV-seropositive patients. 1993. pp. 199–224. 1993. OVID-PsycINFO. Exclude: Not an eligible study design.
  1576. Markowitz JC, Kocsis JH, Christos P, et al. Pilot study of interpersonal psychotherapy versus supportive psychotherapy for dysthymic patients with secondary alcohol abuse or dependence. J Nerv Ment Dis. 2008;196(6):468–74. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 18552624]
  1577. Marks IM, Mataix-Cols D, Kenwright M, et al. Pragmatic evaluation of computer-aided self-help for anxiety and depression. Br J Psychiatr. 2003;183:57–65. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 12835245]
  1578. Marmar CR, Gaston L, Gallagher D, et al. Alliance and outcome in late-life depression. J Nerv Ment Dis. 1989;177(8):464–72. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 2760597]
  1579. Maron E, Eller T, Vasar V, et al. Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: An open-label, naturalistic study. J Clin Psychiatry. 2009;70(7):1054–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19653982]
  1580. Marquez-Gonzalez M, Losada A, Izal M, et al. Modification of dysfunctional thoughts about caregiving in dementia family caregivers: Description and outcomes of an intervention programme. Aging Ment Health. 2007;11(6):616–25. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18074249]
  1581. Marriott M, Kellett S. Evaluating a cognitive analytic therapy service; practice-based outcomes and comparisons with person-centred and cognitive-behavioural therapies. Psychol Psychother. 2009;82(Pt:1):1–72. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18759998]
  1582. Marsden CA, Tyrer P, Casey P, et al. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. J Psychopharmacol. 1987;1(4):244–50. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 22159137]
  1583. Marshall TK, Mazie AS. A cognitive approach to treating depression. Soc Casework. 1987;68(9):540–5. OVID-PsycINFO. Exclude: Not an eligible study design.
  1584. Marti A, Barrachina MTM. The effects of mindfulness-based cognitive therapy: A qualitative approach. Psychol Spain. 2009;13(1):9–16. OVID-PsycINFO. Exclude: Not an eligible study design.
  1585. Martin A, Sanderson K, Cocker F. Meta-analysis of the effects of health promotion intervention in the workplace on depression and anxiety symptoms. Scand J Work Environ Health. 2009;35(1):7–18. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19065280]
  1586. Martin E, Martin S. IPT for treatment-resistant depression. 2006. Wiley-CCTR. Exclude: Not an eligible study design.
  1587. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525–42. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20439549]
  1588. Martinsen EW, Medhus A, Sandvik L. Effects of aerobic exercise on depression: A controlled study. Br Med J. 1985;291(6488):109. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC1416251] [PubMed: 3926074]
  1589. Martinsen EW, Hoffart A, Solberg O. Comparing aerobic with nonaerobic forms of exercise in the treatment of clinical depression: A randomized trial. Compr Psychiatry. 1989;30(4):324–31. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 2667882]
  1590. Martiny K. Adjunctive bright light in non-seasonal major depression. Acta Psychiatr Scand Suppl. 2004;(425):7–28. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15527426]
  1591. Martiny K, Lunde M, Unden M, et al. Adjunctive bright light in non-seasonal major depression: Results from clinician-rated depression scales. Acta Psychiatr Scand. 2005;112(2):117–25. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15992393]
  1592. Martiny K, Lunde M, Unden M, et al. Adjunctive bright light in non-seasonal major depression: Results from patient-reported symptom and well-being scales. Acta Psychiatr Scand. 2005;111(6):453–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15877712]
  1593. Martiny K, Lunde M, Unden M, et al. The lack of sustained effect of bright light, after discontinuation, in non-seasonal major depression. Psychol Med. 2006;36(9):1247–52. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16756691]
  1594. Masand P, Peindl K, Hooper-Wood C, et al. A randomized, double-blind, placebo-controlled, flexible-dose trial of augmentation with OROS methylphenidate in treatment-resistant depression. 2006. Wiley-CCTR. Exclude: Not an eligible study design.
  1595. Mason RA. Efficacy of prosocial behavior as an adjunct to short-term psychotherapy in treating clinically depressed college students. 2004. OVID-PsycINFO. Exclude: Not an eligible study design.
  1596. Masuda A, Nakazato M, Kihara T, et al. Repeated thermal therapy diminishes appetite loss and subjective complaints in mildly depressed patients. Psychosom Med. 2005;67(4):643–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16046381]
  1597. Mathe G, Lopez MD, Frechet M, et al. A comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for the search of the most rapidly and frequently active treatment of depressive syndromes in an oncology service. Biomed Pharmacother. 1987;41(1):13–26. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3300808]
  1598. Mather AS, Rodriguez C, Guthrie MF, et al. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: Randomised controlled trial. Br J Psychiatr. 2002;180:411–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11983637]
  1599. Mathew KL, Whitford HS, Kenny MA, et al. The long-term effects of mindfulness-based cognitive therapy as a relapse prevention treatment for major depressive disorder. Behav Cognit Psychother. 2010;38(5):561–76. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20374671]
  1600. Matinsen EW, Medhus A. Adherence to exercise and patients' evaluation of physical exercise in a comprehensive treatment programme for depression. Nord Psykiatr Tidsskr. 1989;43(5):411–5. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1601. Matsunaga M, Okamoto Y, Suzuki S, et al. Psychosocial functioning in patients with treatment-resistant depression after group cognitive behavioral therapy. BMC Psychiatr. 2010;10:22. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2856539] [PubMed: 20230649]
  1602. Mattes JA. Pergolide to augment the effectiveness of antidepressants: Clinical experience and a small double-blind study. Ann Clin Psychiatr. 1997;9(2):87–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9242894]
  1603. Mattingly G, Ilivicky H, Canale J, et al. Quetiapine augmentation for treatment-resistant depression. 2006. Wiley-CCTR. Exclude: Not an eligible study design.
  1604. Matussek N, Angst J, Benkert O, et al. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients. Adv Biochem Psychopharmacol. 1974;11(0):399–404. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4602669]
  1605. Mausbach BT, Moore R, Roesch S, et al. The relationship between homework compliance and therapy outcomes: An updated meta-analysis. Cognit Ther Res. 2010;34(5):429–38. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2939342] [PubMed: 20930925]
  1606. Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: Humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009;26(1):83–97. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18833573]
  1607. Mayers AG, Baldwin DS, Dyson R, et al. Use of St. John's wort (Hypericum perforatum L) in members of a depression self-help organisation: A 12-week open prospective pilot study using the HADS scale. Prim Care Psychiatr. 2003;9(1):15–20. OVID-Embase. Exclude: Not an eligible study design.
  1608. Maynard CK. Comparison of effectiveness of group interventions for depression in women. Arch Psychiatr Nurs. 1993;7(5):277–83. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 8257196]
  1609. Mayur PM, Gangadhar BN, Subbakrishna DK, et al. Discontinuation of antidepressant drugs during electroconvulsive therapy: A controlled study. J Affect Disord. 2000;58(1):37–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10760556]
  1610. Mazeh D, Shahal B, Saraf R, et al. Venlafaxine for the treatment of depressive episode during the course of schizophrenia. J Clin Psychopharmacol. 2004;24(6):653–5. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 15538129]
  1611. Mbaya P. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol. 2002;17(7):335–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12415551]
  1612. McCabe MP, McGillivray JA, Newton DC. Effectiveness of treatment programmes for depression among adults with mild/moderate intellectual disability. J Intellect Disabil Res. 2006;50(Pt:4):4–47. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16507028]
  1613. McCaffrey R. The effect of healing gardens and art therapy on older adults with mild to moderate depression. Holist Nurs Pract. 2007;21(2):79–84. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 17327752]
  1614. McCaffrey R, Hanson C, McCaffrey W. Garden walking for depression: A research report. Holist Nurs Pract. 2010;24(5):252–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20706087]
  1615. McCall WV, Blocker JN, D'Agostino R Jr, et al. Treatment of insomnia in depressed insomniacs: Effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med. 2010;6(4):322–9. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2919661] [PubMed: 20726279]
  1616. McCann IL, Holmes DS. Influence of aerobic exercise on depression. J Pers Soc Psychol. 1984;46(5):1142–7. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 6737208]
  1617. Mcclanahan TM. A comparative evaluation of cognitive-behavioral therapy and insight-oriented psychotherapy in the treatment of comorbid substance abuse, anxiety, and depression in substance abusing females Mcclanahan. 2001. OVID-PsycINFO. Exclude: Not an eligible study design.
  1618. McClernon FJ, Hiott FB, Westman EC, et al. Transdermal nicotine attenuates depression symptoms in nonsmokers: A double-blind, placebo-controlled trial. Psychopharmacol. 2006;189(1):125–33. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16977477]
  1619. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180–6. OVID-Embase. Exclude: Systematic Review before 2005. [PMC free article: PMC3677201] [PubMed: 21346613]
  1620. McCrone P, Knapp M, Proudfoot J, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: Randomised controlled trial. Br J Psychiatr. 2004;185:55–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15231556]
  1621. McCue RE, Aronowitz J. Accelerated antidepressant response in geriatric inpatients. Am J Geriatr Psychiatr. 1994;2(3):244–6. OVID-Embase. Exclude: Not an eligible study design.
  1622. McCusker J, Cole M, Yaffe M, et al. Project direct: Pilot study of a collaborative intervention for depressed seniors. Can J Commun Ment Health. 2008;27(2):201–18. OVID-Embase. Exclude: Not an eligible population treatment.
  1623. McDowell DM, Levin FR, Seracini AM, et al. Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse. 2000;26(1):25–31. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10718161]
  1624. McEnany GW, Lee KA. Effects of light therapy on sleep, mood, and temperature in women with nonseasonal major depression. Issues Ment Health Nurs. 2005;26(7):781–94. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16126652]
  1625. McEvoy PM, Nathan P. Effectiveness of cognitive behavior therapy for diagnostically heterogeneous groups: A benchmarking study. J Consult Clin Psychol. 2007;75(2):344–50. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17469892]
  1626. McGillivray JA, McCabe MP, Kershaw MM. Depression in people with intellectual disability: An evaluation of a staff-administered treatment program. Res Dev Disabil. 2008;29(6):524–36. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17981010]
  1627. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull. 1987;23(1):169–72. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 3602314]
  1628. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150(1):118–23. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8417553]
  1629. McGrath PJ, Stewart JW, Nunes EN, et al. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. J Clin Psychiatry. 1994;55(8):336–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8071301]
  1630. McGrath PJ, Khan AY, Trivedi MH, et al. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: A STAR*D report. J Clin Psychiatry. 2008;69(12):1847–55. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 19026268]
  1631. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–94. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17177199]
  1632. McKnight DL, Nelson RO, Hayes SC, et al. Importance of treating individually assessed response classes in the amelioration of depression. Behav Ther. 1984;15(4):315–35. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment.
  1633. McLean P, Taylor S. Severity of unipolar depression and choice of treatment. Behav Res Ther. 1992;30(5):443–51. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1520230]
  1634. McLean PD, Hakstian AR. Clinical depression: Comparative efficacy of outpatient treatments. J Consult Clin Psychol. 1979;47(5):818–36. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 389965]
  1635. McLean PD, Hakstian AR. Relative endurance of unipolar depression treatment effects: Longitudinal follow-up. J Consult Clin Psychol. 1990;58(4):482–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2212186]
  1636. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804–14. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC1474035] [PubMed: 16642436]
  1637. McMahon L, Foran KM, Forrest SD, et al. Graduate mental health worker case management of depression in UK primary care: A pilot study. Br J Gen Pract. 2007;57(544):880–5. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2169311] [PubMed: 17976288]
  1638. McNamara K, Horan JJ. Experimental construct validity in the evaluation of cognitive and behavioral treatments for depression. J Couns Psychol. 1986;33(1):23–30. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1639. McNaughton JL. Brief interventions for depression in primary care: A systematic review. Can Fam Physician. 2009;55(8):789–96. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2726093] [PubMed: 19675262]
  1640. McNeil JK, LeBlanc EM, Joyner M. The effect of exercise on depressive symptoms in the moderately depressed elderly. Psychol Aging. 1991;6(3):487–8. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 1930766]
  1641. McPherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: A systematic review. Acta Psychiatr Scand. 2005;111(5):331–40. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15819726]
  1642. McPherson S, Evans C, Richardson P. The: NICE; Depression Guidelines and the recovery model: Is there an evidence base for IAPT? J Ment Health. 2009;18(5):405–14. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched.
  1643. McPherson S, Walker C, Caryle JA. Primary care counsellors' experiences of working with treatment resistant depression: A qualitative pilot study. Couns Psychother Res. 2006;6(4):250–7. OVID-PsycINFO. Exclude: Not an eligible study design.
  1644. McShane G, Mihalich M, Walter G, et al. Outcome of patients with unipolar, bipolar and psychotic disorders admitted to a specialist child and adolescent mental health service. Australas Psychiatr. 2006;14(2):198–201. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16734650]
  1645. Mead GE, Morley W, Campbell P, et al. Exercise for depression. Cochrane Database Syst Rev. 2008;(4) OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18843656]
  1646. Mead N, MacDonald W, Bower P, et al. The clinical effectiveness of guided self-help versus waiting-list control in the management of anxiety and depression: A randomized controlled trial. Psychol Med. 2005;35(11):1633–43. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16219121]
  1647. Mead N, Lester H, Chew-Graham C, et al. Effects of befriending on depressive symptoms and distress: Systematic review and meta-analysis. Br J Psychiatr. 2010;196(2):96–101. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20118451]
  1648. Means KM, O'Sullivan PS, Rodell DE. Psychosocial effects of an exercise program in older persons who fall. J Rehabil Res Dev. 2003;40(1):49–58. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 15150720]
  1649. Medhus A, Heskestad S, Tjemsland L. Mianserin added to tricyclic antidepressants in depressed patients not responding to a tricyclic antidepressant alone: A randomized, placebo-controlled, double-blind study. Nord J Psychiatr. 1994;48(5):355–8. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1650. Meeks S, Looney SW, Van Haitsma K, et al. BE-ACTIV: A staff-assisted behavioral intervention for depression in nursing homes. Gerontologist. 2008;48(1):105–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18381837]
  1651. Meeks TW, Wetherell JL, Irwin MR, et al. Complementary and alternative treatments for late-life depression, anxiety, and sleep disturbance: A review of randomized controlled trials. J Clin Psychiatr. 2007;68(10):1461–71. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17960959]
  1652. Mehdi PR, Sen AK, Sen Mazumdar DP. The usefulness of psychodrama in the treatment of depressed patients. Indian J Clin Psychol. 1997;24(1):82–92. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1653. Mehta P, Sharma M. Yoga as a complementary therapy for clinical depression. Complement Health Pract Rev. 2010;15(3):156–70. OVID-PsycINFO. Exclude: Not an eligible study design.
  1654. Meier RM. Group treatment of depression and withdrawal at a day-treatment center. Int J Partial Hosp. 1982;1(4):349–53. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 10260154]
  1655. Mello MF, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychother Pract Res. 2001;10(2):117–23. Exclude: Not an eligible population treatment. [PMC free article: PMC3330639] [PubMed: 11264335]
  1656. Melvin GA, Tonge BJ, King NJ, et al. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1151–61. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17003660]
  1657. Melzer J, Brignoli R, Keck ME, et al. A hypericum extract in the treatment of depressive symptoms in outpatients: An open study. Forschende Komplementarmedizin. 2010;17(1):7–14. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20215757]
  1658. Mendels J, Stinnett JL, Burns D, et al. Amine precursors and depression. Arch Gen Psychiatr. 1975;32(1):22–30. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 1089400]
  1659. Mendes De, Leon CF, Czajkowski SM, Freedland KE, et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: The Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial. J Cardpulm Rehabil. 2006;26(1):9–15. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16617220]
  1660. Mendlewicz J, Youdim MB. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord. 1980;2(2):137–46. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6448885]
  1661. Mendlewicz J, Kriwin P, Oswald P, et al. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. Int Clin Psychopharmacol. 2006;21(4):227–31. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16687994]
  1662. Mendlowitz SL, Manassis K, Bradley S, et al. Cognitive-behavioral group treatments in childhood anxiety disorders: The role of parental involvement. J Am Acad Child Adolesc Psychiatry. 1999;38(10):1223–9. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 10517054]
  1663. Mendoza RJ, Pittenger DJ, Weinstein CS. Unit management of depression of patients with multiple sclerosis using cognitive remediation strategies: A preliminary study. Neurorehabil Neural Repair. 2001;15(1):9–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11527284]
  1664. Mercier MA, Stewart JW, Quitkin FM. A pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression. J Clin Psychiatry. 1992;53(5):166–70. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1592844]
  1665. Merrill KA, Tolbert VE, Wade WA. Effectiveness of cognitive therapy for depression in a community mental health center: A benchmarking study. J Consult Clin Psychol. 2003;71(2):404–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12699035]
  1666. Merrill RM, Taylor P, Aldana SG. Coronary Health Improvement Project (CHIP) is associated with improved nutrient intake and decreased depression. Nutr. 2008;24(4):314–21. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18296026]
  1667. Meyer B, Berger T, Caspar F, et al. Effectiveness of a novel integrative online treatment for depression (Deprexis): Randomized controlled trial. J Med Internet Res. 2009;11(2):e15. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2762808] [PubMed: 19632969]
  1668. Milak MS, Parsey RV, Lee L, et al. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res. 2009;173(1):63–70. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC3804908] [PubMed: 19446443]
  1669. Milani RV, Lavie CJ, Cassidy MM. Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events. Am Heart J. 1996;132(4):726–32. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8831359]
  1670. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med. 2007;120(9):799–806. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 17765050]
  1671. Milani RV, Lavie CJ, Mehra MR, et al. Impact of exercise training and depression on survival in heart failure due to coronary heart disease. Am J Cardiol. 2011;107(1):64–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 21146688]
  1672. Milea D, Guelfucci F, Bent-Ennakhil N, et al. Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration. Clin Ther. 2010;32(12):2057–72. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 21118742]
  1673. Miljkovic BR, Pokrajac M, Timotijevic I, et al. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. Int Clin Psychopharmacol. 1997;12(4):207–12. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9347381]
  1674. Miller IW, Bishop SB, Norman WH, et al. Cognitive/behavioural therapy and pharmacotherapy with chronic, drug-refractory depressed inpatients: A note of optimism. Behav Psychother. 1985;13(4):320–7. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  1675. Miller IW, Norman WH, Keitner GI, et al. Cognitive-behavioral treatment of depressed inpatients. Behav Ther. 1989;20(1):25–47. OVID-Embase. Exclude: Not an eligible population treatment.
  1676. Miller IW, Norman WH, Keitner GI. Cognitive-behavioral treatment of depressed inpatients: Six- and twelve-month follow-up. Am J Psychiatry. 1989;146(10):1274–9. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 2782470]
  1677. Miller IW, Norman WH, Keitner GI. Treatment response of high cognitive dysfunction depressed inpatients. Compr Psychiatry. 1990;31(1):62–71. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2404660]
  1678. Miller IW, Norman WH, Keitner GI. Combined treatment for patients with double depression. Psychother Psychosom. 1999;68(4):180–5. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 10396008]
  1679. Miller IW, Keitner GI, Ryan CE, et al. Treatment matching in the posthospital care of depressed patients. Am J Psychiatry. 2005;162(11):2131–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1899157] [PubMed: 16263854]
  1680. Miller KK, Perlis RH, Papakostas GI, et al. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectrums. 2009;14(12):688–94. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC4081446] [PubMed: 20394176]
  1681. Miller L, Weissman M. Interpersonal psychotherapy delivered over the telephone to recurrent depressives: A pilot study. Depress Anxiety. 2002;16(3):114–7. Exclude: Not an eligible population treatment. [PubMed: 12415535]
  1682. Miller MD, Pollock BG, Rifai AH, et al. Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Geriatr Psychiatry Neurol. 1991;4(4):226–30. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1789911]
  1683. Miller MD, Paradis CF, Houck PR, et al. Chronic medical illness in patients with recurrent major depression. Am J Geriatr Psychiatr. 1996;4(4):281–90. OVID-PsycINFO. Exclude: Not an eligible study design.
  1684. Mindham RH. Continuation therapy with tricyclic antidepressants in relapsing depressive illness. Bibl Psychiatr. 1981;(160):49–55. Wiley-CCTR. Exclude: Not an eligible study design. [PubMed: 7458885]
  1685. Mino Y, Babazono A, Tsuda T, et al. Can stress management at the workplace prevent depression? A randomized controlled trial. Psychother Psychosom. 2006;75(3):177–82. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16636633]
  1686. Miranda J, Munoz R. Intervention for minor depression in primary care patients. Psychosom Med. 1994;56(2):136–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8008800]
  1687. Miranda J, Chung JY, Green BL, et al. Treating depression in predominantly low-income young minority women: A randomized controlled trial. JAMA. 2003;290(1):57–65. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12837712]
  1688. Miranda J, Azocar F, Organista KC, et al. Treatment of depression among impoverished primary care patients from ethnic minority groups. Psychiatr Serv. 2003;54(2):219–25. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12556604]
  1689. Miranda J, Green BL, Krupnick JL, et al. One-year outcomes of a randomized clinical trial treating depression in low-income minority women. J Consult Clin Psychol. 2006;74(1):99–111. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 16551147]
  1690. Mischoulon D, Opitz G, Kelly K, et al. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: Comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment. Depress Anxiety. 2004;19(1):43–50. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14978785]
  1691. Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008;18(9):639–45. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18539007]
  1692. Mischoulon D, Papakostas GI, Dording CM, et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatr. 2009;70(12):1636–44. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2918427] [PubMed: 19709502]
  1693. Miser WF. Exercise as an effective treatment option for major depression in older adults. J Fam Pract. 2000;49(2):109–10. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10718684]
  1694. Mishra M, Sinha RK. Effect of yogic practices on depression and anxiety. J Projective Psychol Ment Health. 2001;8(1):23–7. OVID-PsycINFO. Exclude: Not an eligible study design.
  1695. Miskowiak KW, Vinberg M, Harmer CJ, et al. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials. 2010;11:97. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2967509] [PubMed: 20942940]
  1696. Misri S, Kendrick K. Treatment of perinatal mood and anxiety disorders: A review. Can J Psychiatry. 2007;52(8):489–98. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17955910]
  1697. Mitchell N, Dunn K. Pragmatic evaluation of the viability of CCBT self-help for depression in higher education. Couns Psychother Res. 2007;7(3):144–50. OVID-PsycINFO. Exclude: Not an eligible study design.
  1698. Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2000;20(4):483–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10917411]
  1699. Mitchell PH, Teri L, Veith R, et al. Living well with stroke: Design and methods for a randomized controlled trial of a psychosocial behavioral intervention for poststroke depression. J Stroke Cerebrovasc Dis. 2008;17(3):109–15. OVID-Medline. Exclude: Not an elligible population design. [PMC free article: PMC2396193] [PubMed: 18436150]
  1700. Mitchell PH, Veith RC, Becker KJ, et al. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: Living well with stroke: Randomized, controlled trial. Stroke. 2009;40(9):3073–8. OVID-Medline. Exclude: Not an elligible population design. [PMC free article: PMC2777736] [PubMed: 19661478]
  1701. Mitchell P. The pharmacological treatment of tricyclic-resistant depression: Review and management guidelines. Aust NZ J Psychiatr. 1987;21(4):442–51. OVID-PsycINFO. Exclude: Not an eligible guideline. [PubMed: 3329512]
  1702. Mittelman MS, Brodaty H, Wallen AS, et al. A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: Effects on caregiver depression. Am J Geriatr Psychiatr. 2008;16(11):893–904. Wiley-CCTR. Exclude: Not an eligible population treatment. [PMC free article: PMC2753499] [PubMed: 18978250]
  1703. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996–1002. OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 16606910]
  1704. Miyasaki JM, Shannon K, Voon V, et al. Appendix F: Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (evidenced-based review): Report of the Quality Standards Subcommitte of the American Academy of Neurology. CONTINUUM Lifelong Learn Neurol. 2007;13(1):193–9. OVID-Embase. Exclude: Not an eligible guideline.
  1705. Moak DH, Anton RF, Latham PK, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003;23(6):553–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14624185]
  1706. Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68(2):356–61. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10780138]
  1707. Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69(6):942–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11777121]
  1708. Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression. Arch Gen Psychiatr. 2005;62(9):1007–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16143732]
  1709. Mohr DC, Hart SL, Marmar C. Telephone administered cognitive-behavioral therapy for the treatment of depression in a rural primary care clinic. Cognit Ther Res. 2006;30(1):29–37. OVID-Embase. Exclude: Not an eligible study design.
  1710. Moldenhauer Z. Adolescent depression: A primary care pilot intervention study. 2004. OVID-PsycINFO. Exclude: Not an eligible study design.
  1711. Moleiro C, Beutler LE. Clinically significant change in psychotherapy for depressive disorders. J Affect Disord. 2009;115(1–2):220–4. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18851885]
  1712. Molenaar PJ, Dekker J, Van R, et al. Does adding psychotherapy to pharmacotherapy improve social functioning in the treatment of outpatient depression? Depress Anxiety. 2007;24(8):553–62. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17131302]
  1713. Moller HJ. Evidence for beneficial effects of antidepressants on suicidality in depressive patients: A systematic review. Eur Arch Psychiatry Clin Neurosci. 2006;256(6):329–43. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16783501]
  1714. Moller HJ, Bottlender R, Grunze H, et al. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord. 2001;67(1–3):141–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11869761]
  1715. Montes JM, Ferrando L, Saiz-Ruiz J. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study. J Affect Disord. 2004;79(1–3):229–34. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15023499]
  1716. Montgomery EC, Kunik ME, Wilson N, et al. Can paraprofessionals deliver cognitive-behavioral therapy to treat anxiety and depressive symptoms? Bull Menninger Clin. 2010;74(1):45–62. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20235623]
  1717. Montoya A, Weiss AP, Price BH, et al. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. Neurosurgery. 1049;50(5):1043–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11950407]
  1718. Moore JD. The effectiveness of bright light treatment on depression in an HIV population. 2009. OVID-PsycINFO. Exclude: Not an eligible study design.
  1719. Moore RG, Blackburn IM. Cognitive therapy in the treatment of non-responders to antidepressant medication: A controlled pilot study. Behav Cognit Psychother. 1997;25(3):251–9. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI.
  1720. Moorey S, Cort E, Kapari M, et al. A cluster randomized controlled trial of cognitive behaviour therapy for common mental disorders in patients with advanced cancer. Psychol Med. 2009;39(5):713–23. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18761755]
  1721. Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997;58(10):437–9. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 9375594]
  1722. Moreno RA, Teng CT, Almeida KM, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: A randomized double-blind trial in a Brazilian sample. Revista Brasileira de Psiquiatria. 2006;28(1):29–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16612487]
  1723. Moreno R, Cunningham AC, Gatchel RJ, et al. Functional restoration for chronic low back pain: Changes in depression, cognitive distortion, and disability. J Occup Rehabil. 1991;1(3):207–16. OVID-PsycINFO. Exclude: Not an eligible study design.
  1724. Morgan AJ, Jorm AF. Self-help interventions for depressive disorders and depressive symptoms: A systematic review. Ann Gen Psychiatry. 2008;7:13. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC2542367] [PubMed: 18710579]
  1725. Morgan ML, Cook IA, Rapkin AJ, et al. Estrogen augmentation of antidepressants in perimenopausal depression: A pilot study. J Clin Psychiatry. 2005;66(6):774–80. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15960574]
  1726. Morgan ML, Cook IA, Rapkin AJ, et al. Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas. 2007;56(1):54–60. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16835012]
  1727. Morishita S, Aoki S. Clonazepam in the treatment of prolonged depression. J Affect Disord. 1999;53(3):275–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10404714]
  1728. Morishita S, Aoki S. Clonazepam augmentation of antidepressants: Does it distinguish unipolar from bipolar depression? J Affect Disord. 2002;71(1–3):217–20. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12167520]
  1729. Morishita S, Arita S. Prophylactic effect of clonazepam augmentation on protracted depression as a mood stabilizer. Int Med J. 2002;9(4):261–4. OVID-Embase. Exclude: Not an eligible population treatment.
  1730. Morishita S, Arita S. Lithium augmentation of antidepressants in the treatment of protracted depression. Int Med J. 2003;10(1):29–32. OVID-Embase. Exclude: Not an eligible study design.
  1731. Morishita S, Arita S. Predictors of response to clonazepam as a mood stabilizer in protracted depression. Int Med J. 2003;10(2):101–4. OVID-Embase. Exclude: Not an eligible study design.
  1732. Morishita S, Arita S. Response period of combined fluvoxamine and milnacipran treatment for depression. Int Med J. 2005;12(1):25–6. OVID-Embase. Exclude: Not an eligible study design.
  1733. Morishita S, Arita S. Clonazepam augmentation of antidepressants: Which is the suitable combined antidepressant? Int Med J. 2007;14(3):195–7. OVID-Embase. Exclude: Not an eligible study design.
  1734. Morishita S, Arita S. Possible predictors of response to clonazepam augmentation therapy in patients with protracted depression. Hum Psychopharmacol. 2007;22(1):27–31. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17191267]
  1735. Morishita S, Sawamura J, Ishigooka J. Characteristics associated with response to clonazepam augmentation therapy in patients with protracted depression. Int Med J. 2009;16(1):9–12. OVID-Embase. Exclude: Not an eligible study design.
  1736. Morishita S, Arita S. The period of onset of action of clonazepam augmentation as a mood stabilizer for protracted depression. Int Med J. 2003;10(1):3–6. OVID-PsycINFO. Exclude: Not an eligible study design.
  1737. Morris DW, Trivedi MH, Fava M, et al. Diurnal mood variation in outpatients with major depressive disorder. Depress Anxiety. 2009;26(9):851–63. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 19306304]
  1738. Morris RG, Morris LW. Cognitive and behavioural approaches with the depressed elderly. Int J Geriatr Psychiatry. 1991;6(6):407–13. OVID-Embase OVID-Embase. Exclude: Not an eligible study design.
  1739. Morrissey M. Mood enhancement and anxiety reduction using physical exercise in a clinical sample. Int J Psychiatr Nurs Res. 1997;3(2):336–44. EBSCO-CINAHL. Exclude: Mixed antidepressants:some failed on SSRI.
  1740. Moscovici L, Kotler M. A multistage chronobiologic intervention for the treatment of depression: A pilot study. J Affect Disord. 2009;116(3):201–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19232745]
  1741. Moshiri E, Basti AA, Noorbala AA, et al. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomed. 2006;13(9–10):607–11. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16979327]
  1742. Motl RW, Konopack JF, McAuley E, et al. Depressive symptoms among older adults: Long-term reduction after a physical activity intervention. J Behav Med. 2005;28(4):385–94. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16049630]
  1743. Mow KE. Treatment of psychoneurosis and depression with medical hypnoanalysis: San Antonio Conference September 22–25, 1994. Med Hypnoanalysis J. 1994;9(4):167–76. OVID-AMED. Exclude: Not an eligible study design.
  1744. Möller HJ, Kissling W, Herberger B, et al. Controlled trial on the possible advantages of a combined therapy with maprotiline and haloperidol in endogenous depression. Pharmacopsychiatr. 1986;19(5):362–4. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 3534899]
  1745. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet. 2009;(Part(3)):341–51. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC2660379] [PubMed: 18618621]
  1746. Mueller BM. St. John’s Wort for depressive disorders: Results of an outpatient study with the Hypericum preparation HYP 811. Adv Ther. 1998;15(2):109–16. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10180997]
  1747. Mufson L, Fairbanks J. Interpersonal psychotherapy for depressed adolescents: A one-year naturalistic follow-up study. J Am Acad Child Adolesc Psychiatry. 1996;35(9):1145–55. Exclude: Not an eligible study design. [PubMed: 8824058]
  1748. Mufson L, Weissman MM, Moreau D, et al. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry. 1999;56(6):573–9. Exclude: Not an eligible population treatment. [PubMed: 10359475]
  1749. Mukaino Y, Park J, White A, et al. The effectiveness of acupuncture for depression: A systematic review of randomised controlled trials. Acupuncture Med. 2005;23(2):70–6. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16025787]
  1750. Mulcahy KA. Beck’s cognitive therapy and aerobic exercise for the treatment of depression Mulcahy. 1998. OVID-PsycINFO. Exclude: Not an eligible study design.
  1751. Mulder RT, Joyce PR, Frampton CM, et al. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatr Scand. 2008;118(2):116–22. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18384467]
  1752. Muller-Oerlinghausen B, Rao ML, Stieglitz RD, et al. Fluvoxamine challenge test, phototherapy, and successive fluvoxamine treatment in patients with non-seasonal depression. Pharmacopsychiatr. 1989;22(5):209–10. OVID-Embase. Exclude: Not an eligible study design.
  1753. Muller-Siecheneder F, Muller MJ, Hillert A, et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol. 1998;18(2):111–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9555596]
  1754. Muller D, Pfeil T, von dD V. Treating depression comorbid with anxiety: Results of an open, practice-oriented study with St John’s wort WS 5572 and valerian extract in high doses. Phytomed. 2003;10 Suppl-30 OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12807339]
  1755. Muller MJ, Seifritz E, Hatzinger M, et al. Side effects of adjunct light therapy in patients with major depression. Eur Arch Psychiatry Clin Neurosci. 1997;247(5):252–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9444494]
  1756. Mulsant BH, Alexopoulos GS, Reynolds CF III, et al. Pharmacological treatment of depression in older primary care patients: The PROSPECT algorithm. Int J Geriatr Psychiatry. 2001;16(6):585–92. OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 11424167]
  1757. Murck H, Held K, Ziegenbein M, et al. Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinol. 2004;29(9):1205–11. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 15219645]
  1758. Murck H, Fava M, Alpert J, et al. Hypericum extract in patients with MDD and reversed vegetative signs: Re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005;8(2):215–21. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15458612]
  1759. Muris P, Bogie N, Hoogsteder A. Effects of an early intervention group program for anxious and depressed adolescents: A pilot study. Psychol Rep. 2001;88(2):481–2. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11351893]
  1760. Murphy BE, Dhar V, Ghadirian AM, et al. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol. 1991;11(2):121–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1829098]
  1761. Murphy BEP, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU 486. J Psychiatr Neurosci. 1993;18(5):209–13. OVID-PsycINFO. Exclude: Not an eligible study design. [PMC free article: PMC1188541] [PubMed: 8297920]
  1762. Murphy DL, Baker M, Goodwin FK, et al. L-tryptophan in affective disorders: Indoleamine changes and differential clinical effects. Psychopharmacologia. 1974;34(1):11–20. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4593517]
  1763. Murphy GE, Simons AD, Wetzel RD, et al. Cognitive therapy and pharmacotherapy: Singly and together in the treatment of depression. Arch Gen Psychiatr. 1984;41(1):33–41. OVID-Embase. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 6691783]
  1764. Murphy GE, Carney RM, Knesevich MA, et al. Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression. Psychol Rep. 1995;77(2):403–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8559866]
  1765. Murray G, Michalak EE, Axler A, et al. Relief of Chronic or Resistant Depression (Re-ChORD): A pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression. J Affect Disord. 2010;123(1–3):243–8. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 19896200]
  1766. Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: A double blind comparison in major depressive disorders. Adv Biochem Psychopharmacol. 1982;32:151–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7046362]
  1767. Mussini M, Agricola R, Coletti MG, et al. A preliminary study on the use of calcitonin in clinical psychopathology. J Int Med Res. 1984;12(1):23–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 6141115]
  1768. Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–4. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 16491133]
  1769. Mynatt S, Wicks M, Bolden L. Pilot study of INSIGHT therapy in African American women. Arch Psychiatr Nurs. 2008;22(6):364–74. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19026925]
  1770. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, et al. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. Br Med J. 1995;310(6977):441–5. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2548821] [PubMed: 7873952]
  1771. Mynors-Wallis LM, Gath DH, Day A, et al. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. Br Med J. 2000;320(7226):26–30. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC27250] [PubMed: 10617523]
  1772. Myskja A, Nord PG. “The day the music died”: A pilot study on music and depression in a nursing home. Nord J Music Ther. 2008;17(1):30–40. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1773. Nabkasorn C, Miyai N, Sootmongkol A, et al. Effects of physical exercise on depression, neuroendocrine stress hormones and physiological fitness in adolescent females with depressive symptoms. Eur J Public Health. 2006;16(2):179–84. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16126743]
  1774. Naeem F, Waheed W, Gobbi M, et al. Preliminary evaluation of culturally sensitive CBT for depression in Pakistan: Findings from Developing Culturally-sensitive CBT Project (DCCP) Behav Cognit Psychother. 2011;39(2):165–73. OVID-PsycINFO. Exclude: Not an eligible population/treatment. [PubMed: 21092353]
  1775. Nagata H, Nozaki M, Nakano H. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res. 2005;31(2):107–14. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15771635]
  1776. Nahas Z, Kunik ME, Orengo CA, et al. Depression in male geropsychiatric inpatients with and without dementia: A naturalistic study. J Affect Disord. 1997;46(3):243–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 9547120]
  1777. Nahunek K, Svestka J, Rysanek R, et al. Further clinical experience with maprotiline in endogenous depressions. Act Nerv Super. 1981;23(3):214–5. OVID-PsycINFO. Exclude: Not an eligible study design.
  1778. Nahunek K, Svestka J, Rysanek R, et al. Full therapeutic success of repeated treatment in most “drug resistant” cases of endogenous depression. Act Nerv Super. 1986;28(4):302–3. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1779. Naismith SL, Diamond K, Carter PE, et al. Enhancing memory in late-life depression: The effects of a combined psychoeducation and cognitive training program. Am J Geriatr Psychiatr. 2011;19(3):240–8. OVID-Embase. Exclude: Not an eligible population/treatment. [PubMed: 20808114]
  1780. Nakajima S, Ishida T, Akaishi R, et al. Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: A chart review. J ECT. 2009;25(3):178–81. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 19710625]
  1781. Nalini NR, Kumaraiah V, Subbakrishna DK. Cognitive behaviour therapy in the treatment of neurotic depression. Nimhans J. 1996;14(1):31–5. OVID-PsycINFO. Exclude: Not an eligible study design.
  1782. Naqvi F, Cervo F, Fields S. Evidence-based review of interventions to improve palliation of pain, dyspnea, depression. Geriatr. 2009;64(8):8–14. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20722311]
  1783. Nardini M, De Stefano R, Iannuccelli M, et al. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res. 1983;3(4):239–50. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6381336]
  1784. Naylor EV, Antonuccio DO, Johnson G, et al. A pilot study investigating behavioral prescriptions for depression. J Clin Psychol Med Settings. 2007;14(2):152–9. OVID-Embase. Exclude: Not an eligible study design.
  1785. Naylor EV. A five-minute bibliotherapy prescription as a physician-delivered treatment for depression. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  1786. Naylor EV, Antonuccio DO, Litt M, et al. Bibliotherapy as a treatment for depression in primary care. J Clin Psychol Med Settings. 2010;17(3):258–71. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20803165]
  1787. Neidig JL. Aerobic exercise training: Effects on depressive symptoms in HIV-infected adults. Ohio State University; 1998. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1788. Neidig JL, Smith BA, Brashers DE. Aerobic exercise training for depressive symptom management in adults living with HIV infection. J Assoc Nurses AIDS Care. 2003;14(2):30–40. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12698764]
  1789. Neil AL, Christensen H. Australian school-based prevention and early intervention programs for anxiety and depession: A systematic review. Med J Aust. 2007;186(6):305–8. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17371212]
  1790. Neimeyer RA, Baker KD, Haykal RF, et al. Patterns of symptomatic change in depressed patients in a private inpatient mood disorders program. Bull Menninger Clin. 1995;59(4):460–71. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8535385]
  1791. Nelson-Gray RO, Herbert JD, Herbert DL, et al. Effectiveness of matched, mismatched, and package treatments of depression. J Behav Ther Exp Psychiatr. 1989;20(4):281–94. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2636233]
  1792. Nelson EL, Barnard M, Cain S. Treating childhood depression over videoconferencing. Telemed J EHealth. 2003;9(1):49–55. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12699607]
  1793. Nelson EL. Cognitive behavioral therapy for childhood depression: A comparison of face-to-face and interactive televideo settings. 2004. OVID-PsycINFO. Exclude: Not an eligible study design.
  1794. Nelson EL, Barnard M, Cain S. Feasibility of telemedicine intervention for childhood depression. Couns Psychother Res. 2006;6(3):191–5. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1795. Nelson JC, Jatlow P, Quinlan DM, et al. Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatr. 1982;39(12):1419–22. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7149903]
  1796. Nelson JC, Mazure CM, Bowers MB Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatr. 1991;48(4):303–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2009031]
  1797. Nelson JC, Docherty JP, Henschen GM, et al. C. Algorithms for the treatment of subtypes of unipolar major depression. Psychopharmacol Bull. 1995;31(3):475–83. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 8668752]
  1798. Nelson JC, Mazure CM, Jatlow PI. Desipramine treatment of major depression in patients over 75 years of age. J Clin Psychopharmacol. 1995;15(2):99–105. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7782495]
  1799. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatr. 2004;55(3):296–300. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14744472]
  1800. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–91. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19687129]
  1801. Nelson MK. Meta-analysis: Hypnotherapy/cognitive-behavioral therapy and its efficacy on depression compared to pharmacotherapy. 2002. OVID-PsycINFO. Exclude: Not an eligible study design.
  1802. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA. 2003;100(24):14293–6. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC283585] [PubMed: 14615578]
  1803. Nemeroff CB, Gharabawi GM, Canuso CM, et al. Augmentation with risperidone in chronic resistant depression: A double-blind placebo-controlled maintenance trial. Neuropsychopharmacol. 2004;29(Supplement 1):S159. [Abstract]
  1804. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159(3):477–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11870016]
  1805. Nemets B, Osher Y, Belmaker RH. Omega-3 fatty acids and augmentation strategies in treating resistant depression. Essential Psychopharmacol. 2004;(6):59–64. Exclude: Not an eligible study design. [PubMed: 15612654]
  1806. Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: A controlled, double-blind pilot study. Am J Psychiatry. 2006;163(6):1098–100. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16741212]
  1807. Netz Y, Yaretzki A, Salganik I, et al. The effect of supervised physical activity on cognitive and affective state of geriatric and psychogeriatric in-patients. Clin Gerontol. 1994;15(1):47–56. OVID-Embase. Exclude: Not an elligible population design.
  1808. Neuberger GB, Aaronson LS, Gajewski B, et al. Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum. 2007;57(6):943–52. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 17665488]
  1809. Neumeister A, Goessler R, Lucht M, et al. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biol Psychiatr. 1996;39(1):16–21. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 8719121]
  1810. Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Effects of tryptophan depletion in drug-free depressed patients who responded to total sleep deprivation. Arch Gen Psychiatr. 1998;55(2):167–72. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9477931]
  1811. Nezu AM. Efficacy of a social problem-solving therapy approach for unipolar depression. J Consult Clin Psychol. 1986;54(2):196–202. Exclude: Not an eligible population treatment. [PubMed: 3700806]
  1812. Nezu AM, Perri MG. Social problem-solving therapy for unipolar depression: An initial dismantling investigation. J Consult Clin Psychol. 1989;57(3):408–13. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 2738213]
  1813. Ng BHP, Tsang HWH. Psychophysiological outcomes of health qigong for chronic conditions: A systematic review. Psychophysiol. 2009;46(2):257–69. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19170945]
  1814. Nguyen PH, Grajeda R, Melgar P, et al. Micronutrient supplementation may reduce symptoms of depression in Guatemalan women. Arch Latinoam Nutr. 2009;59(3):278–86. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19886513]
  1815. Nguyen SD. Simultaneous technique of exercise and psychotherapy (STEP) as an adjunct to multidisciplinary treatment in acute inpatient psychiatric hospitalized older adults with depressive symptoms. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  1816. Nickel MK, Nickel C, Lahmann C, et al. Changes in instrumental activities of daily living disability after treatment of depressive symptoms in elderly women with chronic musculoskeletal pain: A double-blind, placebo-controlled trial. Aging Clin Exp Res. 2005;17(4):293–6. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 16285195]
  1817. Nierenberg AA, Price LH, Charney DS, et al. After lithium augmentation: A retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord. 1990;18(3):167–75. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2139061]
  1818. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14(6):419–23. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7884023]
  1819. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003;23(1):92–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12544380]
  1820. Nierenberg AA, Trivedi MH, Gaynes BN, et al. Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder. Aust NZ J Psychiatr. 2009;43(10):956–67. OVID-Embase. Exclude: Not an eligible study design.
  1821. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report. Psychol Med. 2010;40(1):41–50. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19460188]
  1822. Nieuwenhuijsen K, Bultmann U, Neumeyer-Gromen A, et al. Interventions to improve occupational health in depressed people. Cochrane Database Syst Rev. 2008;(2):CD006237. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18425942]
  1823. Nilforooshan P, Ahmadi A, Abedi MR, et al. Studying the effect of cognitive-behavioral counseling based on interacting cognitive subsystems on depression of infertile couples. Mid East Fertil Soc J. 2006;11(1):43–7. OVID-Embase. Exclude: Not an eligible population treatment.
  1824. Ninan PT, Hassman HA, Glass SJ, et al. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry. 2004;65(3):414–20. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15096082]
  1825. Nisbet Wallis DA. Depression, anxiety and self-esteem: A clinical field study. Behav Change. 2002;19(2):112–20. OVID-Embase. Exclude: Not an eligible study design.
  1826. Nitkin-Kaner Y. Relationships between expressive writing about traumatic events and reduction in depressive symptomatology. 2009. OVID-PsycINFO. Exclude: Not an eligible study design.
  1827. Nolen WA, van de Putte JJ, Dijken WA, et al. L-5HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. Br J Psychiatr. 1985;147:16–22. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 3933601]
  1828. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: A double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand. 1988;78(6):668–75. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3146890]
  1829. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand. 1988;78(6):676–83. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 3146891]
  1830. Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressions. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(1–2):155–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 2664883]
  1831. Nolen WA, Haffmans PMJ, Bouvy PF, et al. Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant. J Affect Disord. 1993;28(3):179–88. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 8104964]
  1832. Nolen WA, Haffmans PM, Bouvy PF, et al. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord. 1993;28(3):189–97. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8408980]
  1833. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, et al. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: A double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281–4. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15707766]
  1834. Noorbala AA, Ramazanzadeh F, Malekafzali H, et al. Effects of a psychological intervention on depression in infertile couples. Int J Gynaecol Obstet. 2008;101(3):248–52. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18321515]
  1835. Nordstrom G, Despiegel N, Marteau F, et al. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J Med Econ. 2010;13(3):516–26. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20698748]
  1836. Norman J, Lowry CE. Evaluating inpatient treatment for women with clinical depression. Res Soc Work Pract. 1995;5(1):10–9. OVID-PsycINFO. Exclude: Not an eligible study design.
  1837. Norman SB, Tate SR, Wilkins KC, et al. Posttraumatic stress disorder’s role in integrated substance dependence and depression treatment outcomes. J Subst Abuse Treat. 2010;38(4):346–55. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 20363091]
  1838. Normann C, Hummel B, Scharer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: A placebo-controlled, double-blind study. J Clin Psychiatry. 2002;63(4):337–44. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12000208]
  1839. Normann C. Olanzapine augmentation therapy in treatment-resistant depression: A double-blind placebo-controlled trial. 2006. Wiley-CCTR. Exclude: Not an eligible study design.
  1840. Nowak G, Siwek M, Dudek D, et al. Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo-controlled study. Pol J Pharmacol. 2003;55(6):1143–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14730113]
  1841. Nozawa K, Sekine A, Hozumi S, et al. Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: Consecutive case series. Psychiatry Clin Neurosci. 2011;65(2):199–202. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 21414094]
  1842. Nunes DF, Rodriguez AL, da Silva HF, et al. Relaxation and guided imagery program in patients with breast cancer undergoing radiotherapy is not associated with neuroimmunomodulatory effects. J Psychosom Res. 2007;63(6):647–55. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18061756]
  1843. Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999;60(9):574–9. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 10520974]
  1844. Nutzinger DO, Cayiroglu S, Sachs G, et al. Emotional problems during weight reduction: Advantages of a combined behavior therapy and antidepressive drug therapy for obesity. J Behav Ther Exp Psychiatr. 1985;16(3):217–21. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 4066968]
  1845. Nystrom C, Hallstrom T. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients: A cross-over study. Acta Psychiatr Scand. 1987;75(4):377–82. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 3035878]
  1846. O’Brien S, McKeon P, O’Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br J Psychiatr. 1993;162:363–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8453432]
  1847. O’Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 2007;41(3–4):326–31. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 16870211]
  1848. O’Dwyer AM, Lightman SL, Marks MN, et al. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 1995;33(2):123–8. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 7759660]
  1849. O’Kearney R, Gibson M, Christensen H, et al. Effects of a cognitive-behavioural internet program on depression, vulnerability to depression and stigma in adolescent males: A school-based controlled trial. Cognit Behav Ther. 2006;35(1):43–54. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16500776]
  1850. O’Kearney R, Kang K, Christensen H, et al. A controlled trial of a school-based Internet program for reducing depressive symptoms in adolescent girls. Depress Anxiety. 2009;26(1):65–72. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18828141]
  1851. O’Kearney Richard, Kang Kanwal, Gibson Malcolm, et al. A CBT internet program for depression in adolescents (MoodGYM): Effects on depressive symptoms, attributional style, self-esteem and beliefs about depression. 2007. pp. 197–204. 2007. OVID-PsycINFO. Exclude: Not an eligible study design.
  1852. O’Laoire S. An experimental study of the effects of distant, intercessory prayer on self-esteem, anxiety, and depression. Altern Ther Health Med. 1997;3(6):38. EBSCO-CINAHL. Exclude: Not an eligible study design. [PubMed: 9375429]
  1853. O’Leary D, Costello F, Gormley N, et al. Remission onset and relapse in depression: An 18-month prospective study of course for 100 first admission patients. J Affect Disord. 2000;57(1–3):159–71. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 10708827]
  1854. O’Leary KD, Beach SR. Marital therapy: A viable treatment for depression and marital discord. Am J Psychiatry. 1990;147(2):183–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2301656]
  1855. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatr. 2002;51(3):253–60. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 11839368]
  1856. Odeberg H, Rodriguez-Silva B, Salander P, et al. Individualized continuation electroconvulsive therapy and medication as a bridge to relapse prevention after an index course of electroconvulsive therapy in severe mood disorders: A naturalistic 3-year cohort study. J ECT. 2008;24(3):183–90. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 18695624]
  1857. Oei TP, Yeoh AE. Pre-existing antidepressant medication and the outcome of group cognitive-behavioural therapy. Aust NZ J Psychiatr. 1999;33(1):70–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10197887]
  1858. Oei TP, Bullbeck K, Campbell JM. Cognitive change process during group cognitive behaviour therapy for depression. J Affect Disord. 2006;92(2–3):231–41. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16542734]
  1859. Oei TPS, Dingle G. The effectiveness of group cognitive behaviour therapy for unipolar depressive disorders. J Affect Disord. 2008;107(1–3):5–21. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17716745]
  1860. Oeland A-M, Laessoe U, Olesen AV, et al. Impact of exercise on patients with depression and anxiety. Nord J Psychiatr. 2010;64(3):210–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 20100135]
  1861. Oh H, Seo W. Decreasing pain and depression in a health promotion program for people with rheumatoid arthritis. J Nurs Scholarsh. 2003;35(2):127–32. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 12854292]
  1862. Okamoto A, Kuriyama H, Watanabe S, et al. The effect of aromatherapy massage on mild depression: A pilot study. Psychiatry Clin Neurosci. 2005;59(3):363. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15896234]
  1863. Okumura K, Furukawa TA. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression. Clin Drug Investig. 2006;26(3):135–42. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17163244]
  1864. Oliwenstein L. Lifting moods by losing sleep: An adjunct therapy for treating depression. Alternative Compl Ther. 2006;12(2):66–70. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1865. Olver JS, Ignatiadis S, Maruff P, et al. Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum Psychopharmacol. 2008;23(8):653–60. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18816504]
  1866. Onder E, Tural U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord. 2003;76(1–3):223–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12943952]
  1867. Ong MK, Rubenstein LV. Wishing upon a STAR*D: The promise of ideal depression care by primary care providers. Psychiatr Serv. 2009;60(11):1460–2. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19880461]
  1868. Ontiveros A, Fontaine R, Elie R. Refractory depression: The addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand. 1991;83(3):188–92. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 1903237]
  1869. Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18(1):20–4. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15681624]
  1870. Organista KC, Munoz RF, Gonzalez G. Cognitive-behavioral therapy for depression in low-income and minority medical outpatients: Description of a program and exploratory analyses. Cognit Ther Res. 1994;18(3):241–59. OVID-PsycINFO. Exclude: Not an eligible study design.
  1871. Ormrod JA, Kennedy L, Scott J, et al. Computerised cognitive behavioural therapy in an adult mental health service: A pilot study of outcomes and alliance. Cognit Behav Ther. 2010;39(3):188–92. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20485996]
  1872. Osborn RL, Demoncada AC, Feuerstein M. Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: Meta-analyses. Int J Psychiatry Med. 2006;36(1):13–34. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16927576]
  1873. Osgood-Hynes DJ, Greist JH, Marks IM, et al. Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: An open U.S.-U.K. study. J Clin Psychiatr. 1998;59(7):358–65. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 9714264]
  1874. Oslin DW, Sayers S, Ross J, et al. Disease management for depression and at-risk drinking via telephone in an older population of veterans. Psychosom Med. 2003;65(6):931–7. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 14645769]
  1875. Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatr. 2005;13(6):491–500. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3172720] [PubMed: 15956269]
  1876. Ostacher MJ, Huffman J, Perlis R, et al. Evidence-based psychopharmacology. New York, NY: Cambridge University Press; 2005. Evidence-based pharmacotherapy of major depressive disorder. OVID-PsycINFO. Exclude: Not an eligible study design.
  1877. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4):256–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10221288]
  1878. Otero FJ, Hernandez-Herrero C, Martinez-Arevalo M-J, et al. Fluoxetine/bentazepam combination in the treatment of dysthymic disorders. Curr Ther Res Clin Exp. 1994;55(5):519–31. OVID-Embase. Exclude: Not an eligible population treatment.
  1879. Otte C, Hinkelmann K, Moritz S, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res. 2010;44(6):339–46. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19909979]
  1880. Otto MW, Powers MB, Stathopoulou G, et al. Adapting cognitive therapy for depression: Managing complexity and comorbidity. New York, NY, US: Guilford Press; 2008. Panic disorder and social phobia. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched.
  1881. Overall JE, Brown D, Williams JD, et al. Drug treatment of anxiety and depression in detoxified alcoholic patients. Arch Gen Psychiatr. 1973;29(2):218–25. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4741512]
  1882. Overholser JC, Schubert DS. Cognitive-behavioral treatment of depression, Part VI: Integrating the use of antidepressant medications. J Contemp Psychother. 1996;26(3):235–50. OVID-PsycINFO. Exclude: Not an eligible guideline.
  1883. Owenby RK, Brown LT, Brown JN. Use of risperidone as augmentation treatment for major depressive disorder. Ann Pharmacother. 2011;45(1):95–100. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 21189367]
  1884. Oxman TE, Barrett JE, Sengupta A, et al. Status of minor depression or dysthymia in primary care following a randomized controlled treatment. Gen Hosp Psychiatry. 2001;23(6):301–10. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11738460]
  1885. Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2008;23(4):321–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18278806]
  1886. Pace TM, Dixon DN. Changes in depressive self-schemata and depressive symptoms following cognitive therapy. J Couns Psychol. 1993;40(3):288–94. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1887. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17671280]
  1888. Pae C-U, Serretti A, Patkar AA, et al. Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence. CNS Drugs. 2008;22(5):367–88. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18399707]
  1889. Pae CU, Patkar AA, Jun TY, et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety. 2007;24(7):522–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17111388]
  1890. Page AC, Hooke GR. Outcomes for depressed and anxious inpatients discharged before or after group cognitive behavior therapy: A naturalistic comparison. J Nerv Ment Dis. 2003;191(10):653–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14555867]
  1891. Page K. Late-life depression. J Compl Med. 2006;5(2):23–9. OVID-AMED. Exclude: Not an eligible study design.
  1892. Pagoto S, Bodenlos JS, Schneider KL, et al. Initial investigation of behavioral activation therapy for co-morbid major depressive disorder and obesity. Psychother. 2008;45(3):410–5. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 22122500]
  1893. Paleacu D, Shutzman A, Giladi N, et al. Effects of pharmacological therapy on gait and cognitive function in depressed patients. Clin Neuropharmacol. 2007;30(2):63–71. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 17414938]
  1894. Palinkas LA, Reedy KR, Shepanek M, et al. A randomized placebo-controlled clinical trial of the effectiveness of thyroxine and triiodothyronine and short-term exposure to bright light in prevention of decrements in cognitive performance and mood during prolonged Antarctic residence. Clin Endocrinol. 2010;72(4):543–50. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19650782]
  1895. Palladino L. Vine of soul: A phenomenological study of ayahuasca and its effect on depression Lisa: Pacifica Graduate Inst. US Palladino. 2010. OVID-PsycINFO. Exclude: Not an eligible study design.
  1896. Palleschi L, De Gennaro E, Sottosanti G, et al. The role of exercise training in aged subjects with anxiety-depression syndrome. Arch Gerontol Geriatr. 1998;27(Suppl 6):381–4. OVID-Embase. Exclude: Not an eligible study design.
  1897. Palmer J, Vacc N, Epstein J. Adult inpatient alcoholics: Physical exercise as a treatment intervention. J Stud Alcohol. 1988;49(5):418–21. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 3216644]
  1898. Palmer JA, Palmer LK, Michiels K, et al. Effects of type of exercise on depression in recovering substance abusers. Percept Motor Skills. 1995;80(2):523–30. OVID-AMED. Exclude: Not an eligible population treatment. [PubMed: 7675585]
  1899. Pancheri P, Scapicchio P, Chiaie RD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol. 2002;5(4):287–94. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12466028]
  1900. Papadimitriou GN, Christodoulou GN, Katsouyanni K, et al. Therapy and prevention of affective illness by total sleep deprivation. J Affect Disord. 1993;27(2):107–16. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 8440806]
  1901. Papakostas GI, Petersen T, Worthington JJ, et al. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol. 2003;18(5):293–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12920390]
  1902. Papakostas GI, Petersen T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: Prevalence and impact on treatment outcome. J Nerv Ment Dis. 2003;191(7):444–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12891091]
  1903. Papakostas GI, Petersen TJ, Farabaugh AH, et al. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J Clin Psychiatry. 2003;64(11):1357–61. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 14658951]
  1904. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65(2):217–21. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15003076]
  1905. Papakostas GI, Petersen TJ, Green C, et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatr. 2005;17(3):161–5. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 16433058]
  1906. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005;66(10):1326–30. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16259548]
  1907. Papakostas GI, Petersen TJ, Burns AM, et al. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006;40(4):370–3. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15978621]
  1908. Papakostas GI, Worthington JJ III, Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006;23(3):178–81. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16528701]
  1909. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis. J Clin Psychiatr. 2007;68(6):826–31. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17592905]
  1910. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: A meta-analysis comparing within- versus across-class switches. Biol Psychiatr. 2008;63(7):699–704. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17919460]
  1911. Papakostas GI, Cooper-Kazaz R, Appelhof BC, et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: A quantitative synthesis of double-blind studies. Int Clin Psychopharmacol. 2009;24(1):19–25. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19092448]
  1912. Papakostas GI, Clain A, Ameral VE, et al. Fluoxetine-clonazepam cotherapy for anxious depression: An exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol. 2010;25(1):17–21. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19898245]
  1913. Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942–8. OVID-Medline. Exclude: Mixed antidepressants; some failed on SSRI. [PubMed: 20595412]
  1914. Papakostas GI, Petersen T, Sonawalla SB, et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiol. 2003;47(3):146–51. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 12759558]
  1915. Pappas GP, Golin S, Meyer DL. Reducing symptoms of depression with exercise. Psychosom. 1990;31(1):112–3. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 2300648]
  1916. Parker AG, Hetrick SE, Jorm AF, et al. The effectiveness of simple psychological and exercise interventions for high prevalence mental health problems in young people: A factorial randomised controlled trial. Trials. 2011;12:76. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC3061928] [PubMed: 21396122]
  1917. Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am J Psychiatry. 2005;162(4):796–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15800157]
  1918. Parker G, Crawford J. Atypical depression: Retrospective self-reporting of treatment effectiveness. Acta Psychiatr Scand. 2009;120(3):213–21. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19291077]
  1919. Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand. 2010;121(4):308–14. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 19594481]
  1920. Parker GB, Crawford J, Hadzi-Pavlovic D. Quantified superiority of cognitive behaviour therapy to antidepressant drugs: A challenge to an earlier meta-analysis. Acta Psychiatr Scand. 2008;118(2):91–7. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18452571]
  1921. Parker JC, Smarr KL, Slaughter JR, et al. Management of depression in rheumatoid arthritis: A combined pharmacologic and cognitive-behavioral approach. Arthritis Rheum. 2003;49(6):766–77. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 14673962]
  1922. Parker KL, Mittmann N, Shear NH, et al. Lithium augmentation in geriatric depressed outpatients: A clinical report. Int J Geriatr Psychiatry. 1994;9(12):995–1002. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1923. Parrish BP, Cohen LH, Gunthert KC, et al. Effects of cognitive therapy for depression on daily stress-related variables. Behav Res Ther. 2009;47(5):444–8. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC2674529] [PubMed: 19269627]
  1924. Pasquini M, Picardi A, Speca A, et al. Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: An open study. Clin Pract Epidemiol Ment Health. 2007;3:3. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC1797174] [PubMed: 17288584]
  1925. Passeri M, Cucinotta D, Abate G, et al. Oral 5’-methyltetrahydrofolic acid in senile organic mental disorders with depression: Results of a double-blind multicenter study. Aging Clin Exp Res. 1993;5(1):63–71. OVID-Medline. Exclude: Not an elligible population design. [PubMed: 8257478]
  1926. Passmore T, Lane S. Exercise as treatment for depression: A therapeutic recreation intervention. Am J Rec Ther. 2006;5(3):31–41. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  1927. Patel V, Weiss HA, Chowdhary N, et al. Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): A cluster randomised controlled trial. Lancet. 2010;376(9758):2086–95. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 21159375]
  1928. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17110825]
  1929. Patkar AA, Peindl K, Mago R, et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Comp J Clin Psychiatr. 2006;8(2):82–7. OVID-Embase. Exclude: Not an eligible study design. [PMC free article: PMC1470647] [PubMed: 16862232]
  1930. Pavao TS, Vianna P, Pillat MM, et al. Acupuncture is effective to attenuate stress and stimulate lymphocyte proliferation in the elderly. Neurosci Lett. 2010;484(1):47–50. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 20709154]
  1931. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: A controlled trial. Arch Gen Psychiatr. 1999;56(9):829–35. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 12884889]
  1932. Paykel ES, Scott J, Cornwall PL, et al. Duration of relapse prevention after cognitive therapy in residual depression: Follow-up of controlled trial. Psychol Med. 2005;35(1):59–68. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15842029]
  1933. Payne DL. Antidepressant therapies in the elderly. Clin Gerontol. 1987;7(2):31–41. OVID-Embase. Exclude: Not an eligible study design.
  1934. Payne H, Stott D. Change in the moving bodymind: Quantitative results from a pilot study on the use of the BodyMind approach (BMA) to psychotherapeutic group work with patients with medically unexplained symptoms (MUSs) Couns Psychother Res. 2010;10(4):295–306. EBSCO-CINAHL. Exclude: Not an eligible study design.
  1935. Payne JK, Held J, Thorpe J, et al. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol Nurs Forum. 2008;(4):635–42. Online. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 18591167]
  1936. Paz-Diaz H, Montes dO, Lopez JM, et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehab. 2007;86(1):30–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17304686]
  1937. Pecheur DR, Edwards KJ. A comparison of secular and religious versions of cognitive therapy with depressed Christian college students. J Psychol Theol. 1984;12(1):45–54. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1938. Peden AR, Rayens MK, Hall LA. A community-based depression prevention intervention with low-income single mothers. J Am Psychiatr Nurs Assoc. 2005;11(1):18–25. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  1939. Peden AR, Rayens MK, Hall LA, et al. Testing an intervention to reduce negative thinking, depressive symptoms, and chronic stressors in low-income single mothers. J Nurs Scholarsh. 2005;37(3):268–74. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16235869]
  1940. Peet M. Essential fatty acids: Theoretical aspects and treatment implications for schizophrenia and depression. Adv Psychiatr Treatment. 2002;8(3):223–9. Exclude: Not an eligible study design.
  1941. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatr. 2002;59(10):913–20. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 12365878]
  1942. Pelham TW, Campagna PD, Ritvo PG, et al. The effects of exercise therapy on clients in a psychiatric rehabilitation program. Psychosoc Rehabil J. 1993;16(4):75–84. OVID-PsycINFO. Exclude: Not an eligible study design.
  1943. Pelton GH, Harper OL, Tabert MH, et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: A pilot study. Int J Geriatr Psychiatry. 2008;23(7):670–6. OVID-Medline. Exclude: Not an elligible population design. [PMC free article: PMC3104294] [PubMed: 18088076]
  1944. Penalba V, McGuire H, Leite JR. Psychosocial interventions for prevention of psychological disorders in law enforcement officers. Cochrane Database Syst Rev. 2008;(3):CD005601. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18646132]
  1945. Pendola DP. Effects of scientific weight training and muscle building nutrition on self-reports of mild to moderate depression. 1996. OVID-PsycINFO. Exclude: Not an eligible study design.
  1946. Peng XD, Huang CQ, Chen LJ, et al. Cognitive behavioural therapy and reminiscence techniques for the treatment of depression in the elderly: A systematic review. J Int Med Res. 2009;37(4):975–82. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19761679]
  1947. Peniston EG, Hughes RB, Kulkosky PJ. EMG biofeedback-assisted relaxation training in the treatment of reactive depression in chronic pain patients. Psychol Record. 1986;36(4):471–81. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1948. Penninx BW, Rejeski WJ, Pandya J, et al. Exercise and depressive symptoms: A comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. J Gerontol B Psychol Sci Soc Sci. 2002;57(2):124–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11867660]
  1949. Perahia DG, Quail D, Gandhi P, et al. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. J Affect Disord. 2008;108(1–2):33–41. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17905442]
  1950. Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349(9065):1594–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9174562]
  1951. Perez V, Puiigdemont D, Gilaberte I, et al. Augmentation of fluoxetine’s antidepressant action by pindolol: Analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol. 2001;21(1):36–45. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11199945]
  1952. Perez V, Soler J, Puidgemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatr. 1999;56(4):375–9. OVID-PsycINFO. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 10197835]
  1953. Perini S, Titov N, Andrews G. Clinician-assisted Internet-based treatment is effective for depression: Randomized controlled trial. Aust NZ J Psychiatr. 2009;43(6):571–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19440890]
  1954. Perino C, Rago R, Cicolini A, et al. Mood and behavioural disorders following traumatic brain injury: Clinical evaluation and pharmacological management. Brain Inj. 2001;15(2):139–48. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11260764]
  1955. Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol. 2002;22(5):474–80. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12352270]
  1956. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatr. 2007;64(6):689–97. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 17548750]
  1957. Perlis RH, Laje G, Smoller JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacol. 2009;34(7):1819–28. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19295509]
  1958. Perraton LG, Kumar S, Machotka Z. Exercise parameters in the treatment of clinical depression: A systematic review of randomized controlled trials. J Eval Clin Pract. 2010;16(3):597–604. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20039997]
  1959. Persons JB, Bostrom A, Bertagnolli A. Results of randomized controlled trials of cognitive therapy for depression generalize to private practice. Cognit Ther Res. 1999;23(5):535–48. OVID-Embase. Exclude: Not an eligible population treatment.
  1960. Persons JB, Roberts NA, Zalecki CA, et al. Naturalistic outcome of case formulation-driven cognitive-behavior therapy for anxious depressed outpatients. Behav Res Ther. 2006;44(7):1041–51. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 16209865]
  1961. Persons JB, Burns DD, Perloff JM. Predictors of dropout and outcome in cognitive therapy for depression in a private practice setting. Cognit Ther Res. 1988;12(6):557–75. OVID-PsycINFO. Exclude: Not an eligible study design.
  1962. Peselow ED, Sanfilipo MP, DiFiglia C, et al. Melancholic/endogenous depression and response to somatic treatment and placebo. Am J Psychiatry. 1992;149(10):1324–34. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 1388334]
  1963. Peter K, Kuhne GE, Kowalik A. Bright light: Therapy in endogenous depression. Psychiatria Danubina. 1992;4(3–4):289–93. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1964. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE. 2008;3(4):e1872. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2268970] [PubMed: 18382661]
  1965. Petersen CL, Zettle RD. Treating inpatients with comorbid depression and alcohol use disorders: A comparison of acceptance and commitment therapy versus treatment as usual. Psychol Record. 2009;59(4):521–36. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  1966. Petersen TJ, Pava JA, Buchin J, et al. The role of cognitive-behavioral therapy and fluoxetine in prevention of recurrence of major depressive disorder. Cognit Ther Res. 2010;34(1):13–23. OVID-Embase. Exclude: Not an eligible population treatment.
  1967. Peterson AL, Halstead TS. Group cognitive behavior therapy for depression in a community setting: A clinical replication series. Behav Ther. 1998;29(1):3–18. OVID-Embase. Exclude: Not an eligible study design.
  1968. Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167(6):668–75. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC3121313] [PubMed: 20231324]
  1969. Pfeiffer E, Baxter D, Candelora E, et al. Finding and treating depression in Alzheimer’s patients: A study of the effects on patients and caregivers. Psychopharmacol Bull. 1997;33(4):721–9. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 9493485]
  1970. Pfeiffer PN, Heisler M, Piette JD, et al. Efficacy of peer support interventions for depression: A meta-analysis. Gen Hosp Psychiatry. 2011;33(1):29–36. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PMC free article: PMC3052992] [PubMed: 21353125]
  1971. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatr. 2009;65(2):181–4. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2727595] [PubMed: 18996507]
  1972. Philip NS, Carpenter LL, Tyrka AR, et al. Augmentation of antidepressants with atypical antipsychotics: A review of the current literature. J Psychiatr Pract. 2008;14(1):34–44. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18212601]
  1973. Philip NS, Carpenter LL, Tyrka AR, et al. Varenicline augmentation in depressed smokers: An 8-week, open-label study. J Clin Psychiatry. 2009;70(7):1026–31. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19323966]
  1974. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks. Br Med J. 1999;319(7224):1534–8. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC28296] [PubMed: 10591711]
  1975. Philips B, Wennberg P, Werbart A, et al. Young adults in psychoanalytic psychotherapy: Patient characteristics and therapy outcome. Psychol Psychother. 2006;79(Pt 1):89–106. Exclude: Not an eligible population treatment. [PubMed: 16611424]
  1976. Philp F, Lucock MP, Wilson AR. Primary care-based guided self-help for depression provided by a nurse practitioner: A pilot evaluation. Prim Care Ment Health. 2006;4(3):159–64. OVID-Embase. Exclude: Not an eligible study design.
  1977. Pierre OJ, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10(5):661–73. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 17477888]
  1978. Pierson K, Addington D, Addington J, et al. Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. Can J Psychiatr. 2006;51(11):715–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17121171]
  1979. Pigott HE, Leventhal AM, Alter GS, et al. Efficacy and effectiveness of antidepressants: Current status of research. Psychother Psychosom. 2010;79(5):267–79. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20616621]
  1980. Pilkington K, Kirkwood G, Rampes H, et al. Homeopathy for depression: A systematic review of the research evidence. Homeopath. 2005;94(3):153–63. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16060201]
  1981. Pilkington K, Kirkwood G, Rampes H, et al. Yoga for depression: The research evidence. J Affect Disord. 2005;89(1–3):13–24. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16185770]
  1982. Pilkington K, Boshnakova A, Richardson J. St John’s wort for depression: Time for a different perspective? Complement Ther Med. 2006;14(4):268–81. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17105697]
  1983. Pilowsky DJ, Wickramaratne P, Talati A, et al. Children of depressed mothers 1 year after the initiation of maternal treatment: Findings from the STAR*D-child study. Am J Psychiatry. 2008;165(9):1136–47. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 18558646]
  1984. Pilu A, Sorba M, Hardoy MC, et al. Efficacy of physical activity in the adjunctive treatment of major depressive disorders: Preliminary results. Clin Pract Epidemiol Ment Health. 2007;3 2007. Article Number: 8. Date of Publication: 09 Jul 2007. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PMC free article: PMC1976311] [PubMed: 17620123]
  1985. Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: A meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006;163(9):1493–501. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16946172]
  1986. Pinquart M, Duberstein PR, Lyness JM. Effects of psychotherapy and other behavioral interventions on clinically depressed older adults: A meta-analysis. Aging Ment Health. 2007;11(6):645–57. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18074252]
  1987. Piper WE, Debbane EG, Garant J. An outcome study of group therapy. Arch Gen Psychiatr. 1977;34(9):1027–32. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 901134]
  1988. Piper WE, Azim HF, McCallum M, et al. Patient suitability and outcome in short-term individual psychotherapy. J Consult Clin Psychol. 1990;58(4):475–81. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2212185]
  1989. Pischke CR, Frenda S, Ornish D, et al. Lifestyle changes are related to reductions in depression in persons with elevated coronary risk factors. Psychol Health. 2010;25(9):1077–100. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20204946]
  1990. Pitchot W, Scantamburlo G, Ansseau M. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine. Psychiatria Danubina. 2010;22(Suppl 1):S106–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 21057413]
  1991. Pittaway S, Cupitt C, Palmer D, et al. Comparative, clinical feasibility study of three tools for delivery of cognitive behavioural therapy for mild to moderate depression and anxiety provided on a self-help basis. Ment Health Fam Med. 2010;6(3):145–54. OVID-Embase. Exclude: Not an eligible population treatment. [PMC free article: PMC2838647] [PubMed: 22477905]
  1992. Pitts J. Combination drug therapy in depression. J Clin Psychiatr. 1985;46(6):205. OVID-Embase. OVID-Embase. Exclude: Not an eligible study design.
  1993. Platania-Solazzo A, Field TM, Blank J, et al. Relaxation therapy reduces anxiety in child and adolescent psychiatric patients. Acta Paedopsychiatr. 1992;55(2):115–20. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1585802]
  1994. Plotkin BJ, Rodos JJ, Kappler R, et al. Adjunctive osteopathic manipulative treatment in women with depression: A pilot study. J Am Osteopath Assoc. 2001;101(9):517–23. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 11575038]
  1995. Pohl A, Nordin C. Clinical and biochemical observations during treatment of depression with electroacupuncture: A pilot study. Hum Psychopharmacol. 2002;17(7):345–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12415553]
  1996. Poirier M-F, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: Double- blind, randomised comparison. Br J Psychiatr. 1999;175:12–6. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 10621762]
  1997. Pons G, Rey E, Matheson I. Excretion of psychoactive drugs into breast milk: Pharmacokinetic principles and recommendations. Clin Pharmacokinet. 1994;27(4):270–89. OVID-Embase. Exclude: Not an eligible guideline. [PubMed: 7834964]
  1998. Pope HG, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(1):105–11. Wiley-CCTR. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 12505808]
  1999. Pope J, Amiaz R, Brennan BP, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol. 2010;30(2):126–34. OVID-Embase. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 20520285]
  2000. Popkin MK, Callies AL, MacKenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatr. 1985;42(12):1160–3. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 4074108]
  2001. Portella MJ, Diego-Adelino J, Puigdemont D, et al. Pindolol augmentation enhances response outcomes in first depressive episodes. Eur Neuropsychopharmacol. 2009;19(7):516–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 19419845]
  2002. Possel P, Horn AB, Groen G, et al. School-based prevention of depressive symptoms in adolescents: A 6-month follow-up. J Am Acad Child Adolesc Psychiatry. 2004;43(8):1003–10. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15266195]
  2003. Posternak M, Novak S, Stern R, et al. A pilot effectiveness study: Placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. Int J Neuropsychopharmacol. 2008;11(1):15–25. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17352847]
  2004. Posternak MA, Zimmerman M. Switching versus augmentation: A prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry. 2001;62(2):135–42. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11247104]
  2005. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005;66(2):148–58. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 15704999]
  2006. Potkin SG, Bell K, Plon L, et al. Rapid antidepressant response with SAMe: A double-blind study. Ala J Med Sci. 1988;25(3):313–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3052140]
  2007. Pouwer F, Nijpels G, Beekman AT, et al. Fat food for a bad mood. Could we treat and prevent depression in Type 2 diabetes by means of omega-3 polyunsaturated fatty acids? A review of the evidence. Diabet Med. 2005;22(11):1465–75. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16241908]
  2008. Powers DV, Thompson LW, Gallagher-Thompson D. The benefits of using psychotherapy skills following treatment for depression: An examination of “Afterwork” and a test of the skills hypothesis in older adults. Cognit Behav Pract. 2008;15(2):194–202. OVID-Embase. Exclude: Not an eligible study design.
  2009. Pöldinger W, Reinhardt B. Neurotropic drugs as co-medication to psychotropics: Combined administration of a neurotropic drug and a tetracyclic antidepressant. Int Pharmacopsychiatry. 1980;15(3):137–42. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 7016800]
  2010. Prasko J, Horacek J, Klaschka J, et al. Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression. Neuroendocrinol Lett. 2002;23(2):109–13. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12011795]
  2011. Price CS, Taylor FB. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety. 2005;(29):149–53. Exclude: Not an eligible population treatment. [PubMed: 16035049]
  2012. Price LH, Charney DS, Heninger GR. Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci. 1985;37(9):809–18. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 4033356]
  2013. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry. 1985;142(5):619–23. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 3920923]
  2014. Price LH, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry. 1986;143(11):1387–92. Wiley-CCTR. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 3096155]
  2015. Price LH, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: Clinical and neurobiological effects. Psychopharmacol. 1987;92(4):431–7. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 2442788]
  2016. Price LH, Charney DS, Delgado PL, et al. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol. 1990;10(5):312–7. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 2258448]
  2017. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatr. 2009;66(5):522–6. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2935847] [PubMed: 19545857]
  2018. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatr. 1984;41(11):1096–104. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6437366]
  2019. Procter A. Enhancement of recovery from psychiatric illness by methylfolate. Br J Psychiatr. 1991;159:271–2. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 1773245]
  2020. Propst LR, Ostrom R, Watkins P, et al. Comparative efficacy of religious and nonreligious cognitive-behavioral therapy for the treatment of clinical depression in religious individuals. J Consult Clin Psychol. 1992;60(1):94–103. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1556292]
  2021. Proudfoot J, Goldberg D, Mann A, et al. Computerized, interactive, multimedia cognitive-behavioural program for anxiety and depression in general practice. Psychol Med. 2003;33(2):217–27. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12622301]
  2022. Proudfoot J, Ryden C, Everitt B, et al. Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: Randomised controlled trial. Br J Psychiatr. 2004;185:46–54. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15231555]
  2023. Prusoff BA, Williams DH, Weissman MM, et al. A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics. Psychopharmacol Bull. 1979;15(2):80–1. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 373008]
  2024. Prusoff BA, Williams DH, Weissman MM, et al. Treatment of secondary depression in schizophrenia: A double-blind, placebo-controlled trial of amitriptyline added to perphenazine. Arch Gen Psychiatr. 1979;36(5):569–75. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 373665]
  2025. Purves DG, Bennett M, Wellman N. An open trial in the NHS of Blues Begone: A new home based computerized CBT program. Behav Cognit Psychother. 2009;37(5):541–51. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19703330]
  2026. Pyne JM, Smith J, Fortney J, et al. Cost-effectiveness of a primary care intervention for depressed females. J Affect Disord. 2003;74(1):23–32. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 12646296]
  2027. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148(2):141–6. OVID-Medline. Exclude: Not an eligible guideline. [PubMed: 18195338]
  2028. Qu F, Cai X, Gu Y, et al. Chinese medicinal herbs in relieving perimenopausal depression: A randomized, controlled trial. J Altern Complement Med. 2009;15(1):93–100. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 19769482]
  2029. Qu W, Qin YY. Improvement of sleep and anxiety in patients of major depression with fluoxetine combined with small dose of olanzapine. Chin J Clin Rehab. 2005;9(8):254–6. OVID-Embase. Exclude: Not an eligible population treatment.
  2030. Qu W, Meng P. Relationship between blood glucose levels in patients with type 2 diabetes mellitus, depression and anxiety and the anti-depression/anxiety intervention. Chin J Clin Rehab. 2005;9(24):213–5. OVID-Embase. Exclude: Not an eligible population treatment.
  2031. Quadbeck H, Lehmann E, Tegeler J. Comparison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine. Neuropsychobiol. 1984;11(2):111–5. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6384815]
  2032. Quah-Smith JI, Tang WM, Russell J. Laser acupuncture for mild to moderate depression in a primary care setting: A randomised controlled trial. Acupuncture Med. 2005;23(3):103–11. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16259308]
  2033. Quayle D, Dziurawiec S, Roberts C. The effects of an optimism and lifeskills program on depressive symptoms in preadolescence. Behav Change. 2001;(18):194–203. Exclude: Not an eligible population treatment.
  2034. Quitkin FM, McGrath PJ, Stewart JW, et al. Remission rates with 3 consecutive antidepressant trials: Effectiveness for depressed outpatients. J Clin Psychiatry. 2005;66(6):670–6. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15960558]
  2035. Rabin AS, Kaslow NJ, Rehm LP. Changes in symptoms of depression during the course of therapy. Cognit Ther Res. 1984;8(5):479–87. OVID-PsycINFO. Exclude: Not an eligible population treatment.
  2036. Rabindranath KS, Daly C, Butler J, et al. Psychosocial interventions for depression in dialysis patients. Cochrane Database Syst Rev. 2005;(3):CD004542. Wiley-CDSR. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 16034936]
  2037. Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry. 1994;55(3):92–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 7915270]
  2038. Ragan JD. Excessive reassurance-seeking, interpersonal rejection, rejection sensitivity and depressive symptoms: An intervention focusing on mediating mechanisms. 2006. OVID-PsycINFO. Exclude: Not an eligible study design.
  2039. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):118–27. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19028540]
  2040. Raisi F, Habibi N, Nasehi AA, et al. Combination of citalopram and nortriptyline in the treatment of severe major depression: A double-blind, placebo-controlled trial. Therapy. 2007;4(2):187–92. OVID-Embase. Exclude: Not an eligible population treatment.
  2041. Rajji TK, Mulsant BH, Lotrich FE, et al. Use of antidepressants in late-life depression. Drugs and Aging. 2008;25(10):841–53. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18808208]
  2042. Ramakrishman K, Kulkarni VN, Paul AD, et al. Clinical experience with dothiepin in an Indian population. J Drug Develop. 1991;4(3):151–9. OVID-Embase. Exclude: Not an eligible study design.
  2043. Ramana R, Paykel ES, Cooper Z, et al. Remission and relapse in major depression: A two-year prospective follow-up study. Psychol Med. 1995;25(6):1161–70. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 8637946]
  2044. Ramasubbu R. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. Ann Pharmacother. 2002;36(4):634–40. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 11918513]
  2045. Ramos L. SAMe as a supplement: Can it really help treat depression and arthritis? J Am Diet Assoc. 2000;100(4):414. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 10767892]
  2046. Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiol. 2004;50(4):322–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 15539864]
  2047. Randall F. Differences between Christian Cognitive Behavioral Therapy and cognitive behavioral therapy as measured by depression and resiliency. 2004. OVID-PsycINFO. Exclude: Not an eligible study design.
  2048. Randlov C, Mehlsen J, Thomsen CF, et al. The efficacy of St. John’s Wort in patients with minor depressive symptoms or dysthymia: A double-blind placebo-controlled study. Phytomed. 2006;13(4):215–21. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16423519]
  2049. Rane LJ, Fekadu A, Wooderson S, et al. Discrepancy between subjective and objective severity in treatment-resistant depression: Prediction of treatment outcome. J Psychiatr Res. 2010;44(15):1082–7. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 20471031]
  2050. Rani NJ, Rao PVK. Impact of yoga training on body image and depression. Psychol Stud. 2005;50(1):98–100. OVID-PsycINFO. Exclude: Not an eligible study design.
  2051. Ransom D, Heckman TG, Anderson T, et al. Telephone-delivered, interpersonal psychotherapy for HIV-infected rural persons with depression: A pilot trial. Psychiatr Serv. 2008;59(8):871–7. Exclude: Not an eligible population treatment. [PubMed: 18678684]
  2052. Rapaport MH, Gharabawi GM, Canuso CM, et al. Corrigendum: “Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation” Neuropsychopharmacol. 2007;32(5):1208. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 16760927]
  2053. Rapp SL. A cognitive-behavioral treatment of older medical inpatients with depressive symptoms. 1998. OVID-PsycINFO. Exclude: Not an eligible study design.
  2054. Rasanen P, Hakko H, Tiihonen J, Mitchell B. Balter Award--1998. Pindolol and major affective disorders: A three-year follow-up study of 30,485 patients. J Clin Psychopharmacol. 1999;19(4):297–302. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10440455]
  2055. Rasanen P, Hakko H, Jokelainen J, et al. Outcome of different types of long-term antidepressant treatments: A 3-year follow-up study of 14182 patients. J Affect Disord. 1999;55(1):67–71. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10512609]
  2056. Rasanen P, Hakko H, Txiihonen J. Pindolol and major affective disorders: A three-year follow-up study of 30,485 patients. J Clin Psychopharmacol. 1999;19(4):297–302. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 10440455]
  2057. Rasgon NL, Altshuler LL, Fairbanks LA, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63(Suppl 7):45–8. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 11995778]
  2058. Rasgon NL, Dunkin J, Fairbanks L, et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: A pilot study. J Psychiatr Res. 2007;41(3–4):338–43. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16697413]
  2059. Rasgon NL, Kenna HA, Williams KE, et al. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: A pilot study. Sci World J. 2010;10:321–8. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 20191245]
  2060. Raskin A. High dosage chlorpromazine alone and in combination with an antiparkinsonian agent (procyclidine) in the treatment of hospitalized depressions. J Nerv Ment Dis. 1968;147(2):184–95. Wiley-CCTR. Exclude: Not an eligible population treatment. [PubMed: 4877904]
  2061. Rasmussen N-A, Schroder P, Olsen LR, et al. Modafinil augmentation in depressed patients with partial responce to antidepressants: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Sympton Checklist (SCL-92) Nord J Psychiatr. 2005;59(3):173–8. OVID-Embase. Exclude: Not an eligible study design. [PubMed: 16208839]
  2062. Ravindran AV, Anisman H, Merali Z, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. Am J Psychiatry. 1999;156(10):1608–17. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10518174]
  2063. Ravindran AV, Kennedy SH, O’Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69(1):87–94. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18312042]
  2064. Ravindran L, Lam R, Chaput Y, et al. Impact of low vs. high dose olanzapine or risperidone on outcome and side effects in non-psychotic treatment resistant depression. 2006. Wiley-CCTR. Exclude: Not an eligible study design.
  2065. Razani J, White KL, White J, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment: A controlled trial. Arch Gen Psychiatr. 1983;40(6):657–61. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6342565]
  2066. Ree MJ, Craigie MA. Outcomes following mindfulness-based cognitive therapy in a heterogeneous sample of adult outpatients. Behav Change. 2007;24(2):70–86. OVID-PsycINFO. Exclude: Not an eligible study design.
  2067. Reed C, Monz BU, Perahia DG, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: Results from FINDER. J Affect Disord. 2009;113(3):296–302. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18603303]
  2068. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(8):1228–336. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18681749]
  2069. Reimherr FW, Martin ML, Eudicone JM, et al. A pooled MADRS/IDS cross-correlation analysis: Clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. J Clin Psychopharmacol. 2010;30(3):300–5. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20473067]
  2070. Reis S, Grenyer BFS. Fearful attachment, working alliance and treatment response for individuals with major depression. Clin Psychol Psychother. 2004;(11):414–24. Exclude: Not an eligible study design.
  2071. Rektorová I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: A national multicentre prospective randomized study. Eur J Neurol. 2003;10(4):399–406. Wiley-CCTR. Exclude: Not an elligible population design. [PubMed: 12823492]
  2072. Rene R. The efficacy of a portable HRV feedback device in conjunction with mental health treatment of clients with major depressive disorder enrolled in a county welfare-to-work program. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  2073. Repetto MJ, Petitto JM. Psychopharmacology in HIV-infected patients. Psychosom Med. 2008;70(5):585–92. OVID-PsycINFO. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18519881]
  2074. Replogle WH, Eicke FJ. Megavitamin therapy in the reduction of anxiety and depression among alcoholics. J Orthomolecular Med. 1989;4(4):221–4. OVID-Embase. Exclude: Not an eligible population treatment.
  2075. Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002;70(4):867–79. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PMC free article: PMC2977927] [PubMed: 12182270]
  2076. Rethorst CD, Wipfli BM, Landers DM. The antidepressive effects of exercise: A meta-analysis of randomized trials. Sports Med. 2009;39(6):491–511. OVID-Embase. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 19453207]
  2077. Rethorst CD, Landers DM, Nagoshi CT, et al. Efficacy of exercise in reducing depressive symptoms across 5-HTTLPR genotypes. Med Sci Sports Exerc. 2010;42(11):2141–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20351589]
  2078. Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract. 1998;47(6):446–52. OVID-Embase. Exclude: Not an eligible population treatment. [PubMed: 9866670]
  2079. Revicki DA, Siddique J, Frank L, et al. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatr. 2005;62(8):868–75. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16061764]
  2080. Reynaert-Dupuis C, Zdanowicz N, Leyman S, et al. Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment. Prim Care Psychiatr. 2002;8(2):63–8. Exclude: Not an eligible study design.
  2081. Reynaert C, Parent M, Mirel J, et al. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacol. 1995;118(2):183–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 7617806]
  2082. Reynolds CF III, Kupfer DJ, Hoch CC, et al. Sleep deprivation effects in older endogenous depressed patients. Psychiatry Res. 1987;21(2):95–109. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3615695]
  2083. Reynolds CF III, Frank E, Perel JM, et al. Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry. 1992;149(12):1687–92. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 1443245]
  2084. Reynolds CF III, Frank E, Perel JM, et al. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am J Psychiatry. 1996;153(11):1418–22. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8890674]
  2085. Reynolds CF III, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: A post hoc comparison of elderly (“young old”) and midlife patients. Am J Psychiatry. 1996;153(10):1288–92. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 8831436]
  2086. Reynolds CF III, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281(1):39–45. Exclude: Not an eligible population treatment. [PubMed: 9892449]
  2087. Reynolds CF III, Smith GS, Dew MA, et al. Accelerating symptom-reduction in late-life depression: A double-blind, randomized, placebo-controlled trial of sleep deprivation. Am J Geriatr Psychiatr. 2005;13(5):353–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15879583]
  2088. Reynolds CF III, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354(11):1130–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 16540613]
  2089. Reynolds CF III, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatr. 2011;68(1):51–60. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC3076045] [PubMed: 21199965]
  2090. Reynolds CFI, Schneider LS, Lebowitz BD, et al. Diagnosis and treatment of depression in late life: Results of the NIH Consensus Development Conference. Washington, DC, US: American Psychiatric Association; 1994. Treatment of depression in elderly patients: Guidelines for primary care. OVID-PsycINFO. Exclude: Not an eligible study design.
  2091. Reynolds WM, Coats KI. A comparison of cognitive-behavioral therapy and relaxation training for the treatment of depression in adolescents. J Consult Clin Psychol. 1986;54(5):653–60. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3534032]
  2092. Richards A, Barkham M, Cahill J, et al. PHASE: A randomised, controlled trial of supervised self-help cognitive behavioural therapy in primary care. Br J Gen Pract. 2003;53(495):764–70. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC1314708] [PubMed: 14601351]
  2093. Richards DA, Suckling R. Improving access to psychological therapies: Phase IV prospective cohort study. Br J Clin Psychol. 2009;48(Pt:4):4–96. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 19208291]
  2094. Richardson T, Stallard P, Velleman S. Computerised cognitive behavioural therapy for the prevention and treatment of depression and anxiety in children and adolescents: A systematic review. Clin Child Fam Psychol Rev. 2010;13(3):275–90. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20532980]
  2095. Richelson E. Treatment of acute depression. Psychiatr Clin North Am. 1993;16(3):461–78. OVID-PsycINFO. Exclude: Not an eligible guideline. [PubMed: 8415232]
  2096. Richeson NE, Spross JA, Lutz K, et al. Effects of Reiki on anxiety, depression, pain, and physiological factors in community-dwelling older adults: Physiological factors in community-dwelling older adults. Res Gerontol Nurs. 2010;3(3):187–99. EBSCO-CINAHL. Exclude: Not an eligible population/treatment. [PubMed: 20635803]
  2097. Rickels K, Csanalosi I, Werblowsky J, et al. Amitriptyline-perphenazine and doxepin in depressed outpatients: A controlled double-blind study. J Clin Psychiatry. 1982;43(10):419–22. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6749826]
  2098. Rickels K, Schweizer E, Case WG, et al. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. J Clin Psychopharmacol. 1998;18(2):145–53. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 9580369]
  2099. Riedel WJ, Schoenmakers E, Vermeeren A, et al. The influence of trazodone treatment on cognitive functions in outpatients with major depressive disorder. Hum Psychopharmacol. 1999;14(7):499–508. OVID-Embase. Exclude: Not an eligible population treatment.
  2100. Riemann D, Konig A, Hohagen F, et al. How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep phase advance and sleep phase delay. Eur Arch Psychiatry Clin Neurosci. 1999;249(5):231–7. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10591988]
  2101. Ries RK, Wittkowsky AK. Synergistic action of alprazolam with tranylcypromine in drug-resistant atypical depression with panic attacks. Biol Psychiatr. 1986;21(5–6):522–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3697440]
  2102. Riggs PD, Mikulich-Gilbertson SK, Davies RD, et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med. 2007;161(11):1026–34. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17984403]
  2103. Rihmer Z, Satori M, Pestality P. Selegiline-citalopram combination in patients with Parkinson’s disease and major depression. Int J Psychiatr Clin Pract. 2000;4(2):123–5. OVID-Embase. Exclude: Not an eligible study design.
  2104. Rihmer Z, Gonda X. Is drug-placebo difference in short-term antidepressant drug trials on unipolar major depression much greater than previously believed? J Affect Disord. 2008;108(3):195–8. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 18280581]
  2105. Riise IS, Holm P. Concomitant isocarboxazid/mianserin treatment of major depressive disorder. J Affect Disord. 1984;6(2):175–9. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 6233349]
  2106. Risos-Rio GER. The effects of a structured live music and arts program on depression, pain control and mood/behavior patterns among nursing home residents. UPNAAI Nursing Journal. 2009;5(1):9–15. EBSCO-CINAHL. Exclude: Not an eligible population treatment.
  2107. Ritchie LG. Group telepsychotherapy for reducing depression: An exploratory study. 2008. OVID-PsycINFO. Exclude: Not an eligible study design.
  2108. Robb SL, Ebberts AG. Songwriting and digital video production interventions for pediatric patients undergoing bone marrow transplantation, part I: An analysis of depression and anxiety levels according to phase of treatment. J Pediatr Oncol Nurs. 2003;20(1):2–15. EBSCO-CINAHL. Exclude: Not an eligible population treatment. [PubMed: 12569430]
  2109. Robbins DR, Alessi NE, Colfer MV. Treatment of adolescents with major depression: Implications of the DST and the melancholic clinical subtype. J Affect Disord. 1989;17(2):99–104. OVID-PsycINFO. Exclude: Not an eligible study design. [PubMed: 2527896]
  2110. Robbins DR, McFarlane W. Lamotrigine use in treatment refractory depression in adolescents. 2006. Wiley-CCTR. Exclude: Not an eligible study design.
  2111. Roberts SH, Bedson E, Hughes D, et al. Folate augmentation of treatment - evaluation of depression (FolATED): Protocol of a randomised controlled trial. BMC Psychiatr. 2007;7:65. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2238748] [PubMed: 18005429]
  2112. Robertson L, Smith M, Castle D, et al. Using the Internet to enhance the treatment of depression. Australas Psychiatr. 2006;14(4):413–7. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17116083]
  2113. Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy: A double-blind trial. J Affect Disord. 1985;9(2):127–36. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 2932485]
  2114. Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. J Neuropsychiatr Clin Neurosci. 2008;20(2):178–84. Wiley-CCTR. Exclude: Not an elligible population design. [PubMed: 18451188]
  2115. Rocco PL, Pacella G, Giavedoni A. Major depression in medical inpatients: A preliminary report on a tentative therapeutic approach with S-adenosyl-L-methionine. Curr Ther Res Clin Exp. 1993;54(2):177–85. OVID-Embase. Exclude: Not an eligible study design.
  2116. Rocha Araujo DM, Vilarim MM, Nardi AE. What is the effectiveness of the use of polyunsaturated fatty acid omega-3 in the treatment of depression? Exp Rev Neurotherapeut. 2010;10(7):1117–29. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 20586692]
  2117. Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol. 2003;18(2):97–9. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 12598821]
  2118. Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: A systematic review. Support Care Cancer. 2007;15(2):123–36. OVID-Medline. Excluded - Systematic review - relevant topic, citations cross-matched. [PubMed: 17058100]
  2119. Roepke S, Merkl A, Dams A, et al. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: An open label trial. Pharmacopsychiatr. 2008;41(5):176–81. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 18763219]
  2120. Rofey DL, Szigethy EM, Noll RB, et al. Cognitive-behavioral therapy for physical and emotional disturbances in adolescents with polycystic ovary syndrome: A pilot study. J Pediatr Psychol. 2009;34(2):156–63. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2902827] [PubMed: 18556675]
  2121. Rogers DR, Ei S, Rogers KR, et al. Evaluation of a multi-component approach to cognitive-behavioral therapy (CBT) using guided visualizations, cranial electrotherapy stimulation, and vibroacoustic sound. Complement Ther Clin Pract. 2007;13(2):95–101. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17400144]
  2122. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial. Br J Nutr. 2008;99(2):421–31. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17956647]
  2123. Rogoz Z, Skuza G, Wojcikowski J, et al. Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol. 2004;56(6):849–55. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15662100]
  2124. Rogoz Z, Dziedzicka-Wasylewska M, Daniel WA, et al. Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. Pol J Pharmacol. 2004;56(6):735–42. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 15662086]
  2125. Rogoz Z, Skuza G, Daniel WA, et al. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Reports. 2007;59(6):778–84. OVID-Medline. Exclude: Mixed antidepressants:some failed on SSRI. [PubMed: 18195470]
  2126. Roh YS, Cho H, Oh JO, et al. Effects of skin rehabilitation massage therapy on pruritus, skin status, and depression in burn survivors. Daehan Ganho Haghoeji. 2007;37(2):221–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 17435407]
  2127. Rohde P, Clarke GN, Mace DE, et al. An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. J Am Acad Child Adolesc Psychiatry. 2004;43(6):660–8. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 15167082]
  2128. Rohde P, Silva SG, Tonev ST, et al. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. Arch Gen Psychiatr. 2008;65(4):447–55. OVID-Medline. Exclude: Not an eligible population treatment. [PMC free article: PMC2587406] [PubMed: 18391133]
  2129. Rohde P, Lewinsohn PM, Seeley JR. Response of depressed adolescents to cognitive-behavioral treatment: Do differences in initial severity clarify the comparison of treatments? J Consult Clin Psychol. 1994;62(4):851–4. OVID-PsycINFO. Exclude: Not an eligible population treatment. [PubMed: 7962890]
  2130. Rohen NA. Analysis of efficacy and mediators of outcome in minimal-contact cognitive bibliotherapy used in the treatment of depressive symptoms. 2003. OVID-PsycINFO. Exclude: Not an eligible study design.
  2131. Rohini V, Pandey RS, Janakiramaiah N, et al. A comparative study of full and partial Sudarshan Kriya Yoga (SKY) in major depressive disorder. Nimhans J. 2000;18(1–2):53–7. Exclude: Not an eligible population treatment.
  2132. Roitman S, Green T, Osher Y, et al. Creatine monohydrate in resistant depression: A preliminary study. Bipolar Disorders. 2007;9(7):754–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 17988366]
  2133. Rokke PD, Tomhave JA, Jocic Z. The role of client choice and target selection in self-management therapy for depression in older adults. Psychol Aging. 1999;14(1):155–69. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10224639]
  2134. Rolland Y, Pillard F, Klapouszczak A, et al. Exercise program for nursing home residents with Alzheimer’s disease: A 1-year randomized, controlled trial. J Am Geriatr Soc. 2007;55(2):158–65. Wiley-CCTR. Exclude: Not an elligible population design. [PubMed: 17302650]
  2135. Romano SJ, Amsterdam JD, Shelton RC, et al. Adjunctive ziprasidone in treatment-resistant depression: Pilot study. 156th Annual Meeting of the American Psychiatric Association; May 17–22; San Francisco CA. 2003. Wiley-CCTR. Exclude: Not an eligible study design.
  2136. Rondanelli M, Giacosa A, Opizzi A, et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: A double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr. 2010;29(1):55–64. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 20595646]
  2137. Roose SP, Glassman AH, Walsh BT, et al. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry. 1986;143(3):345–8. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3953869]
  2138. Roschke J, Wolf C, Muller MJ, et al. The benefit from whole body acupuncture in major depression. J Affect Disord. 2000;57(1–3):73–81. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 10708818]
  2139. Rosen J, Rogers JC, Marin RS, et al. Control-relevant intervention in the treatment of minor and major depression in a long-term care facility. Am J Geriatr Psychiatry. 1997;5(3):247–57. Exclude: Not an eligible population/treatment. [PubMed: 9209567]
  2140. Rosenbaum JF, Fava M, Falk WE, et al. An open-label pilot study of oral S-adenosyl-L-methionine in major depression: Interim results. Psychopharmacol Bull. 1988;24(1):189–94. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 3387521]
  2141. Rosenbaum JF, Fava M, Falk WE, et al. An open-label pilot study of oral S-adenosylmethionine in major depression. An interim report. Ala J Med Sci. 1988;25(3):301–6. OVID-Medline. Exclude: Not an eligible population treatment. [PubMed: 3052138]
  2142. Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990;81(5):432–6. OVID-Medline. Exclude: Not an eligible study design. [PubMed: 2113347]
  2143. Rosenberg D, Depp CA, Vahia IV, et al. Exergames for subsyndromal depression in older adults: A pilot study of a novel intervention. Am J Geriatr Psychiatr. 2010;18(3):221–6. OVID-Medline. Exclude: Not an eligible study design. [PMC free article: PMC2827817] [PubMed: 20173423]
  2144. Ross EA, Hollen TL, Fitzgerald BM. Observational study of an Arts-in-Medicine Program in an outpatient he